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Early diagnosis of Legionnaires’ Disease (LD) is important 
because prompt institution of appropriate treatment may reduce the 
morbidity and mortality associated with this recently-described 
bacterial pneumonia. To determine if there were specific clinical 
features which distinguished patients with LD from those with other 
types of pneumonia, I compared clinical data from the medical records 
of 28 cases of LD pneumonia with those of 29 seronegative control 
pneumonia patients. Features noted significantly more often in the 
LD cases than in the controls included: history of subjective fever 
(P=0.044), arthralgia (P=0.017), presence of high fever on admission 
(P=0.0002), minimal respiratory symptoms (P=0.015) and signs (P=0.049): 
and laboratory findings including the presence of occult blood (P=0.0007) 
or protein (P=0.022) in the urine and hypophosphatemia (P=0.028). Neither 
neurologic nor gastrointestinal symptoms were reported by significantly 
more cases than controls. 
Defervescence occurred more than four days earlier in LD cases 
treated with erythromycin within three days of hospital admission than 
in LD cases not treated with erythromycin (P=0.0001). While not statis¬ 
tically significant, the length of admission was shorter, the number of 
days on supplemental oxygen was less, and clearing of pneumonia on chest 
x-ray was noted earlier in the illness of LD cases treated with erythromycin 
than in cases not so treated. 
In sum, I have identified various features of LD pneumonia which 
may help the physician make an early clinical diagnosis and consider the 
prompt institution of specific antibiotic therapy. 
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Much has been learned about the epidemiology and clinical 
features of Legionnaires' Disease (LD) in the three years since 
the highly publicized epidemic of pneumonia occurred among persons 
attending the 58th annual American Legion convention in Philadelphia 
in July, 1976. By October, 1978, 558 cases associated with 10 out¬ 
breaks and 453 sporadic cases from 43 states and the District of 
Columbia had been confirmed by the Center for Disease Control (CDC) (1). 
Incidence estimates based on a prospective study of pneumonia in 
Seattle, Washington and from serologic data collected by the CDC suggest 
that between 7,000 and 36,000 cases of LD occur in the U.S. each year, 
accounting for roughly 1% of all cases of pneumonia (2). An estimated 
5% of all summertime pneumonia cases may be LD, which has a peak of 
activity in that season when other pneumonias are less common (3). 
The practicing clinician evaluating a patient with pneumonia is 
now faced with a diagnostic and therapeutic problem because of the need 
for specific antibiotic therapy in LD. Case fatality rates reported 
among patients with LD have been about 15%. Currently the sensitivity 
and/or specificity of acute phase diagnostic tests for LD do not allow 
reliable early laboratory confirmation of diagnosis (2). Furthermore, 
erythromycin is recommended for the treatment of LD but is not 
generally used in the treatment of most cases of bacterial pneumonia 
in the older age group in which LD is most common. Clinical studies 
of LD have suggested, however, that certain features of the illness 
may be useful to clinicians in distinguishing cases of LD from pneu- 
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monia of other causes. Unfortunately, the clinical data needed to 
test this hypothesis are presently limited. 
During the investigation of an outbreak of LD in Bridgeport, 
Connecticut, it became apparent that local physicians had been very 
selective when ordering serologic tests for LD and, indeed, had been 
effective in identifying those patients likely to have LD. This study 
uses retrospective comparison of the medical records of LD pneumonia 
cases and non-LD pneumonia controls from Bridgeport to determine if 
there are specific clinical features which distinguish LD pneumonia 
from pneumonia of other etiology. However, because all of the patients 
included in this case-control study were alive at least four months 
after their illness, this study is biased by design towards milder 
forms of illness. Finally, descriptive analysis of clinical data 
from all hospitalized LD cases — including fatalities — provides 
additional information about the spectrum of illness and the response 




Like many small New England cities, Bridgeport has been indus¬ 
trialized since the mid-1800's. It is located on Long Island Sound, 
sixity miles northeast of New York City in Fairfield County, 
Connecitcut. In recent years economic growth has been undermined 
in Bridgeport as the expansion of its suburbs has eroded the city's 
tax base. The same process has left the population of the city with 
large numbers of poor and underskilled persons in need of many social 
services. Several large federally subsidized housing projects have 
been built towards the center of the city while peripheral neighborhoods 
have remained primarily single story one and two family homes. According 
to the U.S. Census, Bridgeport did not increase its population of 
156,000 between 1960 and 1970, a period when the population of the 
state grew by about 20% (4). In 1970 non-whites and persons 65 years 
and older comprised 17.3% and 11.9%, respectively, of the city's popu¬ 
lation, whereas the statewide figures were 6.5% and 9.5%. Women out¬ 
numbered men, with a sex ratio of 0.90 (males/females). The city of 
Bridgeport is served by an active City Department of Health and by 
three modern community hospitals — Bridgeport, Saint Vincent's, and 
Park City Hospital. 
In the fall of 1978, Bridgeport physicians noted that an unusually 
large number of patients were being hospitalized with pneumonia. Just 
a few weeks earlier, outbreaks of Legionnaires' Disease (LD) in the 
garment district of Manhattan and in Norwalk, Connecticut drew considerable 
attention in the regional press. Concern that cases of pneumonia in 
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Bridgeport might represent a local epidemic developed when several of 
these patients were found to have serologic evidence of LD infection. 
To investigate this possibility, public health students from Yale 
University collected data from the three hospitals in Bridgeport and 
demonstrated a significant excess of pneumonia cases in September and 
October relative to the experience of the two previous years. Because 
no previous incidence data for LD are available, it could not be proved 
whether these cases represented an outbreak or whether they simply re¬ 
flected the application of a new diagnostic test to the heterogeneous 
population of pneumonia patients typically found in Bridgeport. A 
variety of lines of evidence suggested, however, that the cases of LD 
did represent a local outbreak. Summary data from the state laboratory 
showed that of all tests for LD submitted during 1978, a much greater 
proportion were positive from the Bridgeport area than from the rest of 
the state, especially during the fall of the year. In addition, the 
lack of evidence for another organism as a cause of the excess of 
pneumonia cases also supported the hypothesis that the epidemic of 
pneumonia was due to an outbreak of LD. 
As part of the Bridgeport epidemiologic study, a questionnaire 
was administered to persons with LD and controls with non-LD pneumonia 
to examine geographic and personal risk factors. Exposure to the 
downtown area was shown to be associated with the development of LD 
although a specific common source of exposure was not identified. 
Neither was there evidence of association of cases with air-conditioning 
systems, excavation, or construction. Examination of host-specific 
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risk factors including age, sex, race, preexisting illness, drinking 
of alcohol, and cigarette smoking failed to show differences between 
cases of LD and other patients generally at risk for the development 
of pneumonia. 
The complete report of this earlier investigation is included 
in Appendix F. 
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III. LITERATURE REVIEW 
A. HISTORICAL ASPECTS 
And, indeed, as he listened to the cries of joy- 
rising from the town, Dr. Rieux remembered that such 
joy is always imperiled. He knew what those jubilant 
crowds did not know but could have learned from books: 
that the plague bacillus never dies or disappears for 
good; that it can lie dormant for years and years in 
furniture and linen-chests; that it bides its time in 
bedrooms, cellars, trunks, and bookshelves; and that 
perhaps the day would come when, for the bane and the 
enlightening of men, it would rouse up its rats again 
and send them forth to die in a happy city (5). 
Events in the "City of Brotherly Love" in the late summer of 
1976 have confirmed the words of Camus. The epidemic of acute febrile 
respiratory disease which occurred primarily among persons attending 
the American Legion convention in Philadelphia generated both excep¬ 
tional public interest and intensive epidemiologic and laboratory 
investigation (2,6-10). 
One hundred and eighty-two cases of Legionnaires' Disease (LD), 
including 29 fatalities, were studied in an epidemiologic investigation 
organized by workers from the CDC. Evidence suggested that the Bellevue- 
Stratford Hotel, and in particular its lobby, provided a common-source 
of exposure for cases; but no specific environmental source was implicated. 
Dissemination of the agent was probably by the airborne route. No evidence 
of secondary spread was noted. The incubation period of this severe 
pneumonic illness was estimated to be between 2 and 10 days. Cases pre¬ 
dominated in males and in persons with past history of chronic disease. 
The mean age of cases was 54.7 years (11). 
After months of searching for toxins and known microbial agents 
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which might have produced the clinical syndrome of fever, cough, and 
pneumonia, McDade and co-workers isolated a bacterium from lung 
tissues in four fatal cases by intraperitoneal inoculation of guinea 
pigs, a technique usually reserved for the isolation of rickettsiae 
and M. tuberculosis (2,12). Using an indirect flourescent antibody (IFA) 
test, they established the etiologic role of the organism in the 
Philadelphia epidemic, in two earlier and previously "unexplained" out¬ 
breaks of febrile respiratory disease in Washington, D.C. and Pontiac, 
Michigan, and in a number of sporadic cases of severe pneumonia. Of 
cases with suitably timed serologic specimens, 91% showed either sero¬ 
conversion or a single positive titer in samples from Philadelphia and 
Washington; in the Pontiac outbreak 87% of these samples were positive (12). 
To further emphasize the fact that LD is not a new disease, but 
rather newly described, McDade and co-workers have recently shown that 
an unclassified agent (OLDA), isolated in 1947 from the blood of a 
patient with a febrile respiratory illness, was the same as the agent 
of LD isolated from the Philadelphia epidemic (13). 
The agent of LD was first demonstrated in lung tissue obtained at 
autopsy using the Dieterle silver-impregnation method, originally 
intended for the staining of spirochetes (14). With this stain, in¬ 
tensely brown to black bacilli 0.4 to 0.8 microns in width and 2 to 4 
microns in length were seen against a pale-yellow background in tissue 
taken from 18 of 26 cases examined. Occasional vacuolated forms up 
to 20 microns in length were also noted. Variable numbers of small 
pleomorphic organisms were observed most consistently in areas of 
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pneumonia, and in greatest numbers within necrotic cellular debris 
in affected alveoli and bronchioles. The organisms were weekly gram 
negative and did not stain with acid-fast, periodic acid-Schiff, 
hematoxylin and eosin, Gridley fungus, and Gomori methenamine silver 
staining methods. That the agent of LD is a bacterium and not a 
rickettsia was established when Weaver grew the organism in culture 
with an iron and cysteine supplemented Mueller-Hinton agar (2). 
Browning of this medium by growing LD bacilli has been noted and may 
indicate melanin formation mediated by bacterial tyrosinase (15). 
Although LD is structurally similar to gram negative bacilli, ex¬ 
perimental work has produced no clear evidence of classic 
endotoxin (16-18). 
Because the agent of LD was unlike any known microbe causing 
human disease, and because of its unique biochemical and micro¬ 
biologic properties Brenner, Steigerwalt, and McDade recently proposed 
that the name Legionella pneumophila be formally adopted (19). The 
term ''Legionellosis" has been proposed for diseases resulting from 
this organism (2,7). 
B. EPIDEMIOLOGY 
Since the development of the IFA test, seventeen outbreaks 
of LD have been identified and described in the U.S. and Europe 
(Table 1) and numerous sporadic cases have been diagnosed in the U.S., 
Australia, Belgium, Canada, Denmark, England, Israel, the Netherlands, 




1. Epidemic Behavior 
LD has been noted repeatedly in explosive common-source out¬ 
breaks with apparent continued dissemination of the agent for several 
days or weeks. Many outbreaks have been associated with large build¬ 
ings such as hotels, hospitals, and a health department building, 
though this association may only reflect the increased likelihood of 
recognizing an outbreak in buildings with large numbers of people (10). 
A hotel in Philadelphia, however, has been involved twice in out¬ 
breaks (10,11,24). Furthermore, several locations where outbreaks have 
occurred — including two hotels and a hospital — have reported ongoing 
endemic LD at unusually high rates (10,25-29). 
Many separate observations suggest that LD is spread by the air¬ 
borne route. An association with airborne exposure to contaminated 
air-conditioning cooling towers or evaporative condensers has been noted 
in four different outbreaks (30-34). Furthermore, intensive study in 
Philadelphia did not implicate a variety of other possible modes of 
spread. Only limited evidence of person-to-person spread has been 
found, although it has been actively sought in many circumstances (7,10,11). 
In a recent letter to the editor of The Lancet, Love et al. describe the 
occurrence of a presumptive (seropositive) case in a physician who cared 
for a patient with LD, apparently acquired in Benidorm, Spain; suggesting 
that secondary spread may occur with repeated close physical proximity 
to infected persons (35). 
2. Ecology of the Agent 
Sporadic cases of LD have been associated with increased exposure 

10. 
to excavation or construction; and excavations for installing a sprinkler 
system were implicated in the Washington outbreak (36,37). In 
Bloomington, Indiana, three serotypes of L. pneumophila were isolated from 
the soil and water of a stream near the site of an outbreak (interestingly, 
because of thermal pollution from a power plant situated upstream from 
the sites of these isolations, this stream may not represent a natural 
setting) (28,34). Recently, Fliermans and co-workers have reported 
isolations of L. pneumophila from South Carolina lakes not associated 
with recognized outbreaks (34). Finally, the agent of LD has been noted 
to survive in distilled and tap water for up to one year (38). These 
findings suggest that the soil and possibly bodies of water serve as 
ecologic niches for _L. pneumophila, though other possible natural 
reservoirs such as plants have not been excluded (39). 
3. Season 
Late summer, early fall seasonality has been pronounced in most 
outbreaks and in sporadic cases. Sporadic cases do occur, at lower 
levels, throughout the year as do cases associated with ongoing noso¬ 
comial outbreaks (1,7,37,40). 
4. Clinical Forms 
Two clinically and epidemiologically distinct forms of 
legionellosis have been noted. Legionnaires' Disease, as described 
in Philadelphia and most other outbreaks, has an incubation period of 
2 to 10 days and is clinically a severe pneumonic illness with a typical 
case fatality ratio of about 15%. In contrast, the illness described 
in outbreaks in Pontiac, Michigan and James River, Virginia had shorter 
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incubations with medians of 36 and 37 hours, and none of these cases 
had pneumonia or died; this milder form of legionellosis has been termed 
Pontiac Fever. Epidemiologically, LD and Pontiac Fever differ 
strikingly with attack rates of about 2% and 95-100%, respectively. 
Factors which determine whether _L. pneumophila produces pneumonic LD 
or Pontiac Fever are unknown. Neither differences in dose of organisms 
nor differences in toxigenicity between strains can explain this 
difference, as larger doses would be expected to produce the short 
incubation form but not the observed mild illness and no important 
differences between strains have been demonstrated. Finally, the theory 
that exposure to non-viable organisms causes Pontiac Fever is contra¬ 
dicted by the isolation of the agent from guinea pigs exposed to the 
health department building in Pontiac during the outbreak (7,11,12,30, 
31,41). 
5. Age and Sex 
Sporadic and outbreak - associated cases of LD tend to occur 
most commonly in men — as opposed to women — during late middle age, 
though cases have been noted in all age categories. Currently, the 
relationship between age at the time of infection by L^. pneumophila 
and host response to infection — either asymptomatic infection or 
clinical illness — is unclear. In Pontiac Fever the age distribution 
of cases matches that of the younger exposed populations, as expected 
with attack rates of nearly 100%. The nearly constant finding of male 
predominence in epidemic and sporadic cases may represent either actual 
differential exposure to the agent or differences in susceptibility 
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for developing illness, a possibility with substantial potential for 
being confounded by variables such as smoking, drinking, and underlying 
illness (7,10). 
6. Race and Occupation 
The suggestion that blacks are at greater risk for developing LD 
than whites, noted by the national sporadic study (37), contrasts with 
experience from outbreaks which has repeatedly shown that the racial 
distribution of cases and population at risk were similar. Furthermore 
the proportion of spradic cases who are black, about 14% nationwide, 
is about the same as the proportion of blacks in the general popula¬ 
tion (7,10,37). 
Infection by the agent of LD has been associated with being a 
construction worker, a cleaner of steam turbine condensers, or being 
a hospital worker in contact with patients with LD; all situations 
possibly associated with increased exposure to the agent (7,10,31,37). 
7. Other Factors 
Cigarette smoking has been associated with increased risk of 
developing LD when cases are compared with age and sex-matched well 
controls. The investigations of the Philadelphia and Vermont epidemics 
and the national sporadic study all found an increased relative risk of 
LD when comparing cases with well acquaintance-controls. However, when 
comparing LD cases with patients with non-LD pneumonia in the Vermont 
and Bridgeport outbreaks, no increased risk specifically for LD was 
noted in association with cigarette smoking. In contrast, the national 
sporadic study did find an increased risk of LD in cigarette smokers 
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when comparing sporadic cases with persons without LD who had sera 
submitted to the CDC for serologic testing. Further studies will be 
required to resolve the question of whether cigarette smoking increases 
the risk of LD to a greater extent than it increases risk of pneumonia 
in general (11,37,42, Appendix F). 
Although excessive alcohol consumption is common in patients 
with LD, it may or may not predispose persons specifically to LD, as 
with cigarette smoking. In the Philadelphia and Bridgeport epidemics, 
no differences were noted in alcohol consumption between cases and 
either well (Philadelphia) or seronegative pneumonia controls 
(Bridgeport). However, cases of LD were associated with excessive 
daily alcohol consumption in the large national sporadic study. The 
well known association of alcohol with a number of other gram negative 
pneumonias — most notably those due to Klebsiella pneumoniae — 
suggests that alcohol consumption increases the risk for both LD and 
other pneumonias non-specifically (7,11,37,43,44, Appendix F). 
Compromised immune competence caused by medications or chronic 
illness has been suggested as a significant risk factor for developing 
LD in hospitalized patients. Immunosuppression with steroids or cyto¬ 
toxic drugs has repeatedly been associated with increased risk for LD 
in nosocomial outbreaks, especially among renal transplant recipients 
and patients with malignancy (7,10,29,42,45-48). Diabetes mellitus 
and the use of diuretics were noted in a national study to be associated 
with increased risk of sporadic LD; however, the same study noted no 
difference in the prevalence of underlying disease between LD and 
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non-LD pneumonia patients — a finding also noted in the Vermont and 
Bridgeport outbreaks. Again, the increased risk of LD associated 
with underlying chronic disease may reflect non-specific increased 
risk in these persons for developing gram negative pneumonia (37,43, 
44, Appendix F). 
8. Incidence 
Despite intensive study of epidemic and sporadic cases, only 
limited estimates of the incidence of LD in the U.S. have been forth¬ 
coming because of difficulty in establishing and testing a large and 
well-defined study population and because LD is not presently a re¬ 
portable illness. In a serodiagnostic study of members of a pre-paid 
health care plan in the Seattle area, the incidence of LD pneumonia 
was estimated at 1.2 cases per 10,000 persons per year; however, this 
estimate was based on only five confirmed cases (3). These LD cases 
constituted 1% of all pneumonia cases studied. Fraser has calculated 
an estimated incidence of LD pneumonia of 0.7 to 2.0 cases per 10,000 
per year by combining the 0.5% to 1.5% seroconversion rate noted in 
paired sera submitted to the CDC for diagnosis of pneumonia with the 
incidence of pneumonia in the U.S. of 130 per 10,000 population per 
year. This estimate depends upon the seroconversion rate in submitted 
paired sera, which has shown wide variation between studies in differ¬ 
ent states (10). Furthermore, this estimate is biased to the extent 
that patients with specimens submitted to the CDC differ from un¬ 
selected cases of pneumonia in the U.S. (7). 

15. 
9. Serologic Surveys and Diagnostic Tests 
Sero-surveys for antibody in well persons in the U.S. have shown 
a generally low prevalence with the notable exception of a number of 
apparently hyperendemic areas. Recently, Storch has reported 1.3% 
"background" seroprevalence of IFA titers > 128 in 1,143 healthy 
volunteers aged 46 years or older in four cities in the U.S. including 
Atlanta, Houston, Rochester, N.Y., and Washington, D.C. (49). However, 
in various outbreaks studied,healthy volunteers from areas not thought 
to be involved in the outbreak showed seroprevalence rates of 4% in 
Los Angeles, 5.7% in Bristol, Tenn., 15% in both Burlington, Vt. and 
Bloomington, Ind., 46% in the Bronx, N.Y., and 24.8% in Manhattan (7,28, 
29,42,49,50). These contrasts suggest that some areas may be hyper¬ 
endemic for infection by the agent of LD (49). 
Alternatively, these regional seroprevalence differences might 
reflect variations in the IFA test or the criteria for positivity rather 
than actual differences in seroprevalence. The extent to which the IFA 
test for LD cross-reacts with antibodies specific for other infections 
has not been fully investigated, although some reports have noted cross¬ 
reactivity in patients with plague, tularemia, leptospirosis, and in 
patients with rising titers to Mycoplasma pneumoniae, Chlamydiae 
psittaci, and Rickettsia rickettsii (10,51-54). Variations exist in the 
method of preparing or growing the test antigens. Another problem is 
the variability of titer determination between different observers and 
different laboratories performing the same IFA test. Because of the 
multiple factors influencing this test, Storch cautions that sero- 
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prevalence results may not be directly comparable in the absence of 
routine standardization using reference samples from the CDC (49). 
Furthermore, all immunoflourescent testing is serogroup specific and 
four distinct serogroups of _L. pneumophila have already been defined; 
others will undoubtedly be recognized in the future (55). Finally, 
because the IFA test measures IgG, and not IgM, single positive titers 
may reflect either recent or remote infection by the agent of LD (7,10, 
51). Thus, while a single isolated IFA titer ^ 256 in association 
with a compatible illness may suggest a presumptive diagnosis, the 
predictive value of a single test is variable and depends upon both 
the assay itself and the population to which it is applied (49). 
Other less variable serologic tests using microagglutination, 
microhemagglutination, and various micro-enzyme-linked-immunosorbent- 
assay (micro-ELISA) methods are being developed, but the sensitivity 
and specificity of these methods have not been well studied and end 
points must still be determined subjectivity (7,10,56,57). The micro¬ 
agglutination method may be useful in distinguishing recent from 
remote infection as it has been shown to be IgM specific (58). Of 
course, serologic methods which depend upon host derived antibody are 
rarely useful in acute phase diagnosis of short incubation period 
illnesses because of the lag time required between infection and the 
appearance of antibody. 
In light of these problems, and the difficulties encountered 
in culturing this fastidious organism, a number of other diagnostic 
tests are being developed with particular emphasis being directed 

17. 
towards those methods which provide diagnostic information in the 
acutely ill patient. Direct flourescent antibody methods have 
been used to demonstrate the presence of the agent in respiratory 
secretions and in both autopsy and biopsy specimens of lung tissue (10 
14,59,60). However, this test has only had 24% sensitivity and there 
have been problems with specificity as well (59,60). Recently, Tilton 
has reported promising results in the development of an ELISA method 
for the detection of LD antigen in the urine of acutely ill patients, 
but the sensitivity and specificity of this test are currently 
unknown (62). Finally, unless polyvalent conjugated antiserum or 
multiple antigen serotypes are used, these methods are also limited 
by their serogroup specificity (10). 
C. CLINICAL ASPECTS 
The spectrum of host response to infection by L. pneumophila 
ranges from asymptomatic infection to mild febrile illness to severe - 
often fatal — pneumonia. Factors influencing the severity of illness 
have not been well defined. Old age, cigarette and alcohol abuse, 
malignancy, and various forms of immunosuppression are common in cases 
of severe clinical illness, though this is true in most other bacte¬ 
rial pneumonia as well (11,29,43,44,47,64). The majority of cases 
described to date have been of the severe pneumonic type with extra- 
pulmonary manifestations and high mortality rates. 
Asymptomatic infection has been documented at least once with 
a rise in IFA titer from less than 32 to 128 in a patient studied 
during an epidemic investigation in Ohio (interestingly, this patient 
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was taking immunosuppressive drugs because of rejection of a cadaver 
kidney transplant) (45). 
Mild febrile respiratory illness was noted in 98 Legionnaires 
present at the Philadelphia convention who did not meet the clinical 
criteria for LD (high fever and cough, or, fever and chest x-ray 
evidence of pneumonia); however, no sera were available from these 
persons (11). Of the 142 Legionnaires who had chest x-rays, 28 (20%) 
had mild illness without pneumonia and 13 of these 28 were serologically 
proven cases. Twenty percent of the 182 cases in the Philadelphia out¬ 
break were not hospitalized. Ambulatory cases were generally younger 
and had lesser frequency of chronic disease than hospitalized cases. 
Similar symptoms were noted in both of these groups, though headache 
and normal chest x-ray were more common in ambulatory — and presumably 
milder — cases (66). 
1. Pontiac Fever 
All of the cases studied in the Pontiac outbreak had mild ill¬ 
ness characterized by chills, fever, myalgia, and headache; only one 
person of the 144 affected was hospitalized, none had evidence of 
pneumonia, and none died. As in Pontiac, the 10 cases of legionellosis 
noted in the James River outbreak had illness with chills, fever, 
myalgia, and headache without pneumonia or fatalities. However, 9 of 
these 10 cases were hospitalized, apparently because of fever and 
elevated white blood counts. Other symptoms noted in these outbreaks 
included dry cough (33% in Pontiac and 60% in James River), nausea or 
vomiting (46% and 60%), and sore throat (33% and 70%). Diarrhea and 
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various neurologic symptoms — notably dizziness, neck pain, confusion, 
and poor coordination — were also prominent during the Pontiac out¬ 
break. Aside from fever and modestly elevated white blood cell 
counts, findings on physical exam and results of laboratory tests 
were unremarkable in both outbreaks. This clinical constellation of 
flu-like symptoms has been referred to as Pontiac Fever (30,31,41). 
2. Legionnaires' Disease 
The severe pneumonic illness typical of cases seen in Legionnaires 
during the Philadelphia epidemic has repeatedly been described in out¬ 
breaks and in sporadic cases and, at this time, accounts for the vast 
majority of reported cases of legionellosis. Because patients studied 
in the Bridgeport outbreak were — by definition — hospitalized with 
pneumonia, the clinical features seen in the severe pneumonic type of 
illness are more pertinent to the present study. 
The illness typically has abrupt onset, usually with malaise, 
fever, chills, dry cough, myalgias, and often with headache. This 
prodromal syndrome resembles the early stages of common viral illnesses, 
with prominent constitutional symptoms and generally minimal respira¬ 
tory complaints (66-69). However, up to 25% of patients have presented 
with primarily gastrointestinal complaints, usually diarrhea, but 
neausea and vomiting or abdominal pain have also been noted. Patients 
with prominent gastrointestinal symptoms have been noted both with and 
without accompanying constitutional and respiratory symptoms (48,64,66). 
The disease progresses during the first few days with increasing 
fever and cough, often with the development of neurologic symptoms 
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and/or diarrhea. Both pleuritic chest pain and mild hemoptysis have 
been noted in about 20% to 40% of cases. Confusion, delerium, poor 
coordination, lethargy, or weakness have been seen in up to 60% of 
cases, often without apparent etiology other than infection (48,50,66, 
70,71). In the Vermont outbreak, however, headache was the only neuro¬ 
logic symptom attributable to LD and was noted by about 40% of cases (64). 
The rapidity of progression of the illness is evident in that half of the 
patients hospitalized during the Philadelphia outbreak were admitted 
within four days after the onset of symptoms (66). 
On physical examination most patients appear acutely ill, febrile, 
and diaphoretic. Temperature is usually over 102°F and often over 104°F; 
and response to antipyretics has usually been minimal. Tachycardia is 
common as expected in febrile illness, however, relative bradycardia has 
been noted as a chracteristic feature of cases in both the Los Angeles 
and Philadelphia outbreaks. Tachypnea and dyspnea reflect the extent 
of the pneumonia. Examination of the chest early in illness commonly 
reveals rales and/or rhonchi; however, signs of consolidation are rare 
until later in the course. Diffuse abdominal tenderness without 
peritoneal signs has been noted in 23% of patients in Philadelphia; 
about one third of patients with abdominal tenderness had a history 
of vomiting or diarrhea. Occult blood has been detected in the stool 
of some patients, particularly in those with diarrhea. Altered mental 
status with confusion, lethargy, or disorientation — disproportionate 
to the extent of fever, hypoxemia, or metabolic derangements — has been an 
outstanding finding on neurologic exam. Patients have not been noted 
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to have focal neurologic signs, muscle tenderness, hepatomegaly, 
lymphadenopathy, rash, or exudative pharyngitis (48,64,66,71). 
Laboratory studies have shown non-specific findings typical of 
bacterial pneumonia as well as evidence of hepatic and renal dysfunction. 
White blood cell counts have usually been modestly elevated (typically 
10,000 to 20,000) with a shift to the left (about two-thirds with more 
than 5% band forms). When measured, the erythrocyte sedimentation rate 
has often been greater than 60 mm./hour (48,64,66). Thrombocytopenia 
and evidence of disseminated intravascular coagulation, though rare, 
have been documented (54,72). Hypoxia and hypocarbia in proportion to 
the degree of pneumonia have been noted in arterial blood gas determi¬ 
nations. Urinalysis showing proteinuria or pyuria is not uncommon and 
chemical or microscopic hematuria have occasionally been noted. Fifteen 
percent of cases described in the Philadelphia outbreak developed renal 
dysfunction ranging from mild transient azotemia to acute renal failure 
with oliguria requiring dialysis; however, other reports have failed to 
show consistent alterations in renal function (48,64,66,73). Hypo¬ 
natremia, probably due to inappropriate secretion of antidiuretic 
hormone, has been noted in from one-third to one-half of cases. Hypo¬ 
phosphatemia was present in about half of the cases tested in Los 
Angeles and was also seen in the Philadelphia cases along with 
hypocalcemia (48,74). Modest transient abnormalities in liver function 
(SGOT, SGPT, LDH, alkaline phosphatase, and total bilirubin) were 
common in patients tested in the Philadelphia and Los Angeles out¬ 
breaks. Unexplained elevations of creatine phosphokinase (CPK) have 
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been rarely noted and it is currently uncertain how frequently renal 
dysfunction in patients with LD is secondary to rhabdomyolysis and 
myoglobinuria. Spinal fluid obtained from lumbar puncture in patients 
with neurologic symptoms has usually shown normal levels of protein, 
glucose, and white cells (48,66,74). 
In most cases, routine bacterial cultures of respiratory secre¬ 
tions, pleural fluid, and spinal fluid do not show pathogens in patients 
with LD and these negative culture results are important findings in 
suggesting the diagnosis of LD (51,68,71). Isolations of _L. pneumophila 
from routine specimens, though currently rare, have been made from 
pleural fluid in immunosuppressed patients and from blood in at least 
two cases (13,67,78). 
The spectrum of acute changes reported in the chest x-rays of 
LD cases are not specifically diagnostic as opposed to other types 
of pneumonia. Patchy or nodular-appearing infiltrates have been noted 
in intersitial, alveolar, and lobar distributions in most cases. 
Progression of infiltrates to multilobar or bilateral involvement 
occurs in over half of all cases despite broad spectrum antibiotic 
therapy (48,64,66). Small, usually unilateral, pleural effusions have 
been noted in up to half of all cases. Cavitation and abscess formation 
in LD have been noted consistently only in immunosuppressed patients (48, 
66,75-77). All reports indicate that clearing of the chest x-ray lags 
behind clinical improvement. 
3. Case-Control Studies 
Comparisons of seropositive LD pneumonia cases with seronegative 
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non-LD pneumonia controls in two outbreaks and in two series of 
sporadic cases have suggested that clinical differentiation of LD 
from pneumonia of other causes depends more on the extrapulmonary 
manifestations of disease than on respiratory findings. All of 
these four studies have noted that neurologic symptoms — ranging 
from headache to alterations in consciousness — occur significantly more 
commonly during LD than in other pneumonias. Both studies of out¬ 
break - associated cases have shown a significantly higher frequency 
of diarrhea at some point during the course of LD than in non-LD 
pneumonia; however, when considering only early symptoms, neither 
study of sporadic LD showed this difference. The mean temperature 
on admission of LD pneumonia patients studied in the 1976 Philadelphia 
epidemic was higher than that of seronegative control pneumonia patients. 
In a study of sporadic cases of LD in Iowa, the mean admission temperature 
of the LD pneumonia patients was higher than that of control patients 
with pneumonia due to mycoplasma pneumoniae but was not significantly 
different from patients with pneumococcal pneumonia. Prodromal toxic 
illness with at least four days of fever, as well as hyponatremia, 
lymphopenia, abnormal liver function tests, and early progression of 
infiltrates on chest x-ray were characteristic of sporadic cases of 
LD studied in England. When considered as a group, renal failure, 
hematuria, or abnormal liver function tests were more common in LD 
cases than controls in the Philadelphia study, but the differences 




4. Differential Diagnosis 
The differential diagnosis of a patient with pneumonia ulti¬ 
mately shown to have LD has been discussed in detail in a clinico- 
pathologic conference reported in the New England Journal of Medicine 
(80). Infections due to viruses (influenza, parainfluenza, measles, 
varicella, and adenovirus), bacteria (pneumococcus and staphylococcus), 
chlamydia (psittacosis and Q fever), fungi (coccidiomycosis, histo¬ 
plasmosis, and blastomycosis), as well as mycoplasma, mycobacteria, 
nocardia, malaria, and aspiration pneumonitis were considered. Non- 
inf ectious possibilities reviewed included toxins, drugs, Goodpasture's 
syndrome, idiopathic pulmonary hemosiderosis, pheochromocytoma, thyroid 
storm, and acute rupture of a papillary muscle. Other sources have 
noted that plague, tularemia, Klebsiella pneumoniae, Haemophilus 
influenzae, and atalectasis secondary to obstruction may produce similar 
illness (71,81). 
5. Treatment and Prognosis 
Erythromycin has been suggested as the drug of choice for the 
treatment of LD. However, no clinical trials have been conducted. 
Clinical evidence favoring the use of erythromycin comes from 
the Philadelphia and Vermont outbreaks where significantly lower case- 
fatality ratios were noted in cases treated with erythromycin compared 
with non-matched cases not treated with erythromycin. These data were 
collected retrospectively and without adequate controls. Therefore 
better survival in patients receiving erythromycin may only reflect 
physicians' prescribing practices where persons with mild pneumonia 
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are given erythromycin, and persons with severe pneumonia are treated 
with other antibiotics. 
On the other hand, laboratory data have shown that erythromycin 
is effective therapy in experimental infections with L. pneumophila 
in guinea pigs and embryonated chicken eggs, and that the organism is 
"sensitive" to erythromycin when tested In vitro. 
Other antibiotics that may be useful in specific therapy include 
rifampin and tetracycline, though clinical experience with these drugs 
has been limited. As in any severe pneumonic illness, supportive therapy 
with supplemental oxygen, mechanically assisted ventilation, intravenous 
fluids, and other measures may be essential in the appropriate management 
of patients with LD (9,67,71). 
Early clinical features of LD associated with poor prognosis have 
included findings of high initial respiratory and heart rates, as well 
as laboratory evidence of severe bacterial pneumonia and/or renal 
dysfunction (bilateral infiltrates on chest x-ray, initial arterial 
p02<50 mm Hg, leukocyte count >14,000, >10% band forms, clinical course 
requiring mechanical ventilation, initial serum sodium ^130 meq/L, urea 
nitrogen >20 mg/dL, creatinine >2.0 mg/dL, and hematuria). Death is 
commonly associated with respiratory failure requiring mechanical 
ventilation and is preceded in some cases by shock. Immunosuppression 
and the presence of chronic disease have also been associated with 




Roughly 250 persons were hospitalized with pneumonia in the 
three hospitals in Bridgeport during the late summer of 1978. Forty- 
nine of these pneumonia patients had positive serologic tests for 
Legionnaires' Disease (LD) and constituted the descriptive study of 
the clinical features of LD. To identify clinical features which 
might have distinguished patients with LD pneumonia from patients 
with other types of pneumonia, 28 of these 49 LD cases were compared 
with 29 pneumonia patients who had negative serologic tests for LD; 
both groups were from Bridgeport and had participated in the original 
epidemiologic study. This is termed the case-control study. 
A. ELIGIBILITY CRITERIA 
All persons included in both the descriptive and the case-control 
studies 1) were admitted to one of the three hospitals in Bridgeport, 
2) had onset of illness between August 1 and October 31, 1978, 3) had 
chest x-ray evidence of pneumonia or infiltrate, and 4) were at least 
18 years old. 
B. CASE DEFINITIONS 
Pneumonia patients meeting the eligibility criteria were 
classified as either LD cases or non-LD pneumonia controls on the 
basis of serologic testing for LD in both studies. Patients with 
four-fold or greater rises in titer (reciprocal of dilution) to 128 
or greater were considered confirmed LD cases; those with titers of 
256 or greater, without evidence of a four-fold or greater rise in 
titer, were termed presumptive cases of LD. Patients with titers of 
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32 or less in specimens obtained at least six weeks after the onset 
of illness were classified as seronegative pneumonia controls. 
Patients with elevated antibody titers to both L^. pneumophila and 
Mycoplasma pneumoniae were considered to have had indeterminate 
infections and were excluded from the analysis, as were patients 
with intermediate LD titers of only 64 or 128. The classification 
is summarized below. 
SEROLOGIC BASIS FOR CLASSIFICATION 
OF STUDY SUBJECTS 
NUMBER OF PATIENTS 
1) Descriptive 2) Case-Control 
IFA Titer_ Classification _Study _Study_ 
$128 with four- Confirmed Case 30 17 
fold rise 
$256 without Presumptive Case 19 11 
four-fold rise 
•^32 At least Control 
6 weeks after 
onset 
64-128 or Indeterminate 
Positive tests 




C. STUDY SUBJECTS 
1. The Descriptive Case Study 
All confirmed and presumptive LD cases identified were included 
in a descriptive study of the clinical features of LD. Most of the LD 
cases had been diagnosed around the time of the Bridgeport outbreak by 
local physicians who had ordered serologic tests for LD. However, four 
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of the 35 persons who had had blood specimens obtained during the 
epidemiologic investigation — roughly six months after the out¬ 
break — were found to have LD titers of 256 or greater and were 
therefore included in the descriptive study as presumptive cases 
of LD. 
The majority of the LD cases diagnosed at the time of the 
Bridgeport outbreak were identified from a list of 47 confirmed and 
presumptive cases prepared by the Epidemiology Section of the 
Connecticut Department of Health Services. This list was compiled 
in December, 1978 and included all cases whose serologic tests had 
been performed between August 1 and November 30, 1978, and who were 
residents of either Bridgeport or one of the three surrounding towns 
of Fairfield, Stratford, and Trumbull. Five of these 47 cases did 
not meet the eligibility criteria and were subsequently excluded 
from this study (two had not been hospitalized, one had onset 
before August 1, 1978, one had no evidence of pneumonia on chest 
x-ray, and one had indeterminate infection). Finally, three of the 
confirmed LD cases included in this study — but not listed by the 
state — were identified from hospital records of patients who had 
either been tested for LD or had had positive serologic test results 
for LD. These cases had been excluded from the state list because 
of residence outside of the towns mentioned in two cases and, in 
one case, because a positive convalescent LD titer had not been 
determined until after November 30, 1978. 
In summary, 45 confirmed had presumptive cases of LD diagnosed 
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by their physicians in the fall of 1978 and A presumptive cases of 
LD identified during the epidemiologic investigation in the spring 
of 1979 met the eligibility criteria and have been included in a 
descriptive case study of LD. 
2. The Case-Control Study 
All LD cases and non-LD pneumonia controls who participated 
in the original epidemiologic case-control study, and who met the 
eligibility criteria noted above, were included in a clinical case- 
control study. 
Of roughly 250 pneumonia patients who met the eligibility 
criteria, 123 were Bridgeport residents; of these 123 patients, 57 
consented to participate and were included in the original epidem¬ 
iologic case-control study. Four additional persons who had 
participated in the epidemiologic study, and yet had been excluded 
from the analysis of that study because of delayed serologic results, 
were included in the clinical case-control study. However, four 
other persons who had been included in the epidemiologic study were 
excluded from the clinical case-control study when it was discovered 
that they had either not met the eligibility criteria (three persons) 
or had indeterminate infection (one person). Thus, a total of 57 
consenting individuals meeting all eligibility criteria were classified 
according to the case definitions as confirmed cases, presumptive cases, 
or seronegative controls and were ultimately included in the clinical 
case-control study. (Information on the participation of the 123 




D. SEROLOGIC TESTING 
Serum specimens from patients included in both studies were 
tested by the Connecticut Health Department Laboratory for evidence 
of infection by L. pneumophila. The indirect flourescent antibody 
(IFA) test used by the state laboratory during calendar year 1978 
was performed with LD antigen provided by the CDC which had been 
prepared from ether-killed Philadelphia 1 serogroup 1 organisms grown 
on artificial medium and suspended in normal 3% yolk sac suspension. 
Beginning in January, 1979, this test was modified by the substitution 
of a heat-killed antigen for the ether-killed preparation of 1978. 
The heat-killed antigen was also prepared from Philadelphia 1 sero¬ 
group 1 organisms and provided to the state laboratory by the CDC. 
Data showing the distribution of positive LD titers in 100 unselected 
VDRL specimens according to the method of antigen preparation are 
included in Appendix C. 
In both versions of the test, LD antigen is acetone-fixed to 
glass slides and then incubated with serial dilutions of patients' 
sera and both positive and negative (non-reactive) reference sera 
provided by the CDC1. Next, the slides are washed with phosphate 
buffered saline to remove human antibody not bound to the slides by 
antigen during the incubation. Anti-Legionella human antibody 
present in the test serum is then indirectly stained by incubating 
the slide with flourescein conjugated anti-human antibody prepared 
^ote, however, that non-reactive controls were eliminated from the 
procedure when the antigen was changed in January, 1979. 
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in rabbits (which is also provided to the state laboratory by the CDC). 
After the staining incubation, unbound anti-human flourescein conjugate 
is washed off the slides and coverslips are applied using carbonate 
buffered glycerol mounting medium. Finally, antibody titers are 
determined by examining the slides under a flourescence microscope; 
the highest dilution showing a specified degree of flourescence is taken 
as the end-point (copies of the CDC's unpublished IFA assay protocols 
are included in Appendices D and E). 
The state laboratory routinely standardized its titer determi¬ 
nations with the CDC by submitting some of the specimens it considered 
positive to the CDC for comparison of titer determinations. 
E. DATA COLLECTION 
The names and hospital chart numbers of all study subjects were 
line-listed by hospital without indicating their serologic status. 
Demographic and clinical information were collected from these records 
using an exhaustive clinical abstract form. Details of the admission 
history, physical examination, radiographic, and laboratory findings 
were obtained as available from the attending and resident admission 
notes, reports of consultations, emergency room (ER) sheets, laboratory 
and radiology reports, and — in some instances — from standard nursing 
admission forms. Data pertinent to the course of illness — including 
treatment — were collected from the discharge summary, physician order 
sheets and progress notes, nursing medication and vital signs records, 
and from radiology and laboratory reports. The information collected 
was recorded on the abstract exactly as it appeared in the chart and 
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the specific source of each item of information was noted. 
A data coding manual was developed and used to categorize 
selected information contained in the abstract form. The clinical 
data selected for coding were thought to be important in evaluating 
pneumonia or likely to aid in distinguishing LD pneumonia from 
pneumonia of other causes. When conflicting information was 
reported by different observers regarding the admission history 
and physical examination, the accepted source of information was 
determined in accord with the following hierarchy: resident, intern, 
attending physician, ER physician, ER and floor admitting nurses. 
Exceptions to this rule were made in favor of a concensus of two or 
more physicians who agreed on an issue and yet were in conflict with 
the opinion favored according to the hierarchy. Laboratory findings 
were coded as reported by each of the three hospitals and were compared 
during the analysis against the normal values reported by the laboratory 
where the test had been performed. 
Sample copies of the clinical abstract and the data coding 
manual have been included in Appendices A and B. 
F. DATA ANALYSIS 
Coded data were analyzed using the Statistical Analysis System 
(SAS) available at the Yale Computer Center (82). The analysis had 
two major segments: 1) to compare the LD cases with the non-LD control 
pneumonia patients, and 2) to determine the clinical manifestations 
seen in this cluster of LD pneumonia patients. 
Tests of statistical significance were calculated using the 
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chi-square or Fisher exact test for categorical data and Student's 




A. DESCRIPTIVE CASE STUDY 
Thirty confirmed and 19 presumptive cases of Legionnaires' 
Disease (LD) were identified among persons aged 18 years and older 
who had been hospitalized in Bridgeport, Connecticut with documented 
pneumonia during the late summer and early fall of 1978. Of the 19 
presumptive cases, four (21%) had positive _L. pneumophila IFA titers 
of 4096, five (26%) had titers of 1024, four (21%) had titers of 512, 
and six (32%) had titers of 256. The mean age of all 49 cases was 
63.0 years, with a range from 26 to 87 years. Thirty-seven cases (76%) 
were men (male-to-female ratio of 3.08) and 39 (80%) were white 
(Table 2). 
1. Symptoms 
The frequency of symptoms noted on admission in the 49 cases 
of LD included in this study are listed in Table 3. A history of 
either subjective or objective fever was noted by 96% of cases and 
temperature averaged 103.6° F on admission. In addition to fever, 
many patients gave a history of various constitutional complaints 
including chills (67%), malaise or myalgia (47%), and weakness or 
fatigue (39%). Respiratory symptoms were not prominent in most cases. 
Although nearly two-thirds reported cough1, only half of these cases 
described the production of any sputum. Furthermore, the majority 
of cases with productive cough noted only scant or mucoid sputum. 
Pleuritic chest pain and dyspnea were noted by only 12% and 18% of 
all cases, respectively. Gastrointestinal complaints were reported 
Excluding patients who reported no change in chronic cough. 
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commonly and were noted in some cases in the absence of respiratory 
symptoms. Anorexia (31%) and nausea (31%) were the most frequent of 
these symptoms whereas abdominal pain (18%), vomiting (16%), and 
diarrhea (10%) were considerably less common. Headache was reported 
by 29% of all cases (including two confirmed cases who complained of 
photophobia associated with headache), but prominent neurologic 
symptoms such as confusion (6%), poor coordination (8%), and vertigo 
or dizziness (10%) were uncommon. 
2. Past History 
Table 4 describes the past medical history of the 49 cases. 
Even though no common underlying disorder was present in more than 
30% of cases, nearly two-thirds gave a history of at least one 
chronic illness. Diabetes mellitus, cardiovascular disease, and 
previous pneumonia were noted in the history of 20% to 30%. Chronic 
lung disease — including asthma, "chronic obstructive pulmonary 
disease" (COPD), emphysema, chronic bronchitis, or interstitial 
fibrosis — was present in only 8% of cases, and a similar proportion 
were immuno compromised due to either malignancy or immunosuppressive 
drug therapy. Only one case (2%) had a history of chronic renal 
disease. Cigarette smoking (at least 1/2 pack per day) and heavy 
alcohol use (at least 3 drinks per day) were reported by 49% and 17% 
of cases questioned, respectively, and two-thirds admitted to some 
alcohol use. 
3. Physical Examination 
Findings reported on admission physical examination consistently 
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suggested an acute infectious process, however striking evidence 
of pulmonary involvement was rare (Table 5). More than half of 
the cases appeared acutely ill or febrile and a similar proportion 
were either tachypneic (respiratory rate 25/min. or more) or in 
frank respiratory distress. Rales or rhonchi were present in about 
two-thirds of cases and were frequently the only findings on chest 
examination. Signs of consolidation such as dullness (12%), bronchial 
breath sounds (8%), and egophony (4%) were reported uncommonly. 
Altered mental status, ranging from subtle disorientation or memory 
loss to confusion, abnormal speech, or stupor, was present in nine (22%) 
of 40 cases examined. Abdominal tenderness was found in 20% of cases, 
usually associated with a history of abdominal pain, vomiting, or 
diarrhea. No cases were reported to have rash, myringitis, 
lymphadenopathy, meningeal or focal neurologic signs. 
4. Laboratory Findings and Chest Radiograph 
Laboratory findings are presented in Table 6. Urinalysis was 
remarkable in many cases, with over three-fourths showing at least 
"1+" protein and nearly two-thirds showing "trace" or greater amounts 
of occult blood within three days of admission. Microscopic hematuria, 
pyuria, and granular casts were uncommon. The white blood cell count 
on admission was typically modestly elevated (mean 12,100/mm. ) with 
a left shift (mean neutrophils 76%, mean band forms 7%). The 
erythrocyte sedimentation rate averaged 39 mm./hour in the eight cases 
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who were tested within four days of admission. Hyponatremia1 was 
present in one-third of cases tested on admission. Two-thirds of 
all cases tested within four days of admission were hypophosphatemic2, 
but only 24% were hypocalcemic3 (none were hypercalcemic). Elevations 
of the SGOT (79%), SGPT (74%), and LDH (67%) were also commonly 
present in cases tested within four days of admission whereas abnormal 
total bilirubin (15%) or alkaline phosphatase (22%) were infrequent. 
Seven cases (16%) had evidence of renal insufficiency4 during admission, 
but none of these cases required dialysis. 
An infiltrate was noted in 96% of cases within 24 hours of 
admission, but this finding is strongly biased by the eligibility 
criteria which required documented pneumonia in all cases (and controls) 
included in this study. This finding is important in light of the 
limited nature of the chest symptoms and signs present on admission. 
Pleural effusion was noted on at least one chest x-ray in 14% of cases 
within four days of admission. 
Normal spinal fluid was found in all six of the cases in which 
it was examined. 
1 Serum sodium of 130 mEq/L or less 
2Serum phosphate of 2.2 mg/dL or less 
3Serum calcium of 8,0 mg/dL or less 
4 At least one serum creatinine greater than 2.5 mg/dL or blood 
urea nitrogen greater than 25 mg/dL at least twice. 
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5. Comparison of Confirmed and Presumptive Cases 
In addition to the descriptive results, Tables 3 through 
6 also show the results of a number of comparisons of the clinical 
features between the confirmed and presumptive LD case groups. In 
general, patients in these groups were clinically similar. 
However, mental confusion noted on either history or physical 
examination was reported in only the confirmed case group, though 
this difference was not statistically significant (P=0.107). Chest 
pain of unspecified type was also reported in only the confirmed 
case group, but the combination of either pleuritic or unspecified 
chest pain was present with similar frequency in the presumptive and 
confirmed cases. The odds ratio favoring a history of vomiting in 
presumptive relative to confirmed cases was 3.21 but was not 
statistically significant (P=0.132). 
The proportion of presumptive cases with a history of chronic 
illness was greater than that of confirmed cases in many of the 
categories examined by this study. A history of either COPD, asthma, 
or previous pneumonia was significantly more frequent in the pre¬ 
sumptive case group than in the confirmed case group (P=0.022). No 
other differences in the past history of these groups were statistically 
significant, but a history of compromised immune competence or chronic 
lung disease were also notably more frequent among the presumptive cases. 
With the exception of fever, the findings on admission physical 
examination were similar in both case groups. The average temperature 
on admission was significantly higher in the confirmed case group, 104.1°F, 
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than in the presumptive case group, 102.7° F (P=0.010). Seven (78%) 
of the nine LD cases with an abnormal neurologic exam were confirmed 
cases. 
Of cases tested, abnormal liver function tests and the presence 
of occult blood, protein, and granular casts in the urine were found 
in a greater proportion of confirmed than presumptive cases. These 
differences were not statistically significant except for urinary 
occult blood (P=0.014) and granular casts (P=0.023). Ten (83%) of 
the twelve cases who were hyponatremic on admission were confirmed 
cases, but this difference failed to reach statistical significance 
(P=0.053). The hematologic and radiologic findings were similar in 
the two case groups. 
6. Treatment 
Table 7 presents the findings related to the treatment of the 
49 LD cases with erythromycin. Slightly less than two-thirds of all 
cases received erythromycin within three days after admission to the 
hospital. Similar proportions of confirmed and presumptive cases 
received erythromycin. 
On the average, defervescence1 occurred significantly earlier 
in the course of illness in LD cases treated (mean 8.44 days) compared 
with cases not treated (mean 12.79 days) with erythromycin (P=0.0001). 
While not statistically significant, the average length of admission 
was shorter, the average number of days of supplemental oxygen therapy 
was less, and clearing of pneumonia on chest x-ray was noted earlier 
defined as the first day of illness (in hospital) with temperature 
less than 100.5°F. 
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in the illness of cases treated with erythromycin; however, these 
variables are less direct measures of the course of pneumonia than 
fever and, as much, may be less sensitive. The average number of 
days between onset of symptoms and hospital admission was about four 
days. This interval was similar in the few cases who were treated 
with erythromycin before admission to the hospital. 
7. Summary of the Descriptive Case Study 
Forty-nine pneumonia patients with serologic evidence of L^. 
pneumophila infection were included in the descriptive case study. 
The average age of the cases was 63 years and 76% were men. A history 
of chronic illness was present in two-thirds, and cigarette smoking 
and alcohol use were commonly reported. 
The average period from onset to admission was four days. 
Cases typically gave a history of fever and constitutional symptoms, 
often associated with a minimally productive cough. Anorexia and 
nausea were also commonly reported but a history of diarrhea was 
infrequent. The typical case appeared acutely ill or febrile on 
physical examination. Rales or rhonchi were commonly present but 
other signs of consolidation were rare. Neurologic symptoms and 
signs were infrequent except for headache. Urinalysis commonly showed 
proteinuria and the presence of occult blood. White blood cell counts 
in most cases were modestly elevated with a left shift. Hypophosphatemia 
and elevated SGOT, SGPT, and LDH were common, hyponatremia was found 
in one-third of cases tested. Though 96% of cases had pneumonia on 
the admission chest x-ray, pulmonary signs and symptoms were usually 
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limited. Defervescence occurred significantly earlier in cases 
treated with erythromycin than in cases treated with other 
antibiotics. 
B. CASE-CONTROL STUDY 
Of the 57 persons ultimately included in the case-control 
study, 17 were confirmed cases of LD, 11 were presumptive cases, 
and 29 were seronegative control pneumonia patients. Eight (73%) 
of the 11 presumptive cases had titers of 512 or greater and only 
3 (27%) and titers of 256. The average age of all 28 cases included 
in the case-control study, 63.2 years, was greater than the average 
age of the 29 controls, 57.7 years, but this difference was not 
statistically significant (P=0.196). Men were noted in greater 
proportion in the LD case group than in the control group (71% vs 
48%) but, again, this difference did not reach statistical signifi¬ 
cance (P=0.075). The proportions of non-whites in both cases (14%) 
and controls (24%) were similar and approximated the city-wide 
figure of 17%. 
The results of the case-control study show that although the 
LD cases were similar in many respects to the seronegative control 
pneumonia patients, certain clinical features may be useful in 
distinguishing LD cases from other patients with pneumonia. 
1. History 
Table 8 shows the frequency of symptoms reported by the LD 
cases and the non-LD controls. While commonly present in both 
cases and controls, history of subjective fever was noted significantly 
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more frequently by LD cases (P=0.044) and the average admission 
temperature was significantly higher in the case group than in the 
control pneumonia patients (103.7° F vs 101.8° F, P=0.0002). Five 
of the 28 LD cases (18%) reported arthralgia compared to none of 
the 29 controls (P=0.017). Cough, sputum, pleuritic chest pain, 
and dyspnea were all more frequently present in the non-LD pneumonia 
controls than in the cases, and these differences were statistically 
significant for dyspnea (41% for controls, 14% of cases, P=0.023), 
and history of either chest pain, dyspnea, or wheezing (59% of controls, 
32% of cases, P=0.015). Non-LD pneumonia controls also gave a history 
of either eye pain or ear pain or sore throat more frequently than the 
cases (28% of controls, 7% of cases, P=0.044). Gastrointestinal 
symptoms were present with similar frequency in cases and controls; 
however, control pneumonia patients had a history of vomiting somewhat 
more frequently than the cases (27% of controls, 7% of cases, P=0.107). 
There were no significant differences in the frequency of any neurologic 
symptoms, or combination of symptoms, between cases and controls. 
Comparison of the past medical history of the LD cases and the 
controls showed that both groups reported history of illness, cigarette 
smoking, and alcohol use with similar — though striking — frequency 
(Table 9). History of both chronic lung disease and diuretic use were 
more frequently noted by controls, but these differences were not 
statistically significant (P=0.060 for both comparisons). 
2. Physical Examination 
Table 10 lists the findings present on admission physical 
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examination in the LD cases and the non-LD pneumonia controls. As 
mentioned, the mean temperature of the case group was significantly 
higher than that of controls. As might be expected, the average 
admission pulse rate was also greater in the cases, 110, than the 
controls, 100 (P=0.035). Wheezes heard on chest exam were found in 
a greater proportion of the controls, 67%, than in the cases, 31% 
(P=0.049). Other features of the physical exam were similar in 
cases and controls, including features of the neurologic exam. 
3. Laboratory Findings and Chest Radiograph 
Laboratory findings noted in LD cases and non-LD control 
pneumonia patients are compared in Table 11. Occult blood was 
present in the urine of 86% of LD cases tested, a significantly 
greater proportion than that of controls, 37% (P=0.0007). LD cases 
were also found to have "1+" or greater proteinuria significantly 
more frequently than controls (70% vs 37%, P=0.022). Although not 
statistically significant, there was a suggestion that the average 
admission total white blood cell count was higher in the LD case 
group (mean for cases 13,040/mm.mean for controls 11,070/mm.^, 
P=0.084). Eight (53%) of 15 LD cases tested within four days of 
admission were hypophosphatemic, compared with only one (8%) of 13 
controls (P=0.028). While not statistically significant, elevated 
LDH (71% vs 41%, P=0.092), SGPT (64% vs 33%, P=0.146), and hypo¬ 
natremia (35% vs 12%, P=0.060) were notably more often present in 
the LD cases. Evidence of renal insufficiency was noted with 




Although an infiltrate was seen with similar frequency on 
the admission chest x-ray of cases and controls, there was a 
suggestion that pleural effusion was present more commonly in cases 
(21%) than controls (7%), but this finding did not reach statistical 
significance (odds ratio = 3.68, P=0.114). 
4. Treatment 
A significantly greater proportion of LD cases, 75%, received 
erythromycin within three days of hospital admission when compared 
with non-LD control pneumonia patients, 45% (P=0.020), as shown in 
Table 12. 
Measures of the length of illness of the non-LD pneumonia 
controls who were treated with erythromycin are compared with those 
of controls not treated to show that the differences in morbidity 
found in the LD cases were not present in non-LD pneumonia patients. 
5. Summary of the Case-Control Study 
The clinical features of 28 LD cases were compared with those 
of 29 non-LD pneumonia controls in the case-control study. Features 
noted significantly more frequently in the cases, and which therefore 
may allow early clinical differentiation of LD cases from patients 
with other pneumonias, included: history of subjective fever, 
arthralgia, presence of high fever on admission, minimal chest symptoms 
and signs; and laboratory findings such as: the presence of occult 
blood or protein in the urine, hypophosphatemia, and possibly 
hyponatremia, elevated LDH and SGPT. In addition to chest symptoms 
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and signs, non-LD controls gave a history of chronic lung disease 
as well as either eye pain or ear pain or sore throat more often 
than cases. Neither neurologic nor gastrointestinal symptoms were 
reported by significantly more cases than controls. 
LD cases received erythromycin within three days of 





During the epidemiologic investigation of the Bridgeport out¬ 
break, it became apparent that local physicians were selective when 
choosing which patients to test for Legionnaires' Disease (LD). Of 
all serologic tests for LD submitted in Connecticut during 1978, the 
proportion which were positive was significantly higher in samples 
from the Bridgeport area, 46%, than in samples from the rest of the 
state, 16% (P less than 0.001, Table 2, Appendix F). Later investi¬ 
gation of unselected persons who had had pneumonia at the same time 
found that only 11% were positive for LD. This suggested that 
physicians were able to diagnose patients who actually had LD from 
clinical features of the illness. The present study was conducted 
to explore the hypothesis that persons with LD pneumonia were 
clinically distinct from other pneumonia patients. 
A. THE DESCRIPTIVE CASE STUDY 
The descriptive study of Bridgeport LD cases indicates that 
they were demographically and clinically similar to cases described 
in other large outbreaks (42,48,64,66). The clinical presentation 
of high fever and prominent constitutional symptoms with only modest 
respiratory symptoms and signs was often suggestive of atypical 
pneumonia: though, occasionally, prominent gastrointestinal or 
neurologic symptoms dominated the early illness. All of the 
laboratory features notably present in the Bridgeport cases have 
been mentioned in earlier reports (71). 
However, our cases were also different in some respects 
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from those in other reports. Most notably, diarrhea and prominent 
neurologic symptoms were noted less frequently in Bridgeport than 
in earlier reports. These contrasts appear to reflect methodologic 
differences between our study — which focused on the early clinical 
presentation — and other studies — which generally included findings 
noted at any time during the illness. Evidence favoring this ex¬ 
planation is present through comparison of our findings with those 
of two smaller studies also designed to investigate the early clinical 
differentiation of LD from other pneumonia patients and through com¬ 
parison with the admission findings in cases from the 1976 Philadelphia 
epidemic. Neither of the earlier comparative studies reported the 
unusually frequent occurrence of diarrhea (69,79). Furthermore, results 
presented in the large descriptive study by Tsai et al. show that the 
symptoms of the Philadelphia cases — including gastrointestinal and 
neurologic — were similar on admission in all respects to cases in 
Bridgeport (66). 
1. Confirmed vs Presumptive Cases 
Comparison of the confirmed and presumptive Bridgeport LD cases 
showed that these groups were clinically similar to each other in many 
respects. However, the differences which were found generally were in 
the same features which differentiated LD cases from other pneumonia 
patients in the case-control study. Furthermore, the direction of 
these differences indicated that — as a group — the clinical features 
of the presumptive cases were intermediate between those of the confirmed 
LD cases and those of the non-LD controls. 
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Clearly, these differences may be due to the inappropriate 
inclusion of some non-LD pneumonia patients in the presumptive 
case group, though 13 of the 19 presumptive cases had positive LD 
titers of at least 512 and the likelihood of a false positive 
diagnosis in these cases is low. Another possible reason, however, 
is that a subset of all of the LD cases were actually clinically 
similar on admission to other pneumonia patients. If this were 
the case, one would expect the physicians not to order acute serum 
specimens for confirmation of LD on these persons until failure to 
respond to therapy or other unusual features suggested the possi¬ 
bility of LD. Unfortunately, the extent to which each of these 
possible explanations is responsible for the differences found 
between the confirmed and presumptive cases cannot be determined 
from the results of this study. 
B. THE CASE-CONTROL STUDY 
Several of the differences found between cases of LD and other 
pneumonia patients in Bridgeport support the results of earlier case- 
control studies. Fever has consistently been reported to be signif¬ 
icantly higher in cases of LD and evidence to this effect was found 
on both history and physical examination in Bridgeport cases (64,69, 
74,79). As mentioned, however, this study did not show differences 
in the reportedly characteristic features of headache, confusion, and 
diarrhea; though, again, other studies generally have not been focused 
on findings present only up until presentation (64,74). Although other 
reports have mentioned that respiratory tract symptoms are generally 
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modest in LD, this study found that a history of either chest pain, 
dyspnea, or wheezing was significantly less frequently present in 
the cases than in the controls. The laboratory findings noted to 
occur more frequently in the LD cases in Bridgeport also confirm 
and extend the results of earlier studies. Although proteinuria 
and hypophosphatemia have both been described in LD, these findings 
have not previously been noted to be significantly more common in 
cases of LD than other pneumonia patients. 
The differences between the results of our case-control study 
and earlier investigations may reflect differences in the size and/or 
design of the studies. Earlier studies have generally been smaller 
than ours and,in some cases, included clinical findings present 
beyond the early portion of the illness. It is also possible that 
the relatively heterogeneous "other pneumonia" control groups differed 
significantly in the various geographical regions. Furthermore, some 
of the presumptive LD cases included in this study may have been 
patients with other types of pneumonia. Finally, though apparently 
unlikely, there may have been actual differences between the 
Bridgeport LD cases and those of the other studies. 
C. TREATMENT 
The efficacy of erythromycin in treating LD has been suggested 
by earlier comparisons of mortality rates and by the results of various 
in vitro laboratory tests. The findings of the present uncontrolled 
study suggest that erythromycin treatment may reduce morbidity due to 
LD. Defervescence in hospital occurred more than four days earlier 

on average in LD cases treated with erythromycin within three days 
of hospital admission (P=0.0001). Other less direct measures 
consistently suggested that erythromycin effectively curtailed the 
duration of illness, but these findings did not reach statistical 
significance. Because only two fatal cases of LD were diagnosed, 
and because most fatal cases of pneumonia were not tested for 
LD, this study could not test the efficacy of erythromycin with 
regards to mortality. 
Pneumonia patients later shown to be cases of LD were treated 
with erythromycin by local physicians significantly more frequently 
than pneumonia patients whose serologic tests were ultimately negative 
for LD. This finding provides additional, independent support for 
the original hypothesis that cases of LD were clinically recognizable 
by physicians. 
D. LIMITATIONS OF THE STUDY 
The reliability of the results of this study may be limited 
by some of the features of a study of this type. 
The impact of any result shown to exist at a given level of 
statistical significance is diminished in proportion to the number 
of tests performed in discovering that result. Although the findings 
of this study may be questioned on the grounds that they result from 
large numbers of comparisons, the fact that they agree closely with 
earlier studies is suggestive that this problem did not substantially 
effect our results. 
Data collected for this study were derived from the medical 
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records of the Bridgeport community hospitals. As such, the results 
of this study are subject to limitations in the detail of available 
clinical reports. However, this limitation may be "appropriate" in 
that the vast majority of cases of LD have been seen by physicians 
in community hospitals. Therefore, useful recommendations regarding 
the clinical diagnosis of LD should ideally be tailored to fit the 
clinical data routinely available to community-hospital-based physicians. 
The possible inclusion of non-LD pneumonia patients in the 
presumptive case group and the somewhat limited participation of the 
original sample frame1 represent important potential sources of bias 
in our findings. If non-LD pneumonia patients were included as cases 
in our study, however, the effect would be a tendency to diminish 
(and not increase) the statistical significance of the differences 
noted between the cases and the controls. The possible effects of 
non-participation of the sample frame on our results are unknown. 
However, the finding of the epidemiologic study that there were no 
apparent differences between persons included in the study and those 
who were not included suggests that the participants were a relatively 
unbiased subset of all possible study subjects. 
E. SUMMARY AND RECOMMENDATIONS 
The results of the case-control study suggest a number of easily 
obtained clues to the differential diagnosis of LD pneumonia. History 
and evidence of high fever (over 102° F) on admission associated with 
an infiltrate and only modest chest symptoms and signs were 
1As detailed in Tables 5 and 6, Appendix F 
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characteristic of cases of LD in Bridgeport. Routine admission 
laboratory findings which were particularly suggestive of LD included 
urinary occult blood and protein, hypophosphatemia, and elevations 
of LDH and SGOT. Finally, there was evidence that early treatment 
with erythromycin may significantly reduce morbidity due to LD. 
At this time, then, when presented with a possible case of 
LD physicians should obtain an acute phase serology specimen and 
consider early institution of erythromycin therapy. 
A prospective study of all patients with summertime pneumonia 
is recommended to address many of the limitations of this and other 
retrospective clinical studies of LD. Such a study would ideally 
be performed during the months when the incidence of LD is maximal 
in an area hyperendemic for infection by L^. pneumophila so that 
an adequate number of cases could be identified. Biases related to 
the retrospective selection of study subjects, and the limited 
sensitivity of studies dependent on data obtained from community 
hospital records, would both be minimized in a prospective study 
which would allow the collection of clinical and epidemiologic data 
from all patients hospitalized with pneumonia in a uniform and 
complete fashion. 
In sum, this study describes the clinical features of cases 
of Legionnaires' Disease from an epidemic in Bridgeport, Connecticut 
and suggests that local physicians were able to effectively diagnose 
and treat cases of LD, apparently because of a distinct clinical 
presentation. Previously limited evidence supporting erythromycin 

as the drug of choice for LD is strengthened by findings that 
morbidity due to LD was reduced in cases treated early in the 
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Table 2. Age, Sex, and Race of Legionnaires' Disease Case Patients and 
Non-Legionnaires' Disease Control Pneumonia Patients According to 
Sero-Diagnostic Status in the Descriptive Case Study and in the 
Case-Control Study 
DESCRIPTIVE CASE STUDY N 
AGE 
Mean (Years) SBM* Range (Years) P Value2 
All Cases . 
All Confirmed Cases . . 




49 63.0 2.575 26 - 87 
30 61.6 2.174 26 - 87 
19 65.2 3.209 32 - 86 
28 63.2 2.565 32 - 87 





S E X 
DESCRIPTIVE CASE STUDY Men Women Sex Ratio P Value 
All Cases ...  . • 37 12 3.08 
All Confirmed Cases .... 6 4.00 
0.356 
All Presumptive Cases . . . • • 13 6 2.17 
CASE-CONTROL STUDY 
Cases . . . 20 e 2.50 
1 
Controls. 15 0.93 
0.073 
DESCRIPTIVE CASE STUDY 
RACE 
Whites Non-Whites P Value 
All Cases. 39 
All Confirmed Cases. 22 




\ | °-3“6 
^■Standard Error of the Mean 
^P values calculated using t-test under the assumption of equal or unequal 
variances, as appropriate; or chi-square test for comparison of proportions 
♦Odds Ratio greater than 3*0; P value greater than 0.05 

62 
Table 3. Frequency of Symptoms on Admission in 49 Cases of Legionnaires' 
Disease According to Case Status 










Fever, Subjective . . 85.7 86.7 84.2 
Objective. . 61.2 70.0 47.4 
Subjective or Objective. . . . . 95.7 96.7 94.1 
in Chief Complaint . . 77.5 80.0 73.7 
Chills. . 67.3 66.7 68.4 
Sweats. . 26.5 30.0 21.0 
Malaise... . 38.8 36.7 42.1 
Myalgia . . 26.5 30.0 21.0 
Malaise or Myalgia. . 46.9 46.7 47.4 
Arthralgia... . 10.2 10.0 10.5 
Back Pain  . 10.2 10.0 10.5 
Arthralgia or Myalgia or Back Pain. . 
or Neck Pain 
. 45.7 47.6 42.9 
Headache. . 28.6 26.7 31.6 
Weakness or Fatigue . . 38.8 36.7 42.1 
Vertigo or Dizziness. . 10.2 6.7 15.8 
Confusion . 6.1 10.0 0.0 + 
Poor Coordination . 8.2 6.7 10.5 
Confusion or Poor Coordination or . . 
Weakness or Fatigue 
. 42.9 40.0 47.4 
Any Neurologic Symptom (Headache, . . 
Confusion, Poor Coordination, Weakness 





Eye Pain or Ear Pain or Sore Throat . . 10.2 10.0 10.5 
Cough. • 65.3 60.0 73.7 
Sputum, Purulent or Hemptysis .... 7.9 7.7 8.3 
Scant or Mucoid . . 23.7 23.1 25.O 
Any Type. . 36.6 35.7 38.5 
Chest Pain, Pleuritic . . 12.2 10.0 15.8 
Unspecified Type. 6.1 10.0 0.0 + 
Pleuritic or Unspecified. . 18.4 20.0 15.8 
Dyspnea, Unspecified Type . . 16.3 16.7 15.8 
Any Type . . 18.4 16.7 21.0 
Any Chest Pain, Dyspnea, or Wheezing. . 34.8 37.0 31.6 
Anorexia. . 30.6 30.0 31.6 
Abdominal Pain or Cramps. . 18.4 16.7 21.0 
Nausea. . 30.6 30.0 31.6 
Vomiting. . 16.3 10.0 26.3 + 
Diarrhea. . 10.2 10.0 10.5 
Nausea or Vomiting.. . 34.9 32.1 40.0 
Abdominal Pain, Nausea, Vomiting, or. 
Diarrhea 
. 46.8 46.4 47.4 
Dysuria, Nocturia, Urgency, Frequency, . 14.3 13.3 15.8 
or Hematuria 
+ Odds Ratio (Confirmed vs Presumptive) greater than 3.0* P value greater than C.05 

63. 
Table 4. Past Medical History of 49 Cases of Legionnaires' Disease 
According to Case Status 









(N«19) P Value1 
History of: 
Pneumonia . . 20.4 13-3 31.6 0.1226 
CCPD^ or Asthma . 8.2 3-3 15.8 0.1208 + 
CCPD, Asthma, or Pneumonia. . 24.5 13.3 42.1 0.0225 * * 
High Blood Pressure .... . 12.2 13.3 10.5 0.7702 
Cardiovascular Disease. . . 
(Myocardial Infarction, 
Angina Pectoris, Congestive 
Heart Failure, "ASCVD") 
. 20.4 20.0 21.0 0.9290 
High Elood Pressure or. . . 
Cardiovascular Disease 
. 28.6 30.0 26.3 0.7809 
Diabetes Mellitus . . 26.5 23.3 31.6 0.5241 
Chronic Renal Disease . . . 2.1 3.3 0.0 0.4337 
Cancer or Corticosteroid or 
Cytotoxic Therapy 
8.2 3.3 15.8 0.1208 + 
Any Chronic Illness (All. . 
noted above) 
. 65.3 56.7 78.9 0.1092 
CONFIRMED PRESUMPTIVE 
ALL CASES CASES CASES 
HABITS Number3 {%) Number Number itl P Value 
Smoking 
None . . 












(43.8)J |- 0.5675 
Drinking 
None or ' 
Regular, 
'Social" .... 











|- 0.1085 + 
MEDICATIONS 
Diuretic . . 5/49 (10.2) 4/30 (13.3) 1/19 ( 5.3) O.3632 
Aspirin or Acetaminophen . • 15/49 (30.6) 8/30 (26/7) 7/19 (36.8) 0.4485 
lp value calculated using chi-square or Fisher exact tests, as appropriate 
2C0PD includes "COPD", Emphysema, Chronic Bronchitis, or Interstitial Fibrosis 
^Number with History/Number Questioned 
*P value less than 0.05 
+0dds Ratio (Confirmed vs Presumptive) greater than 3•0 * P value greater than 0.05 

64. 
Table 5. Vital Signs, Physical Examination Findings, and Selected Combinations 
of Symptoms and Signs on Admission in 49 Cases of Legionnaires' 
Disease According to Case Status 
CASE STATUS 
CONFIRMED PRESUMPTIVE 
ALL CASES CASES CASES 
VITAL SIGNS Mean SEM Mean SEM Mean SEM 
Temperature . . 103.6 0.294 104.1 0.196 102 .7 0.294 0.0104 * * 
Pulse Rate. . 103.6 3.792 109.6 3.448 99.4 4.317 0.0715 
Respiratory Rate. . . . . 24.9 1.068 25.0 1.024 24 .8 1.136 0.9108 
CAS E S T A T U S 
CONFIRMED PRESUMPTIVE 
ALL CASES CASES CASES 
FINDINGS Number3 (%) Number -An Number [%) P Value 
Respiratory Distress . 
or Tachypnea 
. 19/36 (52.8) 11/24 (45.8) 8/12 (66.7) 0.238 
Acutely Ill or Febrile 
Appearance 
. 23/40 (57.5) 13/25 (62.5) 10/15 (37.5) 0.364 
Erythematous Pharyngeal 
Mucosa 
. 11/30 (36.7) 5/18 (27.8) 6/12 (50.0) 0.216 
Rales. . 27/44 (61.4) 17/26 (65.4) 10/18 (55.6) 0.510 
Rhonchi. . 11/28 (39.3) 7/16 (43.7) 4/12 (33.3) 0.576 
Wheezes. . 6/25 (24.0) 4/14 (28.6) 2/11 (18.2) 0.546 
Rales, Rhonchi, or . . 
Wheezes 
. 33/48 (68.7) 20/29 (69.0) 13/19 (68.4) 0.968 
Abdominal Tenderness . . 10/49 (20.4) 4/30 (13.3) 6/19 (31.6) 0.123 




Abnormal Neurologic. . 
Exam (Altered Mental 
. 9/46 (19.6) 7/29 (24.1) 2/17 (11.8) 0.307 
Status, Abnormal Gait, 
Focal Signs) 
CAS E S T A T U S 
CONFIRMED PRESUMPTIVE 
ALL CASES CASES CASES 
SYMPTOMS OR SIGNS Number {%) Number n Number (%) P Value 
Sore Throat or ... . 
Erythematous Pharynx 
. 13/36 (36.1) 6/21 (28.6) 7/15 (46.7) 0.265 
Abdominal Pain or. . . 
Tenderness 
. 15/49 (30.6) 8/30 (26.7) 7/19 (36.8) 0.451 
Confusion on History . 
or Physical Exam 
. 7/10 (70.0) 7/9 (77.8) 0/1 (0.0) 0.107 + 
Any Neurologic Symptom . 36/49 (73.5) 21/30 (70.0) 15/19 (78.9) 0.489 
or Abnormal Neurologic 
Exam 
^■Standard Error of the Mean 
values calculated using t-test under the assumption of equal or unequal 
variances, as appropriate* or chi-square test for comparison of proportions 
3Number with Finding/Number Examined 
*P value less than 0.05 
+Odds Ratio (Confirmed vs Presumptive) greater than 3«0> P value greater than 0.05 

65. 
Table 6. Laboratory Findings in 49 Cases of Legionnaires’ Disease According 







N Mean SEM2 
CASES 
N Mean SEM P Value 
Admissions 
W.E.C. Count (xl03) . . 46 12.15 28 12.64 0.732 18 11. 39 0.731 0.2565 
Band Forms (#) . . . . 46 7.17 28 7.79 1.174 18 6. 22 1.754 0.4450 
Neutrophils (#) . . . . 46 76.22 28 76.50 1.512 18 75. 78 2.402 0.7897 
Lymphocytes (#) . . . 46 13.03 2e 12.93 1.284 18 13. 18 2.439 0.9218 
Max. within 4 Days of 
Admissions 
E.S.R. (mm./hour) . . . 8 39.25 7 39.29 6.406 1 34. 00- 0.7803 
Max. during Admissions 









Number (#) P Value 
Max. within 3 Days of 
Admissions 
Protein, 1+ (21-75 mg#) . . 34/44 (77.3) 23/27 (85.2) 11/17 (64.7) 0.1145 + 
or Greater 
Occult Blood, "Trace" Amt . 25/42 (59.5) 19/27 (70.4) 6/15 (40.0) 0.0547 + 
or Greater 
Occult Blood, "Small" Amt . 19/42 (45.2) 16/27 (59.3) 3/15 (20.0) 0.0143 * 
or Greater 
White Blood Cells, 1+ 11/44 (25.0) 8/27 (29.6) 3/17 (17.6) 0.3714 
(6-10/hpf) or Greater 
Red Blood Cells, 1+ . 9/44 (20.4) 5/27 (18.5) 4/17 (23-5) 0.6883 
(6-10/hpf) or Greater 
Granular Casts, 1+. . 7/44 (15.9) 7/27 (25.9) 0/17 ( 0.0) 0.0232 * 
(6-10/hpf) or Greater 
CHEMISTRY 
On Admissions 
Sodium 130 mEq/L or Less. . 12/36 (33.3) 10/22 (45.4) 2/14 (14.3) O.O531 + 
Within 4 Days of Admissions 
Phosphorus 2.2 mg/dL. . . . 21/33 (63.6) 13/19 (68.4) 8/14 (57.1) 0.5056 
or Less 
Calcium 8.0 mg/dL or ] Less . 8/33 (24.2) 5/19 (26.3) 3/14 (21.4) 0.7461 
Abnormal^ Total BILI. ... 5/34 (14.7) 5/21 (23.8) 0/13 ( 0.0) 0.0731 + 
Abnormal SG0T . . . . 22/28 (78.6) 16/19 (84.2) 6/9 (66.7) 0.2907 
Abnormal SGPT .... 14/19 (73.7) 13/17 (76.5) 1/2 (50.0) 0.4213 
Abnormal LDH. 18/27 (66.7) 12/20 (60.0) 6/7 (85.7) 0.2142 + 
Abnormal ALK PH0S . . 8/36 (22.2) 5/22 (22.7) 3/14 (21.4) 0.9272 
Any Abnormal LFT. . . 28/40 (70.0) 20/25 (80.0) 8/15 (53.3) 0.0780 + 
iNumber Tested, One confirmed LD case with Chronic Lymphocytic Leukemia is not 
included in the Hematology results 
^Standard Error of the Mean 
Value calculated using t-test under the assumption of equal or unequal 
variances, as appropriatej or chi-square test for comparison of proportions 
^Number with Finding/Number Tested 
-At Least. One Assay Result Greater than the Upper Limit of Normal for the Test 
Notedj Upper Limits of Normal are Different in the Three Hospitals in Bridgeport 
and this has been Accounted for in the Data 
*P value less than 0.05 
+Cdds Ratio (Confirmed vs Presumptive) greater than 3.0j P value greater than 0.05 

66. 
Table 7. Frequency of Treatment of 49 Cases of Legionnaires’ Disease with 
Erythromycin and a Comparison of Length of Illness in Cases Treated 
vs Cases Not Treated with Erythromycin 
FREQUENCY OF TREATMENT 
CONFIRMED PRESUMPTIVE 
ALL CASES CASES CASES 
PERIOD WHEN TREATED Number1 (Jt) Number (%) Number {%) P Value2 * 
Erythromycin either Before 
Admission or Up to the Third 
Hospital Day . 34/49 (69.4) 22/30 (73.3) 12/19 (63.2) 0.4514 
Erythromycin either Before 
Admission or Up to the Third 
Hospital Day, Not PEN Allergic . 27/49 (55.D 18/30 (60.0) 9/19 (47.4) 
- 0.6773 
PEN Allergic . . . 7/49 (14.3) 4/30 (13.3) 3/19 (15.8) 
Erythromycin Before 
Admission.. 6/49 (12.2) 3/30 (10.0) 3/19 (15.8) 0.5469 
Erythromycin Before 
Admission, Not PEN Allergic. . . 4/49 ( 8.2) 3/30 (10.0) 1/19 ( 5.3) 
PEN Allergic. 2/49 ( 4.1) 0/30 ( 0.0) 2/19 (10.5) 
- 0.1719 
Erythromycin Within 3 Days 
After Admission. ... . 31/49 (63.3) 21/30 (70.0) 10/19 (52.6) 0.2191 
Erythromycin Within 3 Days After 
Admission, Not PEN Allergic. . . 25/49 (51.0) 17/30 (56.7) 8/19 (42.1) ' 
- 0.4692 
PEN Allergic. 6/49 (12.2) 4/30 (13.3) 2/19 (10.5) 
T R E A T M ENT S T A T U S 
ALL CASES TREATED- ALL CASES NOT TREATED 
WITH ERYTHROMYCIN^ WITH ERYTHROMYCIN 
INTERVAL N4 Mean SEM5 N Mean SEM P Value 
Onset to Admission (Days) . . .34 4.06 0.441 15 4.87 0.827 0.3522 
Admission to Discharge (Days) .34 13.85 1.892 15 18.67 3.172 0.1804 
Day of Illness, Defervescence 
(First Hospital Day with Max. 
.32 8.44 0.514 14 12.79 1.054 0.0001 * 
Temperature Less than 100.5° F) 
Days Treated with .  
Supplemental Oxygen 
3.67 0.890 10 5.20 1.672 0.4039 
Day of Illness, Clearing. . . .28 11.93 0.738 13 15.00 1.652 0.0554 
First Noted on Chest X-Ray 
^■Number Treated/Total Number 
2P values calculated using chi-square test for comparison of proportions; or t-test 
under the assumption of equal or unequal variances, as appropriate, for comparison 
of means 
-^Either Before Admission or Up to the Third Hospital Day 
4Total Number 
^Standard Error of the Mean 
*P value less than 0.05 

67. 
Table 8. Frequency of Symptoms on Admission in Cases of Legionnaires' 1 Disease 
and in Non-Legionnaires' Disease Control Pneumonia Patients 





(N«29) P Value^ 
Fever, Subjective ....  92.9 72.4 0.044 * 
Objective. .  60.7 41.4 0.144 
Subjective or Objective. 92.9 92.3 0.939 
in Chief Complaint . 78.6 55.2 0.061 
Chills. 64.3 62.1 0.662 
Sweats. 21.4 17.2 0.689 
Malaise ....  39.3 31.0 0.514 
Myalgia  32.1 24.1 0.501 
Malaise or Myalgia. 50.0 44.8 0.696 
Arthralgia. 17.9 0.0 0.017 * 
Back Pain . 10.7 6.9 0.610 
Arthralgia or Myalgia or Back Pain or . 
Neck Pain 
• 32.3 27.6 0.346 
Headache. 21.4 17.2 0.689 
Weakness or Fatigue . 39.3 3^.5 0.707 
Vertigo or Dizziness. 3.6 10.3 0.317 
Confusion .....  7.1 10.3 0.669 
Poor Coordination  14.3 6.9 0.363 
Confusion or Poor Coordination or . . . 
Weakness or Fatigue 
• 46.6 37.9 0.516 
Any Neurologic Symptom (Headache, . , . 
Confusion, Poor Coordination, Weakness, 
Fatigue, Vertigo, Seizure, Syncope, 
Memory Deficit) 
• 64.3 56.6 0.660 
Eye Pain or Ear Pain or Sore Throat . . • 7.1 27.6 0.044 * 
Cough . 64.3 79.3 0.207 
Sputum, Purulent or Hemoptysis. 4.5 1-3.0 1 
0.133 
Scant or Mucoid . 22.7 ^3.5 j 
Any Type. 28.6 51.7 0.078 + 
Chest Pain, Pleuritic  10.7 31.0 0.060 + 
Unspecified Type. 10.7 10.3 0.964 
Pleuritic or Unspecified. . • 21.4 37.9 0.173 
Dyspnea, Unspecified Type . 14.3 37.9 0.043 * 
Any Type . 14.3 41.4 0.023 * 
Any Chest Pain, Dyspnea, or Wheezing. . • 32.1 58.9 0.015 * 
Anorexia. 31.0 44.8 0.330 
Abdominal Pain or Cramps. 7.1 13.8 0.407 
Nausea. 21.4 17.2 0.689 
Vomiting. 10.7 27.6 0.107 + 
Diarrhea... 7.1 10.3 0.669 
Nausea or Vomiting. 21.4 27.6 0.587 
Abdominal Pain or Nausea or Vomiting. . 
or Diarrhea 
• 32.1 34.5 0.851 
Dysuria, Nocturia, Urgency, Frequency,, 
or Hematuria 
• 17.9 6.9 0.207 
*P values calculated using chi-square or Fisher exact tests, as appropriate 
*P value less than 0.05 
+Odds Ratio (Cases vs Controls) greater than 3•0 * P value greater than 0.05 

68. 
Table 9. Past Medical History of Cases of Legionnaires' Disease and 
Non-Legionnaires' Disease Control Pneumonia Patients 





(«-29) P Value1 
History ofi 
Pneumonia . 28.6 13.8 0.1713 
COFD2 or Asthma . 10.7 31.0 0.0599 + 
COPD, Asthma, or Pneumonia. 32.1 3^.5 0.8514 
High Blood Pressure .... 10.7 17.2 0.4708 
Cardiovascular Disease. . . 
(Myocardial Infarction, 
Angina Pectoris, Congestive 
Heart Failure, "ASCVD") 
21.4 31.0 0.4103 
High Blood Pressure or. . . 
Cardiovascular Disease 
28.6 41.4 0.3111 
Diabetes Kellitus . 25.0 20.7 0.6982 
Chronic Renal Disease . . . 0.0 3.4 0.5088 
Cancer or Corticosteroid or 
Cytotoxic Therapy 
7.1 0.0 0.2368 
Any Chronic Illness (All. . 
noted above) 







Number {%) P Value 
Smoking 
None. 






10/26 (38.5) _ 0.2699 
Drinking 
None or "Social" . 






5/25 (20.0) 0.2691 
MEDICATIONS 
Diuretic . 3/28 (10.7) 9/29 (31.0) 0.0599 + 
Aspirin or Acetaminophen . . . 9/28 (32.1) 8/29 (27.6) 0.7071 
1? value calculated using chi-square or Fisher exact tests, as appropriate 
2COPD includes "COFD", Emphysema, Chronic Bronchitis, or Interstitial Fibrosis 
3Number with History/Number Questioned 
♦Odds Ratio (Cases vs Controls) greater than 3•0; P value greater than 0.05 

69. 
Table 10. Vital Signs, Physical Examination Findings, and Selected Combinations 
of Symptoms and Signs on Admission in Cases of Legionnaires' 





Mean SEM P Value2 
Temperature . 0.264 101.8 0.382 0.0002 * * 
Pulse Rate. . . . 110.3 3.116 100.3 3.406 0.0350 * 
Respiratory Rate. . . . 0.886 24.9 1.215 0.6202 
CAS es CONTROLS 
FINDINGS Number iJii Number (*) P Value 
Respiratory Distress. 
or Tachypnea 
12/20 (60.0) 15/23 (65.2) 0.7241 
Acutely Ill or Febrile. . . . 
Appearance 
12/22 (54.5) 9/21 (42.9) 0.4434 
Erythematous Pharyngeal . . . 
Mucosa 
5/13 (38.5) 6/16 (37.5) 0.9577 
Rales.. 20/27 (74.1) 15/23 (65.2) 0.4958 
Rhonchi . 8/18 (44.4) 7/15 (46.7) 0.6964 
Wheezes  5/15 (31.2) 10/15 (66.7) 0.0466 * 
Rales, Rhonchi, or Wheezes. . 22/28 (76.6) 20/26 (76.9) 0.8843 
Abdominal Tenderness. 4/28 (14.3) 6/26 (23.1) 0.4060 
Altered Mental Status .... 
(Consciousness, Confusion, 
Orientation, Memory Deficit, 
Speech, "Slow") 
4/23 (17.4) 6/23 (26.1) 0.4747 
Abnormal Neurologic Exam. . . 
(Altered Mental Status, 
Abnormal Gait, Focal Signs) 
4/26 (15.4) 6/28 (21.4) 0.5678 
CASES CONTROLS 
SYMPTOMS OR SIGNS Number (%) Number (*) P Value 
Sore Throat or Erythematous . 
Pharynx 
6/19 (31.6) 9/17 (52.9) 0.1943 
Abdominal Pain or Tenderness. 5/28 (17.9) 7/28 (25.0) 0.5148 
Confusion on History or . . . 
Physical Exam 
4/6 (66.7) 6/7 (85.7) 0.4164 
Any Neurologic Symptom or . . 
Abnormal Neurologic Exam 
19/28 (67.9) 17/28 (60.7) 0.5770 
^-Standard Error of the Mean 
2p values calculated using t-test under the assumption of equal or unequal 
variances, as appropriate* or chi-square test for comparison of proportions 
3Number with finding/Number Examined 
*P value less than 0.05 

70. 
Table 11. Laboratory Findings in Cases of Legionnaires' Disease and in 
Non-Legionnaires’ Disease Control Pneumonia Patients 
CASES CONTROLS 
HEMATOLOGY N1 Mean SEM2 N Mean SEM P Value3 
Admission t 
W.B.C. Count (xlO3) . 
Band Forms {%)  
Neutrophils (jt). 









28 11.07 0.874 
28 6.32 1.448 
28 73.82 2.029 





Max. Within 4 Days of Admission! 
E.S.R. (mm./hour) . 
Max. During Admission! 
5 42 .40 8.346 7 40.29 5.698 0.8322 
W.B.C. Count (xlO^). 27 13 .31 0.684 29 12.21 1.022 0.3752 
CASES CONTROLS 
URINALYSIS Number iiil Number (%) P Value 
Max. Within 3 Days of Admission! 
Protein, 1+ (21-75 m^). 
or Greater 
16/23 (69.6) 10/27 (37.0) 0.0218 * 
Occult Blood, "Trace" Amt .... 
or Greater 
18/21 (85.7) 10/27 (37.0) 0.0007 * 
Occult Blood, "Small" Amt .... 
or Greater 
14/21 (66.7) 9/27 (33.3) 0.0218 * 
White Blood Cells, 1+ . 
(6-10/hpf) or Greater 
7/23 (30.4) 9/27 (33.3) 0.8267 
Red Blood Cells, 1+ . 
(6-10/hpf) or Greater 
4/23 (17.4) 5/27 (18.5) 0.9176 
Granular Casts, 1+. 
(6-10/hpf) or Greater 
4/23 (17.4) 1/27 ( 3.7) 0.1287 
CHEMISTRY 
On Admission! 
Sodium 130 mEq/L or Less. 8/23 (34.8) 3/25 (12.0) 0.0606 + 
Within 4 Days of Admission! 
Phosphorus 2.2 mg/dL or Less. . . 8/15 (53.3) 1/13 ( 7.7) 0.0281 * 
Calcium 8.0 mg/dL or Less . . . . 4/15 (26.7) 2/13 (15.4) 0.4681 
Abnormal^ Total BILI.. 3/15 (20.0) 3/20 (15.0) 0.6977 
Abnormal SGOT  11/15 (73.3) 9/18 (50.0) 0.1720 
Abnormal SGPT . 7/11 (63.6) 4/12 (33.3) 0.1461 + 
Abnormal LDH. 10/14 (71.4) 7/17 (41.2) 0.0921 + 
Abnormal ALK PHOS . 4/18 (22.2) 6/20 (30.0) 0.5867 
Any Abnormal LFT. 14/20 (70.0) 15/24 (62.5) 0.6013 
^-Number Tested, One confirmed LD case with Chronic Lymphocytic Leukemia is not 
included in the Hematology results 
^Standard Error of the Mean 
3p Value calculated using t-test under the assumption of equal or unequal 
variances, as appropriate» or chi-square test for comparison of proportions 
^Number with Finding/Number Tested 
^At Least One Assay Result Greater than the Upper Limit of Normal for the Test 
Notedi Upper Limits of Normal are Different in the Three Hospitals in Bridgeport 
and this has been Accounted for in the Data 
*P Value less than 0.05 
+0dds Ratio (Cases vs Controls) greater than F value greater than 0.05 

71. 
Table 12. Frequency of Erythromycin Treatment in Cases of Legionnaires' Disease 
and Non-Legionnaires' Disease Control Pneumonia Patients and a Comparison 
of Length of Illness in Control Pneumonia Patients Treated vs Controls Not 
Treated with Erythromycin 
FREQUENCY OF TREATMENT 
CASES CONTROLS 
PERIOD WHEN TREATED Number1 {%) Number (* *) P Value^ 
Erythromycin either Before 
Admission or Up to the Third 
Hospital Day . 22/28 (78.6) 13/29 (44.8) 0.0089 * 
Erythromycin either Before 
Admission or Up to the Third 
Hospital Day, Not FEN Allergic . . . . 16/28 (57.1) 10/29 (34.5) j 
PEN Allergic .... . . 6/28 (21.4) 3/29 (10.3) | 
r O.0315 * 
Erythromycin Before 
Admission. (10.7) 2/29 ( 6.9) 0.6105 
Erythromycin Before 
Admission, Not PEN Allergic. . . . ( 7.1) 1/29 ( 3.4) 1 
L- 0.8217 
PEN Allergic. ( 3.6) 1/29 ( 3.4) i 
Erythromycin Within 3 Days 





Erythromycin Within 3 Days After 
Admission, Not PEN Allergic. . . . 
PEN Allergic. 

















|- 0.0637 + 
T R EAT KENT S T A I ' u s 
CONTROLS TREATED CONTROLS NOT TREATED 
WITH ERYTHROMYCIN-^ WITH ERYTHROMYCIN 
INTERVAL N^ Mean sem5 N Mean SEK P Value 
Onset to Admission (Days) . . . . 13 8.38 2.033 16 4.50 1.049 0.1106 
Admission to Discharge (Days) . . 13 14.46 3.526 16 10.50 1.363 0.3106 
Day of Illness, Defervescence . . 
(First Hospital Day with Max. 
Temperature Less than 100.5° F) 
10 9.80 2.026 11 9.18 1.628 0.8130 
Days Treated with . 
Supplemental Oxygen 
12 4.25 2.082 12 0.92 0.288 0.1401 
Day of Illness, Clearing. 9 11.67 2.351 9 9.89 1.513 0.5339 
First Noted on Chest X-Ray 
^Number Treated/Total Number 
2p values calculated using chi-square test for comparison of proportionsi or t-test 
under the assumption of equal or unequal variances, as appropriate, for comparison 
of means 
^Either Before Admission or Up to the Third Hospital Day 
^Total Number 
^Standard Error of the Mean 
*P value less than 0.05 
+0dds Ratio (Cases vs Controls, Treated ve Nat Treated) 
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SC. U.EM0PTySiS. 
5T. Other (specify)_ 
A £ 
// / 
© ftrr^/H***U*Y fcto*T 
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(D. t-Aftq>rrS *A.^ ^ amount_ TXjft«mo»j(9fc>) ~T/PE (stec\fi) 
ft.. Cl&MLJLTTEi . __ _ _ __ ___ 
w. £iopes. . . . ___ _  
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34. 5'*-e/5HftPf • _ij.s. kIokmai __t ft-?Diameter. _Other. __ 
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DATA C 0 D I N G M A N UAL 
VARIABLE 





DECIMAL POINT, COMMENTS 
TYPE ETC. 
HOSPITAL (NONE) 1 FHOSP # 
LLNUMBER LINE LIST NUMBER 2 - 3 # 
CAR01 (NONE) 4 # FIRST CARD, VALUE=1 
BK51 BLANK 5 CARD 1 5 # 
PHONE PHONE DIGIT 6 # SECOND-T O-LA ST DIGIT 
AGE (NONE) 7 - 8 # AGE IN YEARS 
SEX (NONE) 9 # 
RACE (NONE) 10 FRACE # 
BK111 BLANK 11 CARD 1 11 # 
ADMIT DATE OF ADMISSION 12- 17 MMDDYY8 # INF ORMAT =MMDDYY6. 
BK101 BLANK 18 CARD 1 18 # 
DISCHC DATE OF DISCHARGE 19- 24 MMDDYY8 # INF CRMAT =MMDDYY6. 
BK 251 BLANK 25 CARD 1 25 # 
PASDX PAS DIAGNOSTIC CODE 26- 29 # DECIMAL: — 
RECENTAD RECENT HOSPITAL ADMISSION? 30 FYESNO WITHIN PAST 30 DAYS 
CCFEVER FEVER IN CHIEF COMPLAINT? 31 FYESNO # 
CCTYPE TYPE OF CHIEF COMPLAINT 32 FCC # 
BK331 BLANK 33 CARD 1 33 # 
ONSET DATE OF ONSET OF ILLNESS 34- 39 MMDDYY8 # INF ORMAT =MMDDYY6. 
BK401 BLANK 40 CARD 1 40 # 
PRODROME DAYS FROM ONSET TO FEVER OR COUGH 41 FPRODRO # 
SUBFEVER SUBJECTIVE FEVER 42 F STD # 
OBFEVER OBJECTIVE FEVER 43 F STD # 
CHILLS (NONE) 44 F STD # 
MALAISE (NONE) 45 F STD # 
SWEATS (NONE) 46 F STD # 
* NOTE: An OUTPUT FORMAT LIST of all FORmAT values Immediately follows this list of variables 

VARIABLE 





DECIMAL POINT, COMMENTS, 
ETC, 
UR I RECENT URI 47 F STD 4 
HEADACHE (NONE) 40 F STD 4 
NECKPAIN NECK PAIN OR STIFFNESS 49 F STD 4 
BK501 BLANK 50 CARD 1 50 4 
WEAKNESS (NONE) 51 F STD 4 
FATIGUE (NONE) 52 F STD # 
MYALGIA (NONE) 53 F STD 4 
ARTHRAL ARTHRALGIA 54 F STD 4 
ARTHRIT ARTHRITIS 55 F STD 4 
BACKPAIN BACK PAIN 56 F STD 4 
PHOTO PHOTOPHOBIA 57 F STD 4 
VERTIGO VERTIGO OR DIZZINESS 58 F STD 4 
SEIZURE (NONE) 59 F STD 4 
SYNCOPE LOSS OF CONSCIOUSNESS OR SYNCOPE 60 F STD 4 
BK611 BLANK 61 CARD 1 61 4 
CONF USH> CONFUSION (HISTORY) 62 F STD 4 
MEMHX POOR IJIEWORY (HISTORY) 63 F STD 4 
COORD POOR COORDINATION 64 F STD 4 
eyepain EYE PAIN 65 F STD 4 
EARPAIN EAR PAIN 66 F STD 4 
5THROAT SORE THROAT 67 F STD 4 
HOARSE HOARSE VOICE 68 F STD 4 
ANGINA CHEST PAIN, ANGINAL 69 F STD 4 
BK 701 BLANK 70 CARD 1 70 4 
C WTENDER CHEST UJALL TENDERNESS 71 F STD 4 
PLEURISY CHEST PAIN, PLEURITIC 72 F STD 4 
OTHERCP CHEST PAIN, OTHER OR UNSPECIFIED 73 F STD 4 
DOE EXERTIONAL DYSPNEA 74 F STD 4 
WITHIN 2 'WEEKS 

VARIABLE 





DECIMAL POINT, COMMENTS 
TYPE ETC. 
ORTHOP POSITIONAL DYSPNEA (ORTHOPNEA) 75 F STD # 
PND PAROXYSMAL DYSPNEA 76 F STD # 
OTHERSOB DYSPNEA, OTHER OR UNSPECIFIED 77 F STD # 
PALPS PALPITATIONS 78 F STD # 
WHEEZING (NONE) 79 F STD # 
BK801 BLANK 80 CARD 1 80 # 
H0SP2 (NONE) 1 FHOSP # *** BEGIN CARD 2 *** 
LL2 (NONE) 2-3 # LINE LIST NUMBER 
CARD 2 (NONE) 4 # SECOND CARD, VALUE=2 
BK52 BLANK 5 CARD 2 5 # 
COUGH (NONE) 6 F STD # 
SPUTUM (NONE) 7 FSPUT # 
edemahx ANKLE EDEMA (HISTORY) 8 F STD # 
anorexia (NONE) 9 F STD # 
INDICEST INDIGESTION 10 F STD # 
ABPAIN ABDOMINAL pain or cramps 11 F STD # 
NAUSEA (NONE) 12 F STD # 
VOMITING (NONE) 13 FVOM # 
DIARRHEA (NONE ) 14 F STD # 
MELENA (NONE) 15 F STD # 
BK162 BLANK 16 CARD 2 16 # 
DYSURIA (NONE) 17 F STD # 
HEMATUR HEMATURIA 18 F STD # 
URGENCY (NONE) 19 F STD # 
UFREQ URINARY FREQUENCY 20 F STD # 
NOCTURIA (NONE) 21 F STD § 
PNXHX HISTORY OF PNEUMONIA 22 F STD # BEGIN PAST MEDICAL HISTORY 









DECIMAL POINT, COMMENTS, 
TYPE ETC. 
COPDHX HISTORY OF COPD 24 F COPD # 
TBHX HISTORY OF TUBERCULOSIS 25 F STD # 
ASCVDHX HISTORY OF A.S. CORONARY VASC. DISEASE 26 F STD # 
mi hx HISTORY OF MYOCARDIAL INFARCTION 27 F STD # 
A PHX HISTORY OF ANGINA PECTORIS 28 F STD # 
CHFHX HISTORY OF CHF 29 F STD # 
BK302 BLANK 30 CARD 2 30 # 
HBPHX HISTORY OF HIGH BLOOD PRESSURE 31 F STD # 
CANCERHX HISTORY OF MALIGNANT NEOPLASM 32 F STD # 
renalhx HISTORY OF CHRONIC RENAL DISEASE 33 F STD # 
DMHX HISTORY OF DIABETES MELLITUS 34 F STD # 
INSULIN ON INSULIN? 35 F STD # 
penaller PENICILLIN ALLERGY? 36 F PEN # 
STEROIDS ON CORTICOSTEROIDS (EXCEPT TOPICAL)'?' 37 F STD # MEDICATIONS BEFORE ADMISSION 
CHEMO ON CHEMOTHERAPY'7 38 F STD # ALKYLATOR OR CYTOTOXIC AGENT 
ASA ON ANTI-PYRETICS9 39 F STD # 
ABIOTICS ON ANTI-BIOTICS? 40 FABIO W 
DIURETIC ON DIURETICS? 41 F STD # 
SMOKINC CIGARETTE SMOKING 42 FSMOKE # HABITS 
ALCOHOL ALCOHOL CONSUMPTION 43 FETOH # 
HEALTH STATE OF HEALTH 44 F HEALTH # *** BEGIN PHYSICAL EXAM *** 
COLOR (NONE) 45 FCOLOR # 
RESPS RESPIRATIONS 46 FRESPS # 
SMOIST SKIN MOISTURE 47 FSM0I5T # 
STEMP SKIN TEMPERATURE 48 FSTEMP # 
PHARYNX PHARYNGEAL MUCOSA 49 fpharynx # 
BK502 BLANK 50 CARD 2 50 # 
WENING MENINGISMUS? 51 FMENING # 

89. 
VARIABLE POSI- FORMAT DECIMAL POINT, COMMENTS, 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
TRACHEA POSITION OF TRACHEA 52 FTRACH # 
CHEST5IZ CHEST SIZE AND SHAPE 53 FCSIZE # 
CHEXPAN CHEST EXPANSION 54 FEXPAN # 
CHE5PERC CHEST PERCUSSION 55 FPERC 
TUBULAR BRONCHIAL OR TUBULAR BREATH SOUNDS9 56 FAUSC # 
rales rales? 57 FAUSC # 
RHONCHI RHONCHI? 58 FAUSC # 
WHEEZES WHEEZES9 59 FAUSC # 
BK 602 BLANK 60 CARD 2 60 
ECOPHONY EGOPHCNY? 61 FAUSC # 
CHESTRUB AUSCULTABLE RUB9 62 FAUSC # 
DECRB5 DECREASED BREATH SOUNDS9 63 FAUSC # 
pmi APICAL IMPULSE (Pl»lI) 64 F PMI # 
SOUNDS HEART SOUNDS (51 AND 52) 65 FSOUND # 
SYSTIY SYSTOLIC MURMUR9 66 F MG MURMURS NOT DEFINED AS 
SYSTOLIC OR DIASTOLIC ARE 
DIASTm DIASTOLIC muRMUR9 67 F MG # CODED AS SYSTOLIC 
S3 THIRD HEART SOUND? 68 F MG # GALLOPS not defined AS 
ATRIAL OR VENTRICULAR ARE 
S4 FOURTH HEART SOUND? 69 F MG # CODED AS ATRIAL (54) 
BK702 BLANK 70 CARD 2 70 # 
NECKVEIN NECK VEINS 71 FVEIN # 
ABSOUNDS BOWEL SOUNDS 72 FABSNDS # 
ABTENDER ABDOMINAL TENDERNESS? 73 FTENDER # 
LIVER PALPABLE LIVER? 74 FLSM # 
SPLEEN palpable SPLEEN? 75 FLSM # 
ABMASS PALPABLE ABDOMINAL MASS? 76 FLSM # 
STOOL STOOL GUAIAC (OCCULT BLOOD)? 77 F STOOL # 
CYANOSIS CYANOSIS OF THE EXTREMITIES? 78 FCYAN # 
EDEMAPEX PRETIBIAL EDEMA (PHYSICAL EXAM)? 79 FEDEMA # 

90. 
VARIABLE POSI- FORMAT decimal point, comments 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
BK802 blank BO CARD 2 80 # 
H0SP3 (NONE) 1 FHOSP # *** BEGIN CARD 3 *** 
LL3 (NONE) 2-3 # LINE LIST NUMBER 
CARD3 (NONE) 4 THIRD CARD, VALUE=3 
BK53 BLANK 5 CARD 3 5 # 
NEUROEX NEUROLOGIC EXAMINATION 6 FNEURO # "SUMMARY" OF NEURO EXAM 
LOC LEVEL OF CONSCIOUSNESS 7 floc # 
ORIENTED ORIENTED TO DATE, PLACE, PERSON? e F ORIENT # 
CONFUSED CONFUSION (PHYSICAL EXAM)9 9 F STD 4 
BK103 BLANK 10 CARD 3 10 # 
BIZARRE BIZARRE OR PSYCHOTIC? 11 F STD # 
SLOW DESCRIBED A5 SLOW? 12 F STD # 
NiEmPEx MEMORY (PHYSICAL EXAM) 13 F MEM # 
SPEECH (NONE) 14 F SPEECH t? 
TREMOR TREMOR? 15 F STD # 
GAIT GAIT DISTURBANCE? 16 F STD # 
ADMITDAY DAY OF ILLNESS, ADMISSION 17-18 FSDOT # 
ADMITEMP MAX TEMP ON DAY OF ADMISSION 19-22 FSDOT # DECIMAL: —.- 
*** NOTE *** RECTAL TEMPS 
ADMITPR PULSE RATE ASSOCIATED WITH ADMITEMP 23-25 FSDOT ARE ADJUSTED BEFORE CODING 
BY SUBTRACTING 0.5 DEGREES 
TMAX MAX TEMP WITHIN 3 DAYS 26-29 FSDOT DECIMAL: — 
8K303 BLANK 30 CARD 3 30 # 
DEFERVES DAY OF ILLNESS, DEFERVESCENCE 31-32 FDEFERV # DEFERVESCENCE DEFINED AS 
FIRST HOSPITAL DAY WITH 
LATETEMP FEBRILE AFTER DEFERVESCENCE? 33 flatemp * MAX. TEMP. <100.5 F 
FEVER IS DEFINED AS 
ADMITRR RESPIRATORY RATE ON ADMISSION 34-35 FSDOT # TEMP. ^100.5 F 
ADMIT5BP SYSTOLIC BP ON ADMISSION 36-38 FSDOT # 
ADMITDBP DIASTOLIC BP ON ADMISSION 39-40 FDBP # 
MAXRR MAX RESPIRATORY RATE RECORDED 41-42 FSDOT # 
MAXRRDAY DAY OF ILLNESS, MAX RESP RATE 43-44 FSDOT # 

91. 
VARIABLE POSI- FORmAT DECIMAL POINT, COMMENTS 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
ABIOI ANTIBIOTIC ONE 
3ECIN1 DAY OF ILLNESS, BEGIN ANTIBIOTIC ONE 
STOP1 DAY OF ILLNESS, STOP ANTIBIOTIC ONE 
DOSE1 DOSE, ANTIBIOTIC ONE 
ROUTE1 ROUTE, ANTIBIOTIC ONE 
BK563 BLANK 56 CARD 3 
ABI02 ANTIBIOTIC TWO 
BEGIN2 DAY OF ILLNESS, BEGIN ANTIBIOTIC TWO 
STOP2 DAY OF ILLNESS, STOP ANTIBIOTIC TWO 
D0SE2 DOSE, ANTIBIOTIC TWO 
ROUTE 2 ROUTE, ANTIBIOTIC TWO 
BK683 BLANK 68 CARD 3 
ABI03 ANTIBIOTIC THREE 
BEGIN3 DAY OF ILLNESS, BEGIN ANTIBIOTIC THREE 
ST0P3 DAY OF ILLNESS, STOP ANTIBIOTIC THREE 
DOSE3 DOSE, ANTIBIOTIC THREE 
R0UTE3 ROUTE, ANTIBIOTIC THREE 




BK54 BLANK 5 CARD 4 
ABI04 ANTIBIOTIC FOUR 
BEGIN4 DAY OF ILLNESS, BEGIN ANTIBIOTIC FOUR 
ST0P4 DAY OF ILLNESS, STOP ANTIBIOTIC 1 r OUR 
DOSE4 DOSE, ANTIBIOTIC FOUR 
ROUTE4 ROUTE, ANTIBIOTIC FOUR 
BK174 BLANK 17 CARD 4 
45-46 FABIOTIC 4 
47-48 FSDOT 4 
49-50 fsdot 4 
51-54 FSDOT # DECIMAL: —ALL DOSES 
ARE CODED AS GRAMS PER DAY 
55 FROUTE 4 OR MILLIONS OF UNITS PER 
DAY FOR PENICILLINS 
56 4 
57-58 FABIOTIC W 
59-60 FSDOT 4 
61-62 FSDOT 4 
63-66 FSDOT 4 DECIMAL: 
67 FROUTE 4 
68 # 
69-70 FABIOTIC 4 
71-72 FSDOT 4 
73-74 FSDOT 4 
75-78 FSDOT 4 DECIMAL: 
79 FROUTE 4 
80 4 
1 FHOSP 4 *** BEGIN CARD 4 *** 
2-3 # LINE LIST NUMBER 
4 FSDOT 4 FOURTH CARD, VALUE=4 
5 4 
6-7 FABIOTIC 4 
8-9 FSDOT 4 
10-11 FSDOT 4 
12-15 FSDOT 4 DECIMAL: — 
16 FROUTE 4 
17 4 

VARIABLE P05I- FORMAT DECIMAL POINT, COMMENTS 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
ABI05 ANTIBIOTIC EIVE 18-19 FABIOTIC # 
BECIN5 DAY OE ILLNESS, BEGIN ANTIBIOTIC EIVE 20-21 FSDOT # 
ST0P5 DAY OF ILLNESS, STOP ANTIBIOTIC FIVE 22-23 FSDOT # 
D0SE5 DOSE, ANTIBIOTIC FIVE 24-27 FSDOT # DECIMAL: — 
R0UTE5 ROUTE, ANTIBIOTIC FIVE 28 FROUTE # 
BK 294 BLANK 29 CARD 4 29 # 
ABI06 ANTIBIOTIC SIX 30-31 FABIOTIC # 
BEGIN6 DAY OF ILLNESS, BEGIN ANTIBIOTIC SIX 32-33 FSDOT # 
ST0P6 DAY OF ILLNESS, STOP ANTIBIOTIC SIX 34-35 FSDOT # 
D05E6 DOSE, ANTIBIOTIC SIX 36-39 FSDOT # DECIMAL: ----- 
R0UTE6 ROUTE, ANTIBIOTIC SIX 40 FROUTE # 
BK424 BLANK 42 CARD 4 42 # 
COOL DAYS ON COOLING BLANKET 43 FCOOL # INCLUDES ALCOHOL SPONGING 
AS WELL AS BLANKET 
A5A10N DAY OF ILLNESS, BEGIN ASPIRIN ONE 44-45 FSDOT # INCLUDES TYLENOL 
AS ASPIRIN 
AS WELL 
A5A10EE DAY OF ILLNESS, STOP ASPIRIN ONE 46-47 FSDOT # 
A5A1RTE ROUTE, ASPIRIN ONE 48 FROUTE # 
BK494 BLANK 49 CARD 4 49 # 
A5A20N DAY OF ILLNESS, BEGIN ASPIRIN TWO 50-51 FSDOT # 
ASA20fT DAY OF ILLNESS, STOP ASPIRIN TWO 52-53 FSDOT # 
A5A2RTE ROUTE, ASPIRIN TWO 54 FROUTE # 
BK554 BLANK 55 CARD 4 55 # 
A5A30N DAY OF ILLNESS, BEGIN ASPIRIN THREE 56-57 FSDOT # 
ASA30FF DAY OF ILLNE5S, STOP ASPIRIN THREE 58-59 FSDOT # 
ASA3RTE ROUTE, ASPIRIN THREE 60 FROUTE # 
BK614 BLANK 61 CARD 4 61 # 
ROIDS RECEIVED STEROIDS? 62 F ROIDS # EXCLUDES TOPICAL STEROIDS 
LOMOTIL RECEIVED LOMOTIL? 63 FLOMO # 
TUBED REQUIRED MECHANICAL VENTILATOR? 64 FLOMO # 
OXYGEN RECEIVED SUPPLEMENTAL OXYGEN? 65 FLOMO # 

VARIABLE 
NAME VARIABLE LABEL 
P05I- FORMAT 
TION NAME TYPE 
93. 
DECIMAL POINT, COMMENTS, 
ETC. 
DAYSOXY NUMBER OF DAYS ON SUPPLEMENTAL OXYGEN 66-67 FOXY # 
WBC1 WBC ON ADMISSION 68-70 FSDOT § DECIMAL: — 
WBC 2 MAX WBC DURING DAY AFTER ADMISSION 71-73 FSDOT # DECIMAL: —.- 
WBC 3 MAX WBC DURING DAY 2-3 AFTER ADMISSION 74-76 FSDOT # DECIMAL: —.- 
MAXUIBC MAX WBC NOTED DURING ADMISSION 77-79 FSDOT ft DECIMAL: —.- 
BK804 BLANK 80 CARD 4 80 # 
H0SP5 (NONE) 1 FHOSP # *** BEGIN CARD 5 *** 
LL5 (NONE) 2-3 # LINE LIST NUMBER 
CARD5 (NONE) 4 # FIFTH CARD, VALUE=5 
BK55 BLANK 5 CARD 5 5 # 
BANDS1 BANDS (%) ON ADMISSION 6-7 FSDOT # 
BANDS2 BANDS (£) DURING DAY AFTER ADMISSION 8-9 FSDOT # 
BANDS3 BANDS W DURING DAY 2-3 AFTER ADMIT 10-11 FSDOT ft 
SECS1 SEGS (%) ON ADMISSION 12-13 FSDOT # 
SEGS2 SEGS (%) DURING DAY AFTER ADMISSION 14-15 FSDOT # 
SECS3 SEGS (£) DURING DAY 2-3 AFTER ADMIT 16-17 FSDOT ft 
LYMPHS1 LYMPHS {%) ON ADMISSION 18-19 FSDOT If 
LYMPHS2 LYMPHS {%) DURING DAY AFTER ADMISSION 20-21 FSDOT # 
LYMPHS3 LYMPHS {%) DURING DAY 2-3 AFTER ADMIT 22-23 FSDOT ft- 
BK245 BLANK 24 CARD 5 24 ft 
HCT1 HEMATOCRIT ON ADMISSION 25-26 FSDOT # 
HCT3 MIN HEMATOCRIT WITHIN 3 DAYS OF ADMIT 27-28 FSDOT # 
PLATE1 PLATELET COUNT ON ADMISSION 29-31 F PLATE # 
PLATE3 MIN PLATELETS WITHIN 3 DAYS OF ADMIT 32-34 FPLATE # 
ESR4 MAX SED RATE WITHIN 4 DAYS OF ADMIT 35-36 FSDOT it 
SCRAV3 URINE SP GRAV ASSOC MIN NA UP TO DAY 3 37-39 FSDOT it DECIMAL: --IF NO 
NA CODE ADMIT SP GRAV 
SGRAVMIN URINE SP GRAV ASSOC MIN NA NOTED 40-42 FSDOT if DECIMAL: .— IF NO 
NA LEAVE BLANK 
UCLU1 URINE GLUCOSE ON ADMISSION 43 fuclu it 
UGLU3 URINE GLUCOSE MAX UP TO DAY 3 44 FUGLU it 

VARIABLE; POSI- FORMAT DECIMAL POINT, COMMENTS, 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
UPROT1 URINE PRGTEIN ON ADMI55I0N 45 FUPROT 4 
UPR0T3 URINE PROTEIN MAX UP TO DAY 3 46 FUPROT 4 
UOCC8LD1 URINE OCCULT BLOOD ON ADMISSION 47 FUOCCBLD # 
U0CC8LD3 URINE OCCULT BLOOD MAX UP TO DAY 3 48 F U0CC3LD 4 
UWBC1 URINE WBC COUNT ON ADMISSION 49 FUCELLS # 
UU/BC3 URINE WBC COUNT MAX UP TO DAY 3 50 FUCELL5 4 
URBC1 URINE R8C COUNT ON ADMISSION 51 FUCELLS 4 
URBC3 URINE RBC COUNT MAX UP TO DAY 3 52 FUCELLS 4 
UHCAST1 URINE HYALINE CASTS ON ADMISSION 53 FUCELLS 4 
UHCA5T3 URINE HYALINE CASTS MAX UP TO DAY 3 54 FUCELLS 4 
UCCA5T1 URINE GRANULAR CASTS ON ADMISSION 55 FUCELLS 4 
UGCAST3 URINE GRANULAR CASTS MAX UP TO DAY 3 56 FUCELLS 4 
BK575 BLANK 57 CARD 5 57 4 
NA1 SODIUM ON ADMISSION 5B-60 FSDOT 4 
NA2 MIN SODIUM DURING DAY AFTER ADMIT 61-63 FSDOT 4 
N A3 MIN SODIUM DURING DAY 2-3 AFTER ADMIT 64-66 FSDOT 4 
MINNA MIN SODIUM NOTED DURING ADMISSION 67-69 FSDOT 4 
BK705 BLANK 70 CARD 5 70 4 
BUN1 BUN ON ADMISSION 71-72 FSDOT 4 
BUN 2 MAX BUN DURING DAY AFTER ADMISSION 73-74 FSDOT 4 
3UN3 MAX BUN DURING DAY 2-3 AFTER ADMISSION 75-76 FSDOT 4 
GLUCOSE BLOOD GLUCOSE ASSOC WITH MIN NA NOTED 77-79 FSDOT 4 IF NO SODIUM, COD! 
GLUCOSE 
BK805 BLANK 80 CARD_5 80 4 
H0SP6 (NONE) 1 FHOSP 4 *** BEGIN CARD 6 
LLP (NONE) 2-3 # LINE LIST NUMBER 
CARD 6 (NONE) 4 4 SIXTH CARD, VALUE: 
8K56 BLANK 5 CARD 6 5 4 
CREAT1 CREATININE ON ADMISSION 6-8 FSDOT 4 DECIMAL: — 

VARIABLE POSI- FORMAT DECIMAL POINT, COMMENTS, 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
CREAT2 MAX CREATININE ON DAY AFTER ADMIT 9 -11 FSDOT # DECIMAL: — 
CREAT3 MAX CREATININE ON DAY 2-3 AFTER ADMIT 12-14 FSDOT # DECIMAL: — 
badbeans RENAL INSUFFICIENCY DURING ADMISSION? 15 FBEANS # DEFINED AS CREAT >2.5 
NOTED ONCE OR BUN >25 
PH0S1 PHOSPHATE ON ADMISSION 16-17 FSDOT_ # NOTED AT LEAST TWICE 
PH0S4 MIN PHOSPHATE WITHIN 4 DAYS OF ADMIT 18-19 FSDOT 4- DECIMAL: -.- (**BOTH PHOS* 
CA1 CALCIUM ON ADMISSION 20-22 FSDOT # DECIMAL: —.- 
CA4 MIN CALCIUM WITHIN 4 DAYS OF ADMIT 23-25 FSDOT # DECIMAL: —.- 
EARLYCPK MAXCPK WITHIN 3 DAYS OF ADMIT 26-28 FSDOT # 
MAXCPK MAXCPK NOTED DURING ADMISSION 29-31 FSDOT a 
BK326 BLANK 32 CARD 6 32 # 
POT WO ABG P 02 33-34 FSDOT # CODE ONLY FIRST ABG ON 
ROOM AIR} IF FI02 IS NOT 
PCOTWO ABG P C02 35-36 FSDOT # STATED THEN CODE ONLY IF 
NO SUPP 02 ORDERED AND 
PH ABC PH 37-39 FSDOT # CODE ABGDAY AS "X" 
DECIMAL: -.— (PH) 
BKA06 BLANK 40 CARD 6 40 # 
abgday DAY OF ILLNESS, ABC 08TAINED 41-42 FABCDAY # SEE ABOVE NOTE REGARDING 
CODING FOR PERSONS WITH 
BK436 BLANK 43 CARD 6 43 # UNCERTAIN FI02 
BILI1 MAX TOTAL BILI WITHIN 1 DAY OF ADMIT 44-45 FSDOT # DECIMAL: -.- 
8ILI4 MAX TOTAL BILI WITHIN 4 DAYS OF ADMIT 46-47 FSDOT # DECIMAL: -.- 
SCOT 1 MAX SCOT WITHIN 1 DAY OF ADMIT 48-50 FSDOT # 
SCOT 4 MAX SGOT WITHIN 4 DAY5 OF ADMIT 51-53 FSDOT # 
SCPT1 MAX SGPT WITHIN 1 DAY OF ADMIT 54-56 FSDOT # 
SGPT4 MAX SGPT WITHIN 4 DAYS OF ADMIT 57-59 FSDOT # 
LDH1 MAX LDH WITHIN 1 DAY OF ADMIT 60-62 FSDOT # 
LDH4 MAX LDH WITHIN 4 DAYS OF ADMIT 63-65 FSDOT # 
ALKPHOS1 MAX ALK PHOS WITHIN 1 DAY OF ADMIT 66-68 FSDOT # 
ALKPHQS4 MAX ALK PHOS WITHIN 4 DAYS OF ADMIT 69-71 FSDOT # 
PT1 MIN PRO TIME WITHIN 1 DAY OF ADMIT (56) 72-73 FSDOT # PT = PT CONTROL/PT PATIENT 
xl00 ($) 
PT 4 MIN PRO TIME WITHIN 4 DAYS OF ADMIT (*) 74-75 FSDOT # 

96 
VARIABLE POSI- FORWAT deciwal point, cowwents, 
NAME VARIABLE LABEL TION NAWE type ETC. 
ALBUWIN1 WIN ALBUWIN WITHIN 1 DAY OF ADWIT 76-77 FSDOT # DECIWAL: -.- 
ALBUWIN4 WIN ALBUWIN WITHIN 4 DAYS OF ADMIT 76-79 FSDOT # DECIWAL: 
CSF CSF OBTAINED9 80 FCSF # 
H0SP7 (NONE) 1 FHOSP # *** BEGIN CARD 7 *** 
LL7 (NONE) 2-3 # LINE LIST NUWBER 
CAR07 (NONE) 4 # SEVENTH CARD, VALUE=7 
8K57 BLANK 5 CARD 7 5 # 
CXRIOAY DAY OF ILLNESS, INITIAL CXR 6-7 FSDOT # 
CXR1TYPE TYPE OF INFILTRATE, CXR1 8 FCXRTYPE # 
CXR1LOC LOCATION OF INFILTRATE, CXR1 9 FCXRLOC # 
CXR1EFF EFFUSION NOTED ON CXR19 10 FCXREFF # 
CXR2TYPE TYPE OF INFILTRATE, CXR2 11 FCXRTYPE # CXR 2 IS "WORST" FILW 
NOTED UP TO 2 DAYS AFTER 
CXR2L0C LOCATION OF INFILTRATE, CXR2 12 FCXRLOC # CXR 1 
CXR2EFF EFFUSION NOTED ON CXR2? 13 FCXREFF # 
CXR2CHNC CHANGE OF INFILTRATE ON CXR2 (VS CXR1) 14 F CXRCHNG CHANGE IS DEFINED IN TERWS 
OF DENSITY OR LOCATION 
CXR3TYPE TYPE OF INFILTRATE, CXR3 15 FCXRTYPE # CXR 3 IS "WORST" FILW 
NOTED UP TO 1 DAY AFTER 
CXR3L0C LOCATION OF INFILTRATE, CXR3 16 FCXRLOC # CXR 2 
CXR3EFF EFFUSION NOTED ON CXR3? 17 FCXREFF # 
CXR3CHNG CHANCE OF INFILTRATE ON CXR3 (VS CXR2) 18 F CXRCHNG # CHANCE IS DEFINED AS ABOVE 
CXR4TYPE TYPE OF INFILTRATE, CXR4 19 FCXRTYPE # CXR 4 IS "WORST" FILW 
NOTED UP TO 1 DAY AFTER 
CXR4L0C LOCATION OF INFILTRATE, CXR4 20 FCXRLOC # CXR 3 
CXR4EFF EFFUSION NOTED ON CXR4? 21 FCXREFF # 
CXR4CHNG CHANCE OF INFILTRATE ON CXR4 (VS CXR3) 22 FCXRCHNG # 
DAYCLEAR DAY OF ILLNESS, FIRST NOTE CXR CLEARING 23-24 FCLEAR # 
CXRCHF CHF NOTED ON CXR? 25 FCXRCHF # 
NEGBCS NUWBER OF NEGATIVE BLOOD CULTURES 26-2? FSDOT # *** WITHIN 3 DAYS AFTER 
ADWISSION *** 
POSBCS NUWBER OF POSITIVE BLOOD CULTURES 28 FSDOT # *** ALSO WITHIN 3 DAYS 
AFTER ADWISSION *** 
STOOLCX STOOL CULTURE OBTAINED? 29 FSTOOLCX # *** ALSO accept STOOL 
SENT FOR 0 4 P *** 
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variable: POSI- FORMAT DECIMAL POINT, COMMENTS, 
NAME VARIABLE LABEL TION NAME TYPE ETC. 
LD1DAY DATE OF ACUTE LD TITER 30-35 MM0DYY8 # INF ORMAT =MMDDYY6. 
LD1TITEER ACUTE LD TITER 36-39 FSDOT # TITERS OF NON-REACTIVE OR 
NOT SIGNIFICANT 
BK407 BLANK 40 CARD 7 40 # CODED AS 0000 
LD2DAY DATE OF CONVALESCENT LD TITER 41-46 MM0DYY8 # INFORMAT=MMDDYY6. 
LD2TITER CONVALESCENT LD TITER 47-50 FSDOT # 
(TYCO MYCOPLASMA SEROLOGIC STATUS 51 FMYCO # 
OAGENT OTHER AGENTS, SEROLOGIC STATUS 52 FOAGENT 4 
LDSTATUS CASE STATUS 53 FLDSTAT # CATACCRIES BASED ON LD 
SEROLOGY STATUS AND 




NAME VALUES LABELS COMMENTS 
FHOSP 1 = BRIDGEPORT HOSP 
2 r ST VINCENTS HOSP 
3 = PARK CITY HOSP 
OTHER = MISCODED 
F RACE 1 - WHITE 
2 = BLACK 
3 = HISPANIC 
4 = OTHER 
OTHER = MISCODED 
FYESNO 0 - NO 
1 = YES 
.Y s YES, NOT CLEAR 
.N = NO, NOT CLEAR 
.0 = OTHER 
.S = NOT STATED 
OTHER = MISCODED 
FCC 1 s RESPIRATORY 
2 s GASTROINTESTINAL 
3 r NEUROLOGIC 
4 = GENITO URINARY 
5 = VIRAL 
.0 = OTHER 
• S NONE NOTED 
OTHER = MISCODED 
FPRODRO 1 B <1 DAY 4 CLEAR 
2 = 1-3 DAYS 4 CLEAR 
3 = >3 DAYS 4 CLEAR 
4 r <1 4 NOT CLEAR 
5 = 1-3 4 NOT CLEAR 
6 = >3 4 NOT CLEAR 
.N = NO FEVER/COUGH 
. 0 = OTHER 
.5 = NOT STATED 
OTHER = MISCODED 
FSTD 0 s NONE 
1 = PRESENT 
.Y - YES, NOT CLEAR 
»N = NO, NOT CLEAR 
.0 r OTHER 
.5 E NOT STATED 
OTHER = MISCODED 

FORMAT 
NAME VALUES LABELS COMMENTS 
esput 0 S NONE 
1 s MUCOID SPUTUM INCLUDES CLEAR, WHITE, OR YELLOW SPUTUM 
2 a PURULENT SPUTUM INCLUDES GREEN OR BROWN SPUTUM 
3 = TYPE NOT STATED 
4 r MIN HEMOPTYSIS INCLUDES blood-streaked or isolated episode 
5 3 HEMOPTYSIS 
.H r HEMOP, NOT CLEAR 
.P 3 SCANT SPUTUM 
.5 3 NOT STATED 
.0 3 OTHER 
OTHER 3 MISCODED 
FVOM 0 3 NONE 
1 3 VOMITING 
2 3 HEMATEMESI3 
.V Z VOMIT, NOT CLEAR 
. H a HEMAT, NOT CLEAR 
.5 s NOT STATED 
.0 3 OTHER 
OTHER 3 MISCODED 
FCOPD 0 - NO HX 
1 3 "COPD" INCLUDES "COPD", emphysema, chronic BRONCH, OR INTERSTITIAL 
2 3 CHRONIC COUGH FIBROSIS 
. Y 3 YES, NOT CLEAR 
. N 3 NO, NOT CLEAR 
. S 3 NOT STATED 
.0 3 OTHER 
OTHER Z MISCODED 
F PEN 0 — NOT PEN ALLERG INCLUDES "NO KNOWN ALLERGIES" 
1 3 PEN ALLERGIC 
. Y 3 YES, NOT CLEAR 
. N 3 NO, NOT CLEAR 
. S 3 NOT STATED 
. 0 3 OTHER 
OTHER S MISCODED 
FABIO 0 3 NONE 
1 3 PEN OR AMPICIL 
2 3 CEPHALOSPORINS 
3 3 TETRACYCLINES 
4 a TRIMETH/SULFA 
5 3 ERYTHROMYCIN 
6 3 DICLOXACILLIN 
7 3 UNKNOWN TYPE 
8 3 >1, NO ERYTHRO 
9 3 >1, U/ITH ERYTH 
.N 3 NO, NOT CLEAR 
.S Z NOT STATED 
.0 3 OTHER 
OTHER Z MISCODED 

FORMAT 
NAME VALUES LABELS COMMENTS 
FSMOKE 0 ■ NONE 
1 ■ EX-SMOKER INCLUDES PERSONS WHO QUIT AT LEAST 1 MONTH BEFORE ADMIT 
2 ■ <» $ PPD 
3 = >$ AND <2 PPD 
4 = >= 2 PPD 
5 = YES, INDETERM INCLUDES SMOKERS WHERE AMOUNT IS INDETERMINATE 
.S = NOT STATED 
.0 * OTHER 
OTHER * MISCODED 
FETOH 0 = NONE 
1 = "SOCIAL" INCLUDES "SOCIAL" OR "OCCASIONAL" DRINKERS 
2 * REG, <3/DAY 
3 m REG, >* 3/DAY 
4 a YES, INDETERM INCLUDES DRINKERS WHERE AMOUNT IS INDETERMINATE 
5 = EX-DRINKER ALSO INCLUDES "BINGE" DRINKERS 
. S = NOT STATED 
. 0 = OTHER 
OTHER = MISCODED 
fhealth 0 * HEALTHY, NAD "HIERARCHY" PERSONS WITH MORE THAN ONE CATAGORY ARE 
1 ■ FEBRILE CODED AS THE "WORST" CATAGORY LISTED FOR 
2 * ACUTELY ILL WHICH THEY QUALIFY 
3 = CHRONIC ILL *•* OTHER FORMATS WITH "HIERARCHY" ARE DESIGNATED *** 
4 = INDETERMINATE *** "HIERARCHY" AND NO EXPLANATION IS GIVEN *** 
. S a NOT STATED 
. 3 = OTHER 
OTHER = MISCODED 
FCOLOR 0 = NORMAL 
1 = pale 
2 = FLUSHED 
3 = CYANOTIC 
4 « JAUNDICED 
. S = NOT STATED 
. 0 = OTHER 
OTHER = MISCODED 
FRESPS 0 = NORMAL "HIERARCHY" 
1 a COUGH NOTED 
2 = TACHYPNEA (>«25) TACHYPNEA IS DEFINED AS RESP RATE GREATER THAN 25 
3 * RESP DISTRESS RESP DISTRESS INCLUDES "SOB" OR "DYSPNEA" 
. S = NOT STATED 
. o = OTHER 
OTHER = MISCODED 
FSMOIST 0 = NORMAL 
1 = DEHYDRATED INCLUDES "TENTING" 
2 = DRY 
3 = MOIST 
4 = WET INCLUDES "DIAPHORETIC" 
. s * NOT STATED 
„ 0 * OTHER 












VALUES LABELS COMMENTS 
0 * NORMAL 
1 * WARM OR HOT 
2 « COOL OR COLD 
.S « NOT STATED 
.0 * OTHER 
OTHER = MISCODED 
0 a NORMAL "HIERARCHY" 
1 = ERYTHEMATOUS 
2 = WITH EXUDATE 
. S = NOT STATED 
. 0 = OTHER 
OTHER a MISCODED 
0 a SUPPLE 
1 a UNCERTAIN 
2 a PRESENT 
. S = NOT STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a MIDLINE 
1 a DEVIATED L OR R 
.5 a NOT STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NORMAL 
1 a BARREL CHEST DEFINED AS INCftEASEO AUTERQ-POSTERIOR CHEST DIAMETER 
.5 a not STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NORMAL 
1 a OECR L 
2 = DECR R 
3 a OECR L 4 R 
4 a DECR, OTHER 
. S a NOT STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NORMAL 
1 = DECR L 
2 a DECR R 
3 a DECR L 4 R 
4 a DECR, OTHER 
5 a INCREASED 
. S a NOT STATED 
. 0 a OTHER 
OTHER a MISCODED 

FORMAT 









0 = NONE 
1 a ON LEFT 
2 a ON RIGHT 
3 = BILATERAL 
4 a LOCATION NS LOCATION NOT STATED BUT PRESENT 
,S = NOT STATED 
. 0 » OTHER 
OTHER = MISCOOED 
0 * NORMAL 
1 = LAT DISPLACED APICAL IMPULSE DISPLACED LATERALLY 
- S = NOT STATED 
. 0 = OTHER 
OTHER a MISCODED 
0 a NORMAL 
1 a ABNORMAL 
. S a NOT STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NONE 
1 a PRESENT 
. S a not STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NORPHAL 
1 a DISTENDED 
. S a NOT STATED 
. 0 a other 
OTHER a MISCODED 
0 a NORMAL 
1 a INCREASED 
2 a ABSENT 
. S a not STATED 
. 0 a OTHER 
OTHER a MISCODED 
0 a NONE "HIERARCHY*' 
1 a PRESENT 
2 = REBOUND 
. S = NOT STATED 
. 0 a OTHER 
OTHER = MISCODED 
0 a NOT PALPABLE 
1 > PALPABLE 
- S a NOT STATED 
. 0 a OTHER 
OTHER « MISCODED 

FORMAT 
NAME VALUES LABELS comments 
F STOOL 0 S GUAIAC NEGATIVE 
1 s GUAIAC POSITIVE 
. s a NOT STATED 
. 0 = OTHER INCLUDES "NO STOOL" 
OTHER = MISCODED 
fcyan 0 s ABSENT 
1 = PRESENT 
. s = NOT STATED 
. 0 a OTHER 
OTHER X MISCODED 
FEDEMA 0 a ABSENT 
1 a "1+" OR "2*" 
2 a "3*" OR "4*" 
3 = AMT NOT STATED 
. s a NOT STATED 
. o 3 OTHER 
OTHER 3 MISCODED 
FNEURO 0 - "WNL" OR NEG 
1 = ABNORMAL 
. Y = YES, NOT CLEAR 
- N 
3 NO, NOT CLEAR INCLUDES PERSONS WITH NORMAL NEUROLOGIC EXAM EXCEPT FOR 
. s = NOT STATED CHRONIC SIGNS SUCH AS OLD AGE AND TREMOR, HYPOREFLEXIA 
. 0 = OTHER IN DIABETICS, PARESIS WITH HX OF STROKE, ETC. 
OTHER = MISCODED 
FLOC 0 — ALERT "HIERARCHY" 
1 = STUPEROUS INCLUDES PERSONS WHO ARE "DROWSY" 
2 3 COMATOSE INCLUDES PERSONS WHO ARE "UNRESPONSIVE" 
S 3 NOT STATED 
. 0 3 OTHER 
OTHER = MISCODED 
F ORIENT 0 a ORIENTED 
1 = DISORIENTED INCLUDES PERSONS DISORIENTED TO DATE, PLACE, OR PERSON 
. S r NOT STATED 
. 0 3 OTHER 
OTHER a MISCODED 
F MEM 0 3 INTACT 
1 z DEFICIT 
. S s NOT STATED 
. 0 = OTHER 
OTHER 3 MISCODED 
F SPEECH 0 - INTACT 
1 a ABNORMAL INCLUDES PERSONS WITH "SLURRED" OR ABSENT SPEECH 
. S s NOT STATED 
. o 3 OTHER 
OTHER = MISCODED 
F5DOT . s 3 NOT STATED 
• 3 MISSING/NONE 

FORMAT 







.F a FEBRILE AT D/C 
.N a NO FEVER NOTED 
.S * NOT STATED 
0 a NO 
1 = YES 
.F * FEBRILE AT D/C 
.N = NO FEVER NOTED 
.S = NOT STATED INCLUDES 
OTHER r MISCODED 
.A a 100-105 
.B = 106-110 
• C a >110 
.S a NOT STATED 
. = MISSING/NONE 
1 a PENICILLIN 
2 » AMPICILLIN 
3 = OXACILLIN 
4 a CEPHALOSPORIN 
5 a CARBENACILLIN 
6 ■ GENTAMYCIN 
7 a ERYTHROMYCIN 
B = TETRACYCLINE 
9 a RIFAMPIN 
10 a trimeth/sulfa 
11 = I SON IAZ ID 
12 a ETHAMBUTOL 
13 a TICARCILLIN 
14 a DICLOXACILLIN 
15 = CHLORAMPHENICOL 
. a NONE 
OTHER a MISCODED 
0 a po 
1 = IV 
2 a IM 
3 a IV THEN PO 
4 a IM THEN PO 
5 a PO THEN IV 
6 a PO THEN IM 
7 a PR 
8 a PER N/G 
9 a SC 
. a NONE 
OTHER a MISCODED 
o a NONE/NOT STATED 
1 * LESS THAN 2 DAYS 
2 3 2 OR MORE DAYS 
3 3 YES, AMT NS 





name VALUES LABELS 
FROIDS 0 NONE/NOT STATED 
1 K STARTED ON 
2 = CONT'D ON 
3 9 TAPPERED OFF 
4 X YES, NOT CLEAR 
.0 X OTHER 
OTHER MISCODED 
flomo 0 X NONE/NOT STATED 
1 3 YES 
. 0 S OTHER 
OTHER = MISCODED 
FOXY 0 s NONE/NOT STATED 
. Y 3 YES, NOT CLEAR 
. 0 = OTHER 
fplate 999 X ADEQUATE/INCRSD 
. X X DECREASED 
FUGLU 0 X NEGATIVE 
1 X TRACE 
2 X •' 1 
3 s " 2 ♦" 
4 X "3+" 
5 X "4 ♦" 
# X NOT DONE 
OTHER 3 MISCODED 
FUPROT 0 3 NEGATIVE 
1 3 TRACE 
2 s "1 ♦" 
3 3 *2+” 
4 - "3»" 
5 3 «4V 
# 3 NOT DONE 
OTHER = MISCODED 
F UOCC0LD 0 3 NEGATIVE 
1 3 TRACE 
2 = SMALL 
3 = MOOlRATE 
4 X LARCE 
# s NOT DONE 
OTHER r MISCODED 
COMMENTS 
EXCLUDES TOPICAL STEROIDS 
up to 100 mg% 
101 TO 500 MG* 
501 TO 1000 MG* 
1001 TO 1500 MG* 
WORE THAN 1500 MG* 
5 TO 20 l*IC* 
21 TO 75 MG* 
76 TO 150 MG* 
151 TO 750 MG* 
MORE THAN 750 MG/6 
FUCELLS 0 K NONE CODE IN CATAGORY APPROPRIATE FOR MID-POINT OF RANGE IF 
1 X FEW (2-5) COUNT IS GIVEN AS RANGE (EG. REPORTED 20-30 CODE AS 25 
2 X 1* (6-10) WHICH COUNTS AS 3*) 
3 X 2* (11-20) 
4 3 3* (21-50) 
5 = 4* INCLUDES TOO NUMEROUS TO COUNT , X NOT DONE 
OTHER X MISCODED 
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VALUES LABELS COMMENTS 
0 = NO 
1 = YES INCLUDES PERSONS WITH CREATININE >2.5 AT LEAST ONCE OR 
.S = NOT TESTED BUN >25 AT LEAST TWICE 
OTHER * MISCODED 
.X = F102 NOT STATED 
.S = NOT STATED 
. = missing/none 
0 = NONE NOTED 
1 = OBTAINED, WNL 
2 = INCRSD WBC'S 
3 s OTHER ABNORM 
•Y s OBTAINED, NS 
OTHER = MISCODED 
0 r NONE 
1 * PATCHY 
2 = DIFFUSE 
3 = NODULAR 
4 = INTERSTITIAL 
5 = CONSOLIDATED 
6 = MIXED TYPE 
7 = OTHER TYPE 
6 = POSITIVE BUT NS 
.S = NOT STATED 
. = missing/none 
OTHER = MISCODED 
1 » LEFT, NS 
2 « RIGHT, NS 
3 = LEFT, 1 LOBE 
4 = RIGHT, 1 LOBE 
5 * LEFT, >1 LOBE 
6 = RIGHT, >1 LOBE 
7 = BILATERAL 
.S = NOT STATED 
. » MISSING/NONE 
OTHER = MISCODED 
0 = NONE 
1 * LEFT 
2 = RIGHT 
3 « BILATERAL 
4 * YES, LOC NS 
•S = NOT STATED 
. = MISSING/NONE 
OTHER = MISCOOED 
0 » NO CHANGE 
1 = PROGRESSION INCLUDES PROCRESSION/CLEARINC OF EITHER DENSITY OR 
2 * CLEARING LOCATION OF INFILTRATE 
.5 = NOT STATED 
. 3 MISSING/NONE 












values labels COMMENTS 
0 a NEGATIVE CXR 
.X a NOT NOTED BY D/C 
.S * NOT STATED 
0 * NONE SEEN INCLUDES EITHER CARDIOMEGALY OR "CHF" 
1 = 1 FILM NOTES 
2 a >1 FILM NOTES 
.5 = NOT STATED 
OTHER a MISCODED 
0 = NO/NOT STATED INCLUDES STOOL SAMPLES SENT FOR OVA AND PARASITES 
1 = YES 
OTHER » MISCODED 
0 * NEGATIVE 
1 « PRES CASE 
2 = CONF CASE 
.S * NOT TESTED 
OTHER = MISCODED 
0 * ALL NEGATIVE 
1 * PRES CASE 
2 * CONF CASE 
.S « NOT TESTED 
OTHER = MISCODED 
RESPIRATORY PATHOGEN SCREEN INCLUDES SEROLOGIC 
TESTING FOR ALL OF THE FOLLOU/ING: INFLUENZA A 
AND 8, ADENOVIRUS GROUP, PSITTACOSIS CROUP, 
Q FEVER, MYCOPLASMA, AND RESPIRATORY SYNCYTIAL VIRUS 
0 « CONTROL 
1 = DESCRIP P CASE 
2 = DESCRIP C CASE 
3 a PRES CASE-CNTRL 
A * CONF CASE-CNTRL 
OTHER a MISCODED 
CASE DEFINITIONS AS PER METHODS, THIS VARIABLE IS 
BASED ON REVIEW OF SEROLOGIC TEST RESULTS AND LINE 
LISTINGS (USED TO DETERMINE WHETHER SUBJECT HAS 
BEEN INCLUDED IN THE CASE-CONTROL STUDY) 
0 a NO 
1 a YES, AUTOPSY 
2 a YES, NO AUTOP 
.S * INDETERMINATE 






A Comparison of Ether vs Heat-Killed Antigen Preparations in the L. pneumophila 
Indirect Flourescent Antibody Assay 
Distribution of L. pneumophila Indirect Flourescent Antibody Titer in 100 Unselected 
VDRL Specimens According to the Method of Antigen Preparation* 
M E T H 0 D 0 F ANT I G E N PREPARATION 
TITER Ether Killed Heat Killed 





18 % 1 % 
128 20 1 
64 ... . 







‘Specimens tested had been submitted to the Connecticut Health Department 
Laboratory for pre-marital VDRL testing from Hartford residents. 
These data were kindly provided by the Serology Department of the Connecticut 






LEGIONNAIRES' DISEASE INDIRECT 
FLUORESCENT ANTIBODY REAGENTS 
U.S. DEPARTMENT OF HEALTH, EDUCATION AND WELFARE 
PUBLIC HEALTH SERVICE 
Center for Disease Control 

110 
READ THIS BROCHURE IN ITS ENTIRETY 
BEFORE PROCEEDING 
LEGIONNAIRES' DISEASE INDIRECT 
FLUORESCENT ANTIBODY REAGENTS 
INTENDED USE 
These products are for Research Use Only; not for use in diagnostic pro¬ 
cedures. 
SUMMARY AND EXPLANATION OF THE TEST 
The Legionnaires' Disease (LD) indirect fluorescent antibody (IFA) test is an 
immunofluorescence procedure for detection of LD antibodies in human serum.^ 
At the present time this research IFA test appears to be specific for LD; 
however, if possible the test should be used in conjunction with isolation of 
the organism from biopsy or autopsy material^ or demonstration of the organisms 
in tissue specimens.2 
As with any serological test, the most convincing evidence of a recent in¬ 
fection with the bacterium of LD is a fourfold rise in titer between the 
acute phase of illness (within the first week) and convalescent phase (3 to 
5 weeks after onset). In the IFA test for LD, the rise in titer must be to 
at least 128 to be considered positive. A single or standing titer of 2.256 
is considered presumptive evidence of LD at an undetermined time. 
Recently, a new serogroup of LD bacterium was described.2>4 a new serolog¬ 
ically distinct isolate, designated Togus 1, has been placed in serogroup 2. 
The Philadelphia 1 isolate and serologically related or identical isolates 
such as the Knoxville 1 isolate are currently grouped as members of sero¬ 
group 1. 
PRINCIPLES OF THE PROCEDURE 
The IFA test is a "sandwich" immunofluorescence technique which uses a two- 
stage reaction procedure. In the first stage, a given antigen is overlaid 
with dilutions of antiserum (animal or human); then the slides are incubated, 
washed, and dried. In the second stage, the antigen is overlaid with fluor- 
labeled antiglobulin produced against the animal species that provided the 
unlabeled serum applied in the first stage. In this manner, antigens are 
rendered fluorescent by positive antisera which themselves are not labeled. 
The fluorescent dye used to label the antispecies globulin is fluorescein 
isothiocyanate (FITC). When this dye is excited by near ultraviolet-blue 
light, it emits longer wavelengths of light in the yellow-green portion of 
the color spectrum, thereby making visible those immune complexes formed in 
situ. The microscopic appearance of antigen stained by this immunofluores¬ 





1. LEGIONNAIRES' DISEASE ANTIGENS are killed suspensions of LD group 1 
Philadelphia 1 and LD group 2 Togus 1 organisms grown on artificial 
medium and suspended in normal yolk sac (NYS). The final concentration 
of NYS is 0.5%.* Each antigen is packaged separately in 2 ml volumes 
and is at the working dilution. Each contains 0.05% sodium azide as a 
preservative. Store at 4 C. Two ml of antigen, when applied to the 
•I slides as recommended will be sufficient to prepare approximately 1,000 
J-fitfo < < ygllg. 
1 ' . * * * 4 5 *NYS concentration in lots 78-0006K and 78-0007 is 1.02 !>■■(< t 
2. LEGIONNAIRES' DISEASE POSITIVE CONTROL HUMAN SERA are high-titered positive 
sera diluted with normal human sera so that they have IFA titers of 512. 
The sera react with either group 1 or group 2 antigens as indicated on 
the label. They are packaged in 1 ml volumes and contain 0.05 percent 
sodium azide as a preservative. Store at 4 C. Use of 0.01 ml to make 
a 1:16 beginning dilution allows approximately 100 control titrations 
to be performed. 
3. LEGIONNAIRES' DISEASE NEGATIVE CONTROL HUMAN SERUM is a human serum that 
demonstrates less than 1+ fluorescence at dilutions >1:32 when used with 
the reagents described in this brochure. It is packaged in 1 ml volumes 
and contains 0.05 percent sodium azide as a preservative. Store at 4 C. 
Use of 0.01 ml to make a 1:16 beginning dilution allows approximately 
100 control titrations to be performed. 
I 
4. NORMAL 3 PERCENT* CHICKEN YOLK SAC SUSPENSION is an homogenized suspen¬ 
sion of yolk sacs suspended in phosphate buffered saline (PBS) pH 7.2 
to give a 3 percent suspension (wt/vol). The product is dispensed in 
45 ml amounts and is at the working dilution. Sodium azid is added to 
a final concentration of 0.05 percent as a preservative. Store at 4 C. 
When used to make the 1:16 dilution only, 45 ml of yolk sac suspension 
is a sufficient quantity for approximately 300 tests. 
*NYS lots 78-0006K and 78-0008 are 10% suspensions and can be diluted 
1:4 before use. 
5. ANTIHUMAN FLUORESCEIN-LABELED GLOBULIN is the globulin fraction of anti¬ 
human rabbit serum labeled with fluorescein isothiocyanate. The product 
is freeze-dried. Reconstitute with 4 ml* of pH 7.2 PBS. This Is The 
Working Dilution Of The Conjugate. It contains 0.01 percent thimerosal 
as a preservative. Store at 4 C. If 20 ^il of conjugate per well are 
used, 4 ml of conjugate will be sufficient to stain 200 wells. 
*Lots 78-0006K and 78-0009 are packaged in 2 ml amounts; this volume is 
sufficient for approximately 100 wells. 
NOTE: STABILITY OF REAGENTS. Long term stability data for these 
reagents are not yet available; therefore, no expiration dates 
have been assigned. However, if all reagents react as des¬ 
cribed in this brochure when used together, they may be 







A set of reagents (KK0003) including group 1 antigen and positive control 
serum is available. In addition, group 1 antigen, group 2 antigen, group 2 
positive control serum, normal 10 percent yolk sac suspension, and anti¬ 
human globulin are distributed as individual reagents. Group 2 antigen and 
positive control serum can be used with negative control serum, yolk sac 
suspension and conjugates provided as part of set KK0003 or provided as 
individual reagents. 
KK0003 Legionnaires' Disease IFA Reagent Set 
1. Legionnaires' Disease Group 1 Philadelphia 1 Isolate 
Antigen (2 ml) 
2. Legionnaires' Disease Group 1 Positive Control Serum (PCS) 
3. Legionnaires' Disease Negative Control Serum (NCS) 
4. Normal 3 Percent Chicken Yolk Sac Suspension (NYS) 
(Lot 78-0006K. is a 10 percent suspension and can be 
diluted 1:4 before use.) 
5. Antihuman Fluorescein-Labeled Globulin (4 ml) 
(Lot 78-0006K is packaged in 2 ml volumes) 
BA1533 Legionnaires' Disease Group 1 Philadelphia 1 Isolate 
Antigen (2 ml) 
BA1515 Legionnaires' Disease Group 2 Togus 1 Isolate 
Antigen (2 ml) 
BS1525 Legionnaires' Disease Group 2 Positive Control 
Serum (1 ml) 
BG1535 Normal 10 Percent Yolk Sac Diluent (45 ml) 
BE1537 Antihuman Fluorescein-Labeled Globulin for 
Legionnaires' Disease (2 ml) 
Materials Required But Not Provided 
1. Twelve-well acetone resistant 
slides (Cel-line Associates, Inc., P.0. Box 213, 
Minotola, N.J. 08341), or teflon coated slides.^ 
2. Phosphate Buffered Saline, pH 7.2 
Preparation: 
Stock buffer* 40.0 ml 
NaCl 8.5 g 
Distilled water q.s. to 1,000 ml 
*109.6 g Na2HP0^ + 31.5 g NaH2P04*H20 + 




3. Glycerol Mounting Medium 
Preparation: 
0.5 M Carbonate-Bicarbonate buffer* pH 9.0 
Neutral glycerol, reagent grade 
Combine and mix by stirring (do not shake) 
*0.5 M Carbonate-Bicarbonate Buffer, pH 9.0 
A. Stock Solutions 
1. Na2C03 5.3 g 
Q.s. to 100 ml with distilled water. 
2. NaHC03 4.2 g 
Q.s. to 100 ml with distilled water. 
B. Working Solution 
1. 0.5 M Na2C03 stock solution 4.4 ml 
2. 0.5 M NaHC03 stock solution 100.0 ml 
NOTE: Theoretically, a pH of 9.0 should result from 
mixing 4.4 ml of solution 1 with 100.0 ml of 
solution 2; however, as much as 17.0 ml of 
solution 1 may have to be added to 100.0 ml 
of solution 2. For this reason, solution 1 
should be added to solution 2 with constant 
stirring and monitoring on a pH meter until 
the pH of 9.0 is reached. 
Since glycerol-based mounting media slowly 
drop in pH (increase in acidity) upon ex¬ 
posure to air, the pH of the mounting medium 
should be checked on a regular basis. The 
pH of the medium should be at least 8.0 for 
use in this IFA test. 
4. Coverslip, No. 1, 24X60 mm 
5. Pasteur pipettes 
6. Acetone 
7. Staining dishes 
8. Automatic pipettes, filro tips and microdilutors 
9. 13X100 mm test tubes and microtitration equipment 
10. Incubation chamber - large Petri dish with 







11. 37 C Incubator 
12. Distilled water 
13. Fluorescence microscope 
The following microscope assemblies are recommended for the IFA test 
for LD. These assemblies have been evaluated and are known to give 
satisfactory results. 
1. Transmitted illumination 
a. Fluorescence microscope: monocular or binocular equipped 
with a cardioid darkfield condenser. 
b. Light sources: 200 W ultra-high pressure mercury lamp or 
150 W high pressure xenon lamp. 
c. Filters: KG 1 or B1/K2 heat absorbing filter, BG 38 or l(__ 
BG 23 red suppression filter, KP 490 or 2* KP 490 (=kP 500) 
exciter filter, and K 510 or K 515 barrier filter.r-_ 
NOTE: Alternatively, a BG 12 (3 mm) exciter filter in 
combination with an OG 1 or K 510 barrier filter 
may be used; however, serum titration endpoints will 
be decreased approximately one two-fold dilution 
with this filter system. 
d. Eyepieces: 6.3x to lOx. 
e. Magnification range: 250x to 540x. (Wtih some 
assemblies magnifications as 
high as l,000x may be satis¬ 
factory. ) 
2. Epi-illumination 
a. Fluorescence microscope: monocular or binocular. 
b. Light sources: 100 W ultra-high presure mercury lamp, 
200 W ultra-high pressure mercury lamp, or 150 W high 
pressure xenon lamp. 
c. Filters: KG 1 or B1/K2 heat absorbing filter, BG 38 or 
BG 23 red suppression filter^2x KP 490 (=KP 500) exciter 
filtef*; TK 510 dichroic beam splitting mirror^, and K 510 
or K 515 barrier filter/-L (A K 480 edge filter may be 
inserted in the lamp housing to eliminate autofluorescence 
excited by the UV portion of the KP 490 filter). 




e. Magnification range: 250x to 540x. (With some 
assemblies magnifications as 
high as l,000x may be satis¬ 
factory) 
NOTE: In epi-illumination, the intensity of the 
exciting radiation depends on the numerical 
aperture (N.A.) of the objective used; therefore, 
oil immersion objectives with large numerical 
apertures are desirable for all magnifications, 
including lOx. (If a fluorite 40x oil objective 
with an N.A. of 1.3 is used, the serum titration 
endpoints will be increased approximately one 
two-fold dilution). 
If other comparable microscopic assemblies are used, they must 
reproduce the expected control human serum titers within one 
two-fold dilution of the specified endpoints in order to be 
considered satisfactory. To achieve the desired levels of 
reactivity, comparable microscope assemblies may require adjust¬ 
ments as follows: to lower serum endpoints, use broad-band pass 
filters, dry objectives of moderate numerical aperture, and/or 
a binocular head; to raise serum endpoints, use interference 
filters, immersion (or dry) objectives of high numerical aperture, 
and/or a monocular head. Use of low intensity light sources such 
as the tungsten halogen lamps may produce unsatisfactory results. 
Procedural Outline 
If large numbers of specimens are to be examined or if a small number of 
positives is expected, reagents and time can be saved by screening patients' 
sera at the 1:64 and 1:128 dilutions before complete titrations are done. 
1. Preparation of Antigen Slides 
a. Make sure antigen is evenly suspended by shaking vigorously. 
b. Apply antigen(s) to wells on slides using a pasteur pipette. 
Flood the well with antigen, then aspirate the excess back 
, into the pipette - this should leave approximately 400 
' organisms per field (at a magnification of 340x). 
c. Air dry slides for 30 minutes. 
d. Fix the slides in acetone for 15 minutes at room temperature. 
e. Air dry slides. 
2. Dilution of patients' sera and positive and negative control sera 
a. Make an initial 1:16 dilution of each serum in NYS by adding 
0.01 ml of serum to 0.15 ml NYS. 
b. Make twofold dilutions 1:32 to 1:1024 of each serum in micro¬ 
titer plates (or test tubes) using equal volumes of sera 
(0.05 ml) and PBS (0.05 ml). 

116. 
c. Do the same for the positive control serum. 
d. Make 1:32 and 1:64 dilutions of the negative control serum. 
3. Screening of sera 
a. Add the 1:64 and 1:128 dilutions of each patients' serum 
acute and convalescent or single serum) to antigen bearing 
slides. Add the 1:32 and 1:64 dilutions of the negative 
control serum and the 1:32 through the 1:1024 dilutions of 
the positive control serum to antigen bearing slides. 
b. Incubate at 37 C for 30 minutes in a moist chamber. Rinse 
briefly with PBS, then place in PBS for 10 minutes. 
Gently blot dry. 
c. Reconstitute the antihuman conjugate as directed and add to 
the slides (approximately 20/ul/well). Incubate at 37 C 
for 30 minutes. Rinse briefly with PBS, then place in PBS 
for 10 minutes. Rinse briefly with distilled water. 
Gently blot dry. 
d. Mount coverslips with the glycerol mounting medium and examine 
the slides with an appropriately equipped fluorescence micro¬ 
scope (see Material Required But Not Provided). 
4. Titration of sera 
Positive sera for which endpoint titers are to be obtained are processed 
as above using all dilutions of each serum, along with positive and 
negative control sera. 
NOTE: To avoid wash-over of antibody from well to well, slides 
~ bearing strongly positive sera (_> 1024) should be rinsed 
separately. 
Reading of Results 
Light sources, magnification, kinds of objectives, eyepieces etc., influence 
intensity of staining. Reading of endpoints with each microscope assembly 
must be made with reference to the positive control serum(s) used with the 
antigen(s) and conjugate provided. 
Record brightness of staining at each dilution. The intensity of staining 
of the bacterial cells may vary at a given dilution; however, the degree 
of staining intensity recorded is based on the overall appearance of the 
smear. 
4+ * Maximal fluorescence; brilliant yellow-green staining 
3+ “ Bright yellow-green staining 
2+ “ Definite but dim yellow staining 
1+ = Barely visible staining 




Staining endpoint: 1+ 
Serum titration endpoint (titer): the recipricol of the highest dilution 
of aerum giving at least a 1+ fluorescence of a_t least half the number 
of LD bacteria in the field. 
RESULTS 
A fourfold rise in titer to >128 from the acute to the convalescent phase 
provides evidence of a recent infection. A standing or single titer of 
2256 provides presumptive evidence of infection at an undetermined time. 
The reagents provided with this brochure are research reagents. Collection 
of information needed to determine their sensitivity and specificity is not 
yet complete; therefore, results obtained should not be used as a basis for 
making patient treatment decisions. 
LIMITATIONS OF PROCEDURE 
Variation in intensities may be observed when different microscopic 
assemblies are used. Testing of sera should not be attempted unless, 
when used with the antigen and conjugate provided, the positive control 
serum gives the expected titer within one two-fold dilution and the 
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READ THIS BROCHURE IN ITS ENTIRETY 
BEFORE PROCEEDING 
LEGIONELLA INDIRECT FLUORESCENT 
ANTIBODY RESEARCH REAGENTS 
intended use 
These products are tor Research Use only; not for use in diagnostic 
procedures. 
SUMMARY AND EXP Li'.' VT ION Or i ILL TL.T 
The Legionella indirect fluorescent antibody (IFA) test is an immuno¬ 
fluorescence procedure for detection of anti-Legiouelia antibodies in 
human serum.* At the present time this research IFA Lest appears to be 
specific for Legionella organisms; however, if posjib'.e th_ test should be 
used in conjunction with isolation of the organism fr in biopsy or autopsy 
material* or demonstration of the orgmisms iu ti •, > > e specimens. ** Thus 
far, four distinct serogroups have been described. 
As with any serological test, the most convincing serological evidence of 
a recent infection with the Legionella bacterium is a fourfold rise in 
titer between the acute phase of illness (within the first week) and 
convalescent phase (3 to 3 weeks after onset). In the Legionella IFA 
test, the rise in titer must be to at least 128 to be considered positive. 
A single or standing titer of >256 is considered presumptive evidence of 
Legionella Infection at an undetermined time. Current data indicate that 
titers of 32 and 64 in the absence oi detectable d: e are common. 
PRINCIPLES 01 i ilE PRGuijDI KE 
The IFA test is a "sandwich" immunofluorescence technique which uses a 
two-stage reaction procedure. In the lirst stage, a given antigen is 
overlaid with dilutions of antiserum (animal or human); then the slides 
are incubated, washed, and dried. In the second stage, the antigen is 
overlaid with fluor labeled antiglobulin produced against the animal 
species that provided the unlabeled serum applied in the first stage. In 
this manner, antigens are tendered fluorescent by positive antisera which 




The fluorescent dye used to label the antispecies globulin is iluorescin 
isothiocyanate (FITC). When this dye is excited by near ultravoilet-blue 
light, it emits longer wavelengths of light in the yellow-green portion of 
the color spectrum, thereby making visible those immune complexes formed 
in situ. The microscopic appearance of antigen stained by this immuno¬ 
fluorescence technique is indistinguishable from ttiat stained by the 
direct method. 
REAGENTS 
1. LEGIONELLA ANTIGENS are trilled suspensions of Legionella organisms 
serogroup Philadelphia 1serogroup 2 Togus 1, serogroup 3 
Bloomington 2, and serogroup 4 Los Angelcsl organisms grown on 
artificial medium and suspended in normal yolk sac (NYS). The final 
concentration of NYS is 0.5%.* * Each antigen is packaged separately 
and as part of a polyvalent (serogroups 1, 2, 3, and 4) product in 2 
ml volumes and is at the working dilution. Each contains 0.05% 
sodium azide as a preservative. Store at 4 C. Two ml of antigen, 
when applied to the slides as recommended will be sufficient to 
prepare approximately 1,000 wells. 
*NYS concentration in lots 78-0006K and 78-0007 is 1.0%. 
2. LEGIONELLA POSITIVE CONTROL HEM"! SERA are high-titered positive sera 
diluted with normal human sera so that they have ItA titers of 128 to 
512. See addendum 1 for titers assigned to each lot. The serogroup 
with which each serum is reactive is indicated on the label. They 
are packaged in 1 ml volumes and contain 0.05 ncrcent sodium azide as 
a preservative. Store at 4 C. Use of 0.01 ml to make a 1:16 
beginning dilution allows approximately 100 control titrations to be 
performed. 
3. NORMAL 3 PERCENT* CHICKEN YOLK SAC SUSPENSION is an homogenized 
suspension of yolk sacs suspended in phosphate buffered saline (PBS) 
pH 7.2 to give a 3 percent suspension (wt/vol). The product is 
dispensed in 45 ml amounts and is at the working dilution. Sodium 
azide is added to a final concentration of 0.05 percent as a 
preservative. Store at 4 C. When used to make the 1:16 dilution 
only, 45 ml of yolk sac suspension is a sufficient quantity for 
approximately 300 tests. 
*NYS lots 78-0006K and 78-0008 are 10% suspensions and can be diluted 
1:4 before used. 
4. ANTIHUMAN Ig FLUORESCEIN-LABELED GLOBULIN is the globulin fraction of 
antihuman rabbit serum labeled with fluorescein isothiocyanate. When 
used as directed, this conjugate does not detect Igtl through heavy 
chain (u) specific reactions. However, extremely sensitive 
specificity tests show that the conjugate cross reacts with Ig.T, 
presumably through anti-light chain moieties. The product is freeze- 
dried. Reconstitute with 4 ml* of pH 7.2 PBS. This Is The Working 




preservative. Store at 4 C. if 20 ul of conjugate per well are 
used, 4 ml of conjugate will be sufficient to stain 20U wells. *Lots 
78-0006K and 78-0009 are packaged in 2 ml amounts; this volume is 
sufficient for approximately 100 wells. 
NOTE: STABILITY OF REAGENTS. Long term stability data for these 
reagents are not yet available; therefore, no expiration dates 
have been assigned. However, if all reagents when used 
together react as described in this brochure, they may be 
considered satisfactory for use. 
PROCEDURES 
Materials Provided 
A set of reagents (KK0U03) including serogroup 1 antigen positive control 
serum, yolk sac diluent and antihuman on jugate is avail lble. in 
addition, group 1 antigen, serogroup 2 antigen, serogroup 2 positive 
control serum, serogroup 3 antigen, group 4 antigen, and 3 percent yolk 
sac suspension, and antihuman globulin are distributed as individual 
reagents. Serogroups 2, 3, 4, and polyvalent (1, 2, 3, 4) antigen and 
serogoup 2 positive control serum can be used with yolk sac suspension and 
conjugates provided as part of set KK0003 or provided as individual 
reagents. 
1. KK0003 Legionella IFA Reagent Set 
a. Legionella Serogroup 1 Philadelphia i Isolate Antigen (2 ml) 
b. Legionella Serogroup 1 Positive Control Serum (PCS) 
c. Normal 3 Percent Chicken Yolk Sac Suspension (NYS) 
















BC 1 366 
BE1537 
Legionella Serogroup 1 Philadelphia 1 Strain Antigen (2 ml) 
Legionella Serogroup 2 Togus 1 Strain Antigen (2 mi) 
Legionella Serogroup 2 Positive Control Serum (1 ml) 
Legionella Serogroup 3 Bloomington 2 Strain Antigen (2 nl) 
Legionella Serogroup 4 Los Angeles 1 Strain Antigen (2 ml) 
Legionella Polyvalent (Serogroups l, 2, 3, and 4) Antigen 
Normal 3 Percent Yolk Sac Diluent (45 ml) 
Antihuman Fluorescein-Ijbe I ed CLobuLir. lor Legionella (2 ml) 
Materials Required But Not Provided 
1. Twelve-well acetone resistant 
slides (Cel-line Associates, Inc., P.0, box 213, 





2. Phospnate Buffered Saline, pH 7.2 
Preparation: 
Stock buffer* 40.0 ml 
HaCl 8.5 g 
Distilled water q.s. to 1,000 ml 
*109.6 g Na2HPO4 + 31.5 g NaH2P04*H20 + 
distilled water q.s. to 4 liters. 
3. Glycerol Mounting Medium 
Preparation: 
0.5 M Carbonate-Bicarbonate buffer* pH 9.0 1 part 
Neutral glycerol, reagent grade 9 parts 
Combine and mix by stirring (do not shake). 
*0.5 M Carbonate-Bicarbonate Buffer, pH 9.0 
A. Stock Solutions 
1. Na2C03 5.3 g 
Q.s. to 100 ml with distilled water. 
2. NaHC03 
Q.s. to 100 ml with distilled water. 
B. Working Solution 
1. 0.5 M N32CO3 stock solution 4.4 ml 
2. 0.5 M NaHC03 stock solution 100.0 ml 
NOTE: Theoretically, a pH of 9.0 should result from mixing 4.4 
ml of solution 1 with 100.0 ml of solution 2; however, as 
much as 17.0 ml of solution 1 may have to be added to 
100.0 ml of solution 2. For this reason, solution 1 
should be added to solution 2 with constant stirring and 
monitoring on a pH outer until the pH of 9.0 is reached. 
Since glycerol-based mounting media slowly drop in pH 
(increase in acidity) upon exposure to air, the pH of the 
mounting medium should be checked on a regular basis. The 
pH of the medium should be at least 8.0 for use in this 1FA 
test. 
4. Coverslip, No. 1, 24X60 mm 
5. Pasteur pipettes 
6. Acetone \ 




tt. Automatic pipettes, fibro tips and rr.icroc'.tutors 
Q. 11X100 mm test Lubes and microtitraLLon equipment 
10. Incubation chamber - large Petri dish with moistened filter paper, or 
comparable moisture retaining chamber 
11. 37C incubator 
12. Distilled water 
13. Fluorescence microscope 
The following microscope assemblies 
for LD. These assemblies have been 
satisfactory results. 
are recommended for the IFA test 
evaluated and are known to give 
1. Transmitted illumination 
a. Fluorescence microscope: monocular or binocular equipped 
with a cardioid darkfield condenser. 
b. Light sources: 200 W ultra-high pressure mercury lamp or 150 
W high pressure xenon lamp. 
c. Filters: KG 1 or B1/K2 heat absorbing filter, BG 38 or BG ii 
red suppression filter, K.P 490 or 2x KP 490 (=kP 500) exciter 
filter should be inserted in the lamp housing to eliminate 
autofluorescence excited by the UV portion of the K_P 490 
filter). 
NOTE: Alternatively, a BG 12 (3 mm) exciter filter in 
combination with an UG 1 or K 510 barrier filter may be 
used; however, serum titration endpoints will be decreased 
approximately one two-fold dilution with this filter 
system. 
d. Eyepieces: 6.3x to 10x. 
e. Magnification range: 230x to 540x. (With some assemblies 
magnifications as high as 1,OOOx may be 
satisfactory.) 
2. Epi-illuuination 
a. Fluorescence microscope: monocular or binocular. 
b. Light sources: 100 W ultra-high pressure mprrury lamns, 200 W 





c. Filters: K.G 1 or B1/K2 heat absorbing filter, bG 38 or liG 23 red 
suppression filter, 2x KP 490 (**KP 500) exciter filter, TK 510 
dichroic beam splitting mirror, and k 51U or k 515 barrier 
filter. (A K 480 edge filter should be inserted in the lamp 
housing to eliminate autofluorescence excited by the UV portion 
of the KP 490 filter). 
d. Eyepieces: 6.3x to lOx. 
e. Magnification range: 250x to 540x. (With some assemblies 
magnification as high as l,000x may be 
sat 1sfactory.) 
NOTE: In epi-illumination, the Intensity of the exciting radiation 
depends on the numerical aperture (N.A.) of the objective 
used; therefore, oil immersion objectives with large numerical 
apertures are desirable for all magnifications, including lOx. 
(If a fluorite 40x oil objective with an N.A. of 1.3 is used, 
the serum titration endpoints will be increased approximately 
one two-fold dilution). 
If other comparable microscopic assemblies are used, they must 
reproduce the expected con. t ro 1 ' human seiurn titers within one two-fold 
dilution of the specified endpoints in order to be considered 
satisfactory. To achieve the desired levels ot reactivity, 
comparable microscope assemblies may require adjustments as follows: 
to lower serum endpoints, use broad-band pass filters, dry objectives 
of moderate numerical aperture, and/or a binocular head; to raise 
serum endpoints, use interference filters, immersion (or dry) 
objectives of high numerical aperture, and/or a monocular head. Use 
of low intensity light sources such as the tungsten halogen lamps may 
produce unsatifactory results. 
Procedural Outline 
If large numbers of specimens are to be examined or 11 a small number of 
positives is expected, reagents and time can be saved by screening 
patients' sera at tlie 1:64 and 1:128 dilutions before complete titrations 
are done. — " 
1. Preparation of Antigen Slides 
a. Make sure antigen is evenly suspended by shaking vigorously. 
b. Apply antigen(s) to wells on slides using a pasteur pipette. 
Flood the well with antigen, then aspirate the excess back into 
the pipette - this should leave approximately 400 organisms per 
field (at a magnification of approximately 340'''). 




d. Fix die slides in acetone for 13 minutes at room temperature. 
e. Air dry slides. 
2. Dilution of patients' sera and positive control serum 
a. Make an Initial 1:1b dilution of each serum in NYS by adding 
0.01 ml of serum to 0.15 ml NYS. 
V b. Make twofold dilutions 1:32 to 1:1024 of each serum in microtiter 
plates (or test Lubes) using equal volumes of sera (0.05 ml) and 
PBS (0.05 ml). 
c. Do the same for the positive control serum. 
3. Screening of sera 
a. Add the 1:64 and 1:128 dilutions of each patients' serum acute 
and convalescent or single serum) to antigen bearing slides. Add 
the 1:64 through the 1:1024 dilutions of the positive control 
serum to antigen bearing slides. Add PbS to one antigen well to 
>' serve as a conjugate control. * - 
b. Incubate at 37 C for 30 minutes in a moist chamber. Rinse 
briefly with PBS, then piaec in PBS for iU minutes. Gently blot 
dry. 
c. Reconstitute the antihuman conjugate as directed and add to the 
slides (approximately 20 ul/v. 11). Incubate at 37 C for 30 
minutes. Rinse briefly with I'Ba, then place In PBS for 10 
minutes. Rinse briefly with distilled water. Gently blot dry. 
d. Mount coverslips with the glycerol mounting medium and examine 
the slides with an appropriately equipped fluorescence microscope 
(see Material Required But Not Provided). 
4. Titration of sera 
Positive sera for which endpoint titers are to be obtained are 
processed as above using all dilutions of each serum, along with the 
positive control serum. 
NOTE: To avoid wash-over of antibody from well to well, slides 
bearing strongly positive sera (M024) should be rinsed 
separately. , 
Reading of Results 
Light sources, magnification, kinds of objectives, eyepieces etc., 




microscope assembly must be made with reference to the positive control 
serum(s) used with the antigen(s) and conjugate provided. 
Record brightness of staining at each dilution. The intensity of staining 
of the bacterial cells may vary at a given dilution; however, the degree 
of staining intensity recorded is based on the overall appearance of the 
smear. 
4+ = Maximal fluorescence; brilliant yellow-green staining 
3+ =* Bright yellow-green staining 
2+ =* Definite but dim yellow-green staining 
1+ « Barely visible yellow-green staining 
Negative m Absence of yellow-green specific fluorescence 
Staining endpoint: Id- 
Serum titration endpoint (titer): the rccipricol of the highest dilution 
of serum giving at least a 1+ yellow-green fluorescence of at least half 
the number of Legionella bacteria in the field. 
RESULTS 
A fourfold rise in titer to >128 from the acute to the convalescent phase 
provides evidence of a recent infection. A standing or single titer of 
>256 provides presumptive evidence of infection at an undetermined time. 
Single titers of less than 256 are not considered evidence of infection. 
The reagents provided with the brochure are research reagents. Collection 
of information needed to determine their sensitivity and specificity is 
not yet complete; therefore, results obtained should not be used as a 
basis for making patient treatment decisions. 
LIMITATIONS OF PROCEDURE 
Variation in Intensities may be observed when different microscopic 
assemblies are used. Testing of sera should not be attempted unless, when 
used with the antigen and conjugate provided, the positive control serum 
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LEGIONELLA INDIRECT FLUORESCENT ANTIBODY RESEARCH REAGENTS 
Addendum 1 
Legionella Serogroup 1 Positive Control Serum 
CAT NO LOT NO IFA TITER 
BS1528 77-0358K 256 
BS1528 78-0006K 256 
BS1528 78-0290K 512 
BS1528 79-0103K 256 
Legionella Serogroup 2 Positive Control Serum 
CAT NO LOT NO IFA TITER 
BS1525 78-0297 • 512 
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An outbreak of pneumonia occurred in Bridgeport, Connect¬ 
icut in the fall of 1978. A number of the outbreak-associated 
cases were found to show serologic evidence of infection by the 
agent of Legionnaires' Disease (LD). A case-comparison study 
was carried out on 21 confirmed and 7 presumptive cases of LD 
and 29 seronegative pneumonia patient controls, all hospital¬ 
ized in Bridgeport in the fall of 1978. A telephone question¬ 
naire was used to investigate geographic environmental exposures 
and medical histories of both cases and controls, with the in¬ 
tent of determining place exposure or host-specific factors 
predisposing to LD. Comparisons between cases and controls 
revealed no significant differences in demographic characteris¬ 
tics or clinical risk factors. Because a substantial number 
of LD cases were found to have onset in the week of 9/3/78, 
further comparisons were made between those cases with week of 
9/3 onset, cases with other onset, and controls. When cor 
pared to both 9/3 onset cases and controls, LD cases of otho" 
onset appeared to have had significant exposures to downtown 
Bridgeport. The possible involvement of LD-contaminate: cool¬ 
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In the fall of 1978, a large number of persons hospitalized with 
pneumonia in Bridgeport were found to have Legionnaires' Disease(LD). 
Because more cases were diagnosed in Bridgeport than in most other areas 
of Connecticut, both local physicians and the state and local health de¬ 
partments were concerned that this represented an epidemic. Information 
on previous incidence was unavailable because identification of the 
causative organism of LD was first reported in late 1977. The dates of 
onset of the LD cases clustered in early September and mid-October. 
This suggested that the cases may have had a common time and/or place 
of exposure where they came into contact with the LD bacterium. Because 
most of the previously described clusters were associated with exposure 
to specific buildings or defined geographic areas, the State Health 
Department proposed this investigation as a suitable student project 
with these specific purposes! l) to determine if an outbreak of LD had 
occurred in Bridgeport, 2) to characterize descriptively the epidemioloyv 
of LD in that area, 3) to investigate the possibility that the cases 
had a common source of exposure and 4) to investigate the kinds of 
exposures experienced by LD cases and persons who had non-LD pneumonias. 
BACKGROUNDi 
Bridgeport is a heavily industrialized city of almost 156,000 
people located on Long Island Sound approximately 60 miles from New York 
City. It major industries include General Electric, Remington Arms, 
Acme United and United Illuminating. Like many northeastern, industri¬ 
alized cities, it is struggling with a shrinking tax base caused by the 




population of Bridgeport Includes a high percentage of poor, underskilled 
persons in need of many social services. Demographically, according to 
the 1970 census, non-whites comprise 17.7% of the population. Persons 
over 65 years of age comprise 11.9% of the population, which is slightly 
higher that the U.S. average. 
Bridgeport is served by three hospitals - Bridgeport, St. Vincent's, 
and Park City - and has an active City Department of Health. The city has 
anumber of large housing projects that are near the downtown area with 
the better neighborhoods located at the periphery of the city. 
LITERATURE REVIEW 1 
In the almost three years the first well publicized outbreak cr 
LD in Philadelphia, much has been learned about the epidemiology of this 
1-4 
illness. Legionnaires' Disease is caused by a newly discovered family 
5-7 
of bacteria that are extremely difficult to grow on normal culture media. 
From the various outbreaks, where a common source of exposure was iden¬ 
tified, the incubation period has been estimated at from 2-10 days.* 
LD is a non-descrJ.|rt illness in its early stages with increasing fever, 
muscle aches and a dry cough. In various reports, nausea, vomiting and/or 
diarrhea have been described in from 20-40% of cases. By the time medical 
attention is sought, the patient, who is usually a person over 50 years 
of a£e with a history of smoking, has a frank pneumonia that, in the 
more serious cases, progresses despite antibiotic treatment.*’ ® *° The 
case fatality rate has been estimated at approximately 15%, although 
4 8 
this undoubtably reflects underdiagnosis of milder cases. Erythromycin 
is felt to be the drug of choice after having been associated with a lower 
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case fatality rate than other antibiotics in the Philadelphia outbreak.1 
Since the Philadelphia outbreak approximately 15 other outbreaks 
have been described throughout the world. It is from these occurences 
that most of the known epidemiology has come.11 The outbreaks have tended 
to occur in the late summer or early fall with exposure to the vicinity 
of a single building or group of buildings being associated with subse¬ 
quent development of the disease. In some of the outbreaks specific air 
conditioning or ventilation systems have been implicated as the means of 
dissemination of the organism. Several of the buildings were undergoing 
construction or had nearby excavation at the time of or just before the 
outbreak. There has been no documentation of person-to-person spread. 
Because of this, there has been a search for the bacteria's natural reser¬ 
voir that has been unsuccessful thus far. Testing of various animals and 
birds from sites of the outbreaks have failed to demonstrate carriage of 
the organism. The only environmental isolations have been from cooling 
towers and evaporative condensers of air cooling systems from the sites 
of outbreaks. In an outbreak in Bloomington, Indiana, the organism was 
Isolated from the banks of a small, thermally-polluted stream. The asso¬ 
ciation of recent construction and excavation with several of the outbreaks 
has suggested the soil as a natural reservoir, but the organism has not 
12-16 
been isolated from the soil at these construction sites. 
In addition to the outbreak-associated cases, several hundred 
4 
sporadic cases have been reported. The onsets of these sporadic cases 
tended to cluster in the late summer and early fall. These patients have 




case-control study where the sporadic LD cases were compared with persons 
of similar age, gender, and state of origin and who had ijhImbb submitted 
for LD testing that were negative, persons with LD were more likely to 
smoke cigarettes, be heavy users of alcohol, have construction near their 
17 
home, and to be non-white rather than white. 
As noted, little Incidence data for LD Is available because of the 
very recent discovery of this disease and its diagnostic test. One pro¬ 
spective study on bloods collected during respiratory illnesses from pa¬ 
tients in the Seattle area suggests that 1.2-3*^ persons per 10,000 con¬ 
tract the disease annually. However, the absolute number of cases found 
18 
in this study was very small. A number of non-random prevalence sero- 
surveys have been performed, generally in conjunction with the evaluation 
of outbreaks. The rate of elevated antibody titers (1«128) has been as 
high as 13& in populations not exposed to the building implicated, sug- 
12-14 
gesting that LD may be endemic in local areas. 
Clearly, much needs to be done to elucidate the reservoir of the 
organism, the clinical spectrum of the disease, and its incidence in 
various communities and select populations. 
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A. Descriptive Investigation 
1) An Epidemic of Pneumonia 
The initial hypothesis we sought to test was that an unexpected 
excess of pneumonia cases were admitted to the three hospitals in Bridge¬ 
port (Bridgeport Hospital, Park City Hospital, and 5t. Vincent's Hospital) 
during the late summer of 1979. As suggested Dy serologic confirmation 
in a number of cases, this excess of pneumonia cases was presumably due 
to infections by the agent of LD. 
Population data for the City of Bridgeport were obtained from the 
1970 U.5. Census to be used as denominator data in the calculation of 
city-wide rates. Each of the three hospitals in Bridgeport made available 
their Professional Activities Service (PAS) data regarding discharges and 
deaths for each month of 1976, 1977, and 1978. from this data we were 
able to calculate both pneumonia-specific discharge and pneumonia-specific 
death rates for each of these months. The pneumonia-specific discharges 
and deaths were ascertained on the basis of primary discharge diagnosis, 
using all I.C.D.A. codes from 480 to 486, inclusively. From the data we 
were able to compare these pneumonia-specific rates for each of the six 
months from July to December for 1978 with the same months of the previous 
two years. These comparisons tested whether there had been a significant 
excess of pneumonia cases in Bridgeport in the late summer of 1978. 
2) Changing Physician Awareness 
As noted, LD is a "new" disease. This etiologically defined infectious 
disease, and its specific sero-diagnostic test, were first described in 
December, 1977. Since then there has been an erratically progressive 




well publicized outbreaks of LD in New York City and Norwalk earlier in 
the summer of 1978, Bridgeport physicians' indices-of-suspicion for considering 
LD in the differential diagnosis of pneumonia were undoubtedly increasing 
at the time of the Bridgeport outbreak. This may have led to an increased 
rate of serologic testing of patients with pneumonia by Bridgeport physicians 
and hence to an increase in the total number of cases diagnosed. However, 
increased testing would be expected to lower the proportion of all tests 
that were positive, if there were no epidemic. Therefore, summary data 
were obtained from the State Department of Health regarding numbers of 
positive and total specimens tested during 1979. These numbers were broken 
down into two categories: (1) those from Bridgeport, three surrounding 
cities, and Norwalk, and (2) those from the rest of the state (most specimens 
from the Norwalk outbreak were submitted directly to the C.D.C. and 
were not included in our data). The proportion of positive tests and the 
total number of positive tests from the Bridgeport area were compared 
with the analogous data for the rest of the state in order to assess the 
impact of variations in the rates of serologic testing for LD. 
B. Case-Comparison Study 
Results from the descriptive investigation suggested that there had 
indeed been an epidemic of pneumonia in Bridgeport. Therefore, we conducted 
a case-comparison study to more fully describe the epidemic, to identify 
risk factors for developing LD, and to identify possible environmental 
sources of the agent of LD in Bridgeport. Results of this study were 
intended to allow institution of preventive measures in Bridgeport and to 




1) Chart Review 
Over 250 hospital charts for all patients with primary discharge 
diagnosis of pneumonia and with discharge date between August 1 and 
November 30, 1978 were provided for review by the three hospitals. These 
charts were identified from the PAS listings and allowed us to confirm 
that we had been complete in ascertaining all target pneumonia cases. 
Demographic data abstracted included: (1) name, (2) age, (3) sex, (4) race, 
(5) occupation, (6) address, end (7) phone number. Clinical data abstracted 
included: (1) primary discharge diagnosis, (2) dates of onset, admission, 
discharge, and date of chest radiograph first positive for pneumonia or 
infiltrate, (3) past history of other diseases, (4) severity of illness 
(maximum temperature, use of respirator, fatality), (5) results of cultures 
and serologic tests, and (6) name of physician (Table 1). 
7) The Sample frame 
From these records, we established a study population of 123 patients 
satisfying the following epidemiologic and clinical criteria; all subjects: 
(1) were hospitalized in one of the three hospitals in Bridgeport, (?) had 
onset of illness between August 1 and October 31, 1978, (3) were residents 
of Bridgeport, (4) were at least 18 years of age, (5) had primary discharge 
diagnosis of pneumonia, and (6) had a positive chest radiograph for pneumonia 
or infiltrate. Pertinent data from the chart review were line-listed 
by case for all study subjects. In addition, we characterized the study 
population according to gender, race, age, week of onset, underlying illness, 
history of smoking, and severity of illness. 
3) Case Definitions 




cla ssified as either cases, controls, or indeterminate based upon the 
results of serologic testing. Cases included subjects showing either 
seroconversion with a four-fold or greater rise in titer (reciprocal of 
dilution) to 128 or higher between acute and convalescent phase samples 
(confirmed case), or a single positive titer of 256 or higher in a 
convalescent phase specimen (presumptive case). Controls included subjects 
whose convalescent serologic test was negative (titer less than 256). 
Serologic testing was conducted by the Connecticut State Department of 
5 
Health using the indirect flourescent antibody test for LD. Subjects 
without adequate convalescent phase specimens were considered indeterminate. 
4) Ethics Committee Review 
A protocol for developing a questionnaire, surveying the study subjects, 
and obtaining serologic specimens was presented to and approved by the Yale 
Human Investigations Committee. The protocol was then presented to the 
appropriate committees of each of the hospitals in Bridgeport, and was 
approved after minor revisions. 
5) Telephone Questionnaire 
Consent was obtained from six confirmed LD cases and their physicians. 
1 7 
Using the questionnaire from the national sporadic LD study as a guide, 
members of the study team conducted in-depth in-person interviews with the 
six LD cases. This information was used to develop a telephone questionnaire 
specific to the Bridgeport outbreak. Our questionnaire was designed to 
ascertain information regarding geographic and environmental exposures 
during the two weeks before onset of illness using both open and direct 
questioning interview techniques. In addition, we used direct questioning 




6) Data Collection 
The private physicians of the study subjects were informed of the 
study's purposes and asked to consent to our contacting their patients. 
Study subjects for whom we obtained physician consent were then mailed 
a letter of introduction. The letter informed subjects of the nature of 
the study and urged them to try to recall their activities during the two 
weeks before onset of illness. During March, 1979 we administered our 
questionnaire to all available consenting study subjects, or their closest 
available contact in those cases where the subject was incompetent. Subjects 
who could not be reached were sent a final letter asking that they call 
a member of the study group, collect, to complete the questionnaire. 
Consenting subjects with inadequate convalescent serology specimens 
had a blood sample drawn, at no charge, at their hospital. In those cases 
where the subject could not go to the hospital, nurses from the City 
Department of Health went to the subjects' homes to obtain specimens. 
Samples were carefully processed and forwarded to the State laboratory for 
testing. In addition, all convalescent phase samples were tested for 
evidence of mycoplasma pneumoniae infection by complement fixation assay. 
7) Data Analysis 
Data collected in the case-control study were used to identify risk 
factors predisposing to developing ID, and to locate possible environmental 
sources of the agent of LD. 
To evaluate possible case contacting biases in the case- comparison 
study, we compared the persons included with the persons not included by 
demographic and clinical characteristics obtained from chart review. 




of LD, we first line-listed all data from open questions relating to 
places visited for each subject. Because the epidemic curve showed a 
distinct clustering of cases with dates of onset during the week beginning 
September 3, 1978, we divided cases into two groups: (1) those with onset 
during that week, and (2) all other cases of LD. These two groups were 
compared with each other in a separate analysis. 
Two large maps of the city were obtained from the Office of City 
Planning and we mapped all locatable data from our line listing by color 
coding subjects as "9/3 Cases," "Other Cases," and "Controls." On the 
second map, using the same procedure, we mapped no more than two locations 
per subject; these being selected on the basis of longest (time) exposure - 
usually residence and place of work. Locations outside or the city were 
listed separately by subject to identify other possible common sources 
of exposure. 
To avoid spurious clustering of points attributable to a single subject, 
we mapped only locations at least 800 feet distant from other locations 
listed for that subject. Preference was again given to the location 





Twenty-one cases of Legionnaires* disease we*-e confirmed by 9-fold titer 
rises in city of Bridgeport residents during the period August 1 through October 31. 
1978, The incidence rate is 5.36/10,000 per year which is about four times that 
l8 
found in the Seattle virus watch. 
Two additional methods were used to determine whether or not these cases 
constituted an outbreak. The first is a comparison of seropositive results/ speci¬ 
mens submitted from Bridgeport, three surrounding towns, and Norwalk versus the rest 
of the state for 1978. This comparison assessed the effect of increased physician 
awareness in increasing the number of specimens submitted and consequently, the 
likelihood of Legionnaires' disease diagnosis. Table 2 shows that 9.5,9$ of persons 
from Bridger>ort, three surrounding towns, and Norwalk who had sera sent for 
the diagnosis of Legionnaires' disease were positive, whereas only 15.7$ of 
persons who had sera submitted from the rest of the state were positive. There were 
an unknown number of samples submitted directly to the Center for Disease Control 
from the Norwalk outbreak. These are not included in the numbers given here. 
Given that Dhvsician awareness of the Dossibility of Legionnaires' disease in the 
BridgeDort area in fall 1978 could lead to more submitted specimens overall, it 
might be exDected that the seropositivitv rate would have decreased. The higher 
rate provides additional support to the hypothesis that an outbreak occurred. 
The second method examined the temporal distribution of pneumonias in 1978 
versus previous years through a month-by-month comparison of proportion of dis¬ 
charges attributed to nneumonia. As can be seen in Graph 1, total number of pneu¬ 
monia discharges from the three hospitals in Bridgeport appears high in September 
and October 1978. The month of December 1977 also appears to be high. When these 
figures are expressed as a per cent of total discharges to control for fluctuation 
in the number of discharges per month, see Graph 2, the increase in September and 
October 1978 are again striking. The December 1977 peak probably represents an 




the rates in September and October 1978 to be highly significantly different from 
oast years. The months of July, August, November, and December 1978 are not 
different from past years (see Table j). This data suggests that the impression 
of an increase in the number of oatients requiring hosDitalization for pneumonia 
during September and October 1978 was real and mav reflect a community outbreak 
of Legionnaire's disease. 
The number of deaths attributed to pneumonia per month in 1978 as a proportion 
of the number of cases of pneumonia discharged when compared to average monthly 
proportions for 1976 and 1977 showed no significant differences even in September 
and October. This suggests that although more oatients with pneumonia were being 
hospitalized, they were not more severelv ill than in past years. (Table 4) 
With our suspicion of an outbreak apparently confirmed, we determined from 
abstraction of hospital charts 123 Bridgeport residents meeting the study criteria 
of pneumonia documented by positive chest X-ray who had onset between August 1 
and October 31• 1978, required hospitalization, and were over 18 years of age. 
Table 5 gives the results of our efforts to enroll these persons in the study. 
Although our overall response rate is 46$ (80$ in persons with known Legionnaires' 
disease and 33$ in persons not known to have Legionnaires' disease), the 29 per¬ 
sons who completed our questionnaire and had negative serological testing for 
^gionnaires' disease represent 57$ of the group with no previous diagnosis of 
Legionnaires' disease who were reachable when deaths (9$), physician refusals 
for patient contact (3$), and those unreachable by phone (16$) or mail (11$) 
are excluded. Serological testing results are pending on an additional 11$, 
Table 6 presents the information which is available from chart review material 
on the entire sampling frame. Fifty-seven persons were included in the study, and 
66 persons were not. Selected demographic and clinical characteristics of the 
two subsets were compared , and no statistically significant differences 




ference between the two groups. The clinical characteristics of the two 
groups are similar also with only a slightly higher participation rate 
of those with a past history of respiratory illness. The participation 
of smokers and non-smokers was notably similar. Graph 3 shows by week of 
onset, the entire samplfe frame, those included and those not included in 
the study. People who died were excluded from the study. 
Cage-Comparison Study 
We were able to interview 25(7950 of the 32 persons with confirmed 
or presumptive LD that had been diagnosed at the time of their hospitali¬ 
zation in the fall. Serum was obtained and the questionnaire was adminis¬ 
tered to 31(3^50 of the 90 persons hospitalized with pneumonia who had 
either had no previous testing or an inadequate convalescent specimen. 
One person was also interviewed who was previously not found to have LD 
on the basis of paired serologic specimens sent by his physician. Of 31 
persons from whom sera was obtained, 3 were found to have an LD antibody 
titer7 256 implying previous exposure to the LD bacterium. These 3 were 
considered presumptive cases and added to the 25 persons previously diag¬ 
nosed as having LD. The remaining 29 persons were from our non-LD pneumo¬ 
nia control group. All persons included in the study had mycoplasma com¬ 
plement fixation testing, none of which were positive. The epidemic 
curve (Graph 4), which compares the dates of onset of the patients with 
LD and those with other pneumonias, shows a pronounced peak in the week 
beginning September 3 among the persons with LD. 
Questionnaire Analysis 




versus the controls. At the time of their Illnesses, the cases had a 
median age of 64.5 years (33“87 range) while the median for the controls 
was 62 (23-90 range). Seventy-one % of the cases were male compared with 
only 48% of the controls, for a gender ratio of 2.5*1 males to females 
among the cases. However, this difference is not statistically significant 
= 2.78, p^.l) The cases and controls were similar in racial compo¬ 
sition and approximated the racial distribution of the population of 
the city. There was a tendency for the cases to be from a higher socio¬ 
economic class than were the controls as compared by level of education 
and proportion employed. This difference also does not reach statistical 
significance. None of the cases were employed in construction or excava¬ 
tion work. 
Clinical risk factors that may predispose one to develop pneumonia 
in general or LD in particular are compared in Table 8. Although a past 
history of an underlying medical illness was common, none of the illnesses 
studied were significantly more common among persons with LD than among 
controls. Smoking was also common among both cases and controls. These 
proportions were not significantly different 1 l) when smokers were com¬ 
pared to non-smoker, 2) when smoking was stratified by number of pack 
years smoking, or 3) when smoking was stratified by age and number of 
pack years and tested by the Mantel Haenszel method. Alcohol consumption 
was also not significantly different when the proportion of heavy drinkers 
was compared, or when the proportion of persons reporting alcohol con¬ 
sumption was compared. 
Comparison of exposures in and around the home or workplace also 




trols. Similar proportions of cases and controls reported exposure to 
construction and/or excavation, either at work or at home (Table 9). 
There were no differences in the types of heating systems, presence of 
room or central air conditioning in the home, house construction material, 
number of families per building, and exposure to pets (Table 10). 
Geographic movements of the cases and controls in the two weeks 
before the onset of illness were examined by two types of questions. Per¬ 
sons were first asked to recall the usual activities and places visited 
around the city and then recall special persons or locations visited out¬ 
side their routine. Spot mapping of these activities gave us no evidence 
of unusual geographic clustering except for 4 cases and only 1 control 
who lived in 2 adjacent buildings in the downtown area. Remapping of 
patients activities including only home and work(or other prolonged expo¬ 
sures, e.g. Senior Citizens Center) again showed no pronounced clustering 
of the LD cases versus the controls. However, when compared to either con¬ 
trols or LD cases with onset during the week of 9/3< a high proportion 
of the LD cases with onsets outside the week of 9/3 appeared to reside 
or work in Downtown Bridgeport. There were no differences in the propor¬ 
tion of cases and controls who visited the eight specific buildings in 
downtown Bridgeport about which we asked (Table 11). Direct questioning 
about streets revealed one, West Avenue, was much more likely to hsve been 
visited in the 2 weeks before onset of illness by persons with LD (ps.005). 
Another street, Funston Avenue, was also significantly associated with 




Comparison of Cases with 9/3 Onset vs Other Onset 
Cases of LD were further inspected for differences between those 
cases with onset in the week of 9/3/78 and those cases with onset in 
weeks other than 9/3/78. Twelve cases had onset in the week of 9/3» while 
16 cases were designated as other than 9/3 onset (Table 12). Demographi- 
cally, while the age distribution was not significantly different between 
these groups, race approaches statistical significance (p053) with More 
non-whites among the cases of LD who did not have their onset during the 
week of 9/3« Comparisons with regard to classical risk factors and expo¬ 
sure to excavation and construction were also non-significant. As men¬ 
tioned previously, mapping geographic movements appeared to demonstrate 
that a higher proportion of the non-peak LD cases held major work or res¬ 
idence exposures to downtown Bridgeport. On direct questioning, none of 
the buildings inquired about were visited by a higher proportion of LD 
cases in either group. However, the 9/3 onset non-LD cases were signifi¬ 
cantly more likely to have visited one of the 3 downtown streets specifi¬ 






This investigation was made difficult by the lack of information regarding 
the usual incidence of U) in Bridgeport or any other area. Therefore, our early 
efforts were directed at develoDing ways of assessing whether the cases seen rep¬ 
resented merely the application of a newly available test to a heterogeneous popu¬ 
lation of patients with pneumonia or whether these cases represented an increase 
over an uncertain baseline. The available data does clearly suggest that there 
were more patients with pneumonia hospitalized during September and October 1978 
than would have been expected from the past experience. This naturally assumes 
th^t physicians' indications for admitting patients with pneumonia have not 
changed significantly over the last several years. That much of this increase 
is likely to be due to LD is not as certain, primarily because we have no way of 
determining wh^t proportion of the cases of pneumonia were LD in past years. 
However, the seasonal distribution of known LD outbreaks and the lack of evidence 
for another organism causing many of the cases of pneumonia in Bridmooort do sup¬ 
port the hypothesis that much of the excess pneumonia observed was attributable 
to LD. 
A recent report of yearly incidence based on Seattle virus watch data found 
lB 
that 1.2 persons p®” ve=r developed clinically apparent LD. However, they 
described only five confirmed cases and only one required hosoit=lization. This 
gives an adjusted rate of hospitalization for LD of 0.24/10,000 persons per year, 
or about l/20th of the rate that occurred in Bridgeport in the fall of 1978. This 
further suggests that the Bridgeport experience represented an outbreak of LD. 
It is of interest that despite the large numb®- of patients if end '.fied ’>ith 
LD, the overall severity of the cases of pneumonia seen in the fall of 197Q did net 
appear to be greater than in past years. This is somewhat at variance with the 
early reports of LD where the case fatality rate was approximately 15$. There are 
several possible reasons for this. We were unable, retrospectively, to determine 




cases of LD. Alternatively, the physicians in Bridgeport, more aware of LD as a 
possible cause of pneumonia th.-n physicians in earlier outbreaks, may have both 
diagnosed more of the milder cases and may have instituted erythromycin therapy 
earlier in the treatment of patients with pneumonia. 
Despite the Dast experience where outbreaks of LD have been linked to expo¬ 
sures in very circumscribed geographic a^eas, we were unable to find a specific 
buildinfT or of buildings th = t we^e possible common places of exposure. Our 
investigation was hindered by the understandable difficulty that many persons 
had in recalling their activities six to seven months earlier. Nevertheless, 
this limitation was lesc marked than it would have been with younger persons be¬ 
cause advanced ace and compromised health, had caused m-my persons to have few 
activities outside their homes. An additional problem was deciding what con¬ 
stituted an adeou=te geographic exposure. Several cases from the Philadelphia 
outbreak had merely walked by the implicated hotel. We felt that we were unable 
to ascertain precisely this degree of de+-il because of the time factor. In the 
Philadelphia outbreak the attack rate among the Legionnaires increased with increas 
ins; time scent in the hotel lobby. Our mapping of place of residence and place of 
work only amonc the cases and controls was designed to be analogous to this by 
selecting for places of prolonged exposure. This mapping suggested that cases of 
LD other than those with onset durinc tKe week of September 3rd we’-e much more like 
lv to have spent large portions of their time downtown. This is supported by the 
data obtained by direct ouestionins? of the cases regarding streets visited. The 
Streets that were selected were all approximately the same lenrth (5-6 blocks). 
Three were locate'? in the downtown area but off the main shopping streets. The 
other three were located in residential areas near the periphery of the city. 
The strong association of LD cases with one street, West Avenue, suggests that 
exposure to this area of the downtown section was a possible area of exposure to 
the LD organism. However, the validity of the association is called into Question 




Funston Avenue, located on the north side of the city. The five cases who visited 
Funston Avenue attended church there, but severs! of these cases also had ex¬ 
posure to the downtown area. 
The strongest geographic association occurs when the cases with onset during 
the we°k of September 3rd and cases with other onset are compared. All three down¬ 
town streets are significantly associated with being a case of LD with onset out¬ 
side the wee'' of 9/3. Furthermore, the comparison of these other LD cases 
separately with the non-LD controls shows a very high statistical association 
(%’ = 7.7, o^0.006) for exposure to any of the downtown streets. Sixteen (57$) 
of the 28 total LD cases had exposure to the downtown area. Of the 16 LD cases 
with '-'n?"x outside the we01' of Serx '■pr 3rd, +h° me'-eer*a-o increases to 87^ 
versus 27$ of the September 3rd cases. 
This geographic association suggests that frequent prolonged exposure to the 
downtown area of Bridgeport was a risk factor for the development of LD, especially 
amonr cases whose illness did not begin during the week of September 3rd. However, 
we were unable to demonstrate a specific building or location that represented the 
highest risk. This association may merely reflect the known epidemiology of the 
LD organism, namely that it apparently colonizes large coolin'' towers. Large office 
buildings which are likelv to have such towers are more likely to be located in 
downtown areas. There is precedent for a more general downtown area being implicated 
as a place of exposure. In the Philadelphia outbreak a portion of the identified 
cases occurred in persons classified as Broad Street pneumonias. These persons 
did not h’ve direct contact with the hotel but rather had scent time in the downtown 
area near the hotel. In the outbreak at St. Elizabeth's Hospital in Washington, D.C. 
development of pneumonia was associated with spending time on the hospital grounds 
as opposed to being confined indoors. 
The cases comprising this geographic cluster had their dates of onset over a 
six to eight week period of time. Therefore, we must hypothesize that the source 




The inability to identify a common geographic exposure for the cases of ID 
who had onset in the week of September 3rd is disturbing. They had minimal ex¬ 
posures to the downtown ares with none residing or working in downtown Bridgeport. 
No activities in common were identified for Labor Dav weekend which immediately 
preceded their onset of illness. It is possible th=t a common exposure did occur 
that we were unable to identify because of an inability to recall specific locations 
visited six to seven months earlier. This would be more likely to occur if the 
exoosure was of relatively short duration yet intense. 
The results our comparison of cases and controls with regard to clinical risk 
factors and personal health habits are at variance with the study reported by 
Storch £t al.^ We found no association between smoking, heavy alcohol consumption, 
construction near the home,or race, and later acquisition of LD. In the Storch 
study these characteristics were found to be significantly associated with LD. 
However, the study had several methodologic flaws that might have SDuriouslv lead 
to these associations. 
Although they compared persons who were known to have LD with persons known 
to be ner=tive for LD, a review of the history of 59 of their sero-negative con¬ 
trols revealed th=t only ?6# had had pneumonia. Thus the association they found 
with LD and smoking and heavy drinking, both of which are known to predispose to 
pneumonia in general, might merely reflect that a larger portion of the controls 
had a non-pneumonic illness than did the cases. We were able to control for this 
by reouirinr th^t both cases and controls had clinically apparent pneumonia on 
X-ray. When we took this bi3s in selection of controls into account, wc did not 
find the association they reported to be statistically significant. 
They also found that persons with LD were more likely to be black than were 
their sero-negative controls. However, as we mentioned previously the known epi¬ 
demiology of the LD organism suggests that it colonizes large water cooling towers 




Thus, it is very possible that cases of pneumonia in urban areas are more likely 
to be LD than cases from suburban and rural areas. Since blacks are more heavily 
represented among urban populations, failure to control for place of residence 
may lead to an overrepresentation of suburban and rural residents who are primarily 
Caucasian, among seronegative controls. In their study Storch et al controlled for 
residence only on the basis of state of origin. This bias in the selection of 
controls might also explain the association they found with construction. The 
higher density of buildings in urban areas may mean that an urban resident is more 
likely to live near a building undergoing construction. We were better able to 
control for this by confining our study to cases of pneumonia in residents of the 
city of Bridgeport. We did not investigate the cases that were diagnose^ in 
residents of nearby towns. 
In several of the early reports on patients with LD it was noted that a high 
proportion of cases had a history of serious underlying illness. However, both 
our study and the one by Storch et al^ did not find that the proportion was higher 
among persons with LD and persons with non-LD pneumonia. Similarly, despite the 
association with air conditioning in several outbreaks, room or central air 
conditioning have not been implicated in this or other studies of sporadic cases 
of LD. 
The low rate of availability of persons in our sampling frame is a major limita¬ 
tion of the present study. Despite our inability to determine systematic differences 
between those cases and controls included and those persons we were unable to in¬ 
clude, the overall conclusions have to be considered with this limitation in mind. 
Another difficulty, the effect of which we are unable to satisfactorily evaluate, 
is the problem of inaccurate recall of activities and exposures during the two 
weeks before onset of illness. 
Finally, approximately 25^ of our cases were persons in whom only a single 
positive serum specimen was available. It is possible that these people had been 
exposed to the organism several years before and that the illness they had in the 
fall of 1978 was caused by some other organism. The likelihood that this is the 

157. 
case is impossible to estimate because of the lack of information on age-specific 
sero-prevalence rates in the Bridgeport area. 
The strengths of the study include that LD cases were compared to LD-negative 
controls and that both cases and controls had pneumonia as their primary diagnosis. 
In addition, by concentrating specifically on residents of the city of Bridgeport, 
we minimized some of the biases introduced by place of residence. 
Our study suggests that LD may principally affect persons who are not different 
from those at risk for many forms of pneumonia. Geographic exposures of cases 
suggested that downtown Bridgeport was associated with a higher risk of developing 
LD although no specific source was identified. Because a causative organism for 
the majority of pneumonias may not be determined, the availabilitv of a relatively 
SDecific test couDled with soecific therapeutic intervention provides reason 
enough to make the LD bacterium an important organism for study. However, the 
propensity for explosive outbreaks serves to increase the relative importance 





1) Environmental Sa-pling 
The LD bacteriuir. has been isolated fron water collected from cooling 
towers in other outbreaks. Here, with no single ventilation system impli¬ 
cated, we cannot direct the sampling to a specific place. Nevertheless, it 
is likely that the area near West Avenue and John St, has only a few such 
towers. There is precedent from the Bloomington outbreak for positive spe¬ 
cimens to be obtained several months after the onset of cases. 
Generally, disinfection of such towers does not appear to be covered 
by sanitary codes. However, to maintain efficiency of coolinc systems, 
various slimieides are used to prevent accumulation of slimes on heat exchan¬ 
ger surfaces. Whether these are effective in preventing growth o'1 the orga¬ 
nism is unknown. There is preliminary evidence to suggest that hyperchlor¬ 
ination o' the water may effectively inhibit growth of LD bacteria. 
Thus, we would recommend sampling of the water from these towers 
to test for the LD bacterium. In addition, it mieht be useful to survey 
the anti-contaminating procedures generally used in the maintenance of these 
towers. 
2) A major limitation of our study was the inability to contact many 
of the persons originally included in the sampling frame, A prospective 
study, when the questionnaire is administered early after admission and 
paired sera are routinely collected on patients admitted with pneumonia,would 
permit control of these potential errors. Clearly, an opportune time might 




3) Although the evidence is quite convincing that the LD seen last fall 
represents as outbreak, it is still possible that the Bridgeport area rep¬ 
resents a local area of hyperendemnicity. A serosurvey of selected popula¬ 
tions for prevalent antibody titer would be an important way to evaluate 
this possibility, 
4) It is still possible that with increased efforts, a portion of the 
patients not included could be contacted and included in the study. The limited 
time available to carry out our study made extensive efforts to reach 




1) Chart Review 
2) Sample frame 
3) Data Collection 
a) Case Status 
5) LD Cases 
TABLE 1 
CASE-COMPARISON STUDY SUBJECTS 
CRITERIA NUMBER OF PATIENTS 
1) Primary discharge diagnosis ^50 
of pneumonia 
2) Discharged from a Bridgeport 
hospital between August 1 and 
November 30, 1978 
1) Onset of illness between August 1 123 
and October 31, 1978 
2) Resident of Bridgeport 
3) At least 18 years of age 








Included in study 
Not included in study 
Confirmed case (seroconversion) 
Presumptive cases (seropositive] 
Control cases (seronegative) 





a) Week of 9/3/78 12 




1078 SEROPOSITIVTTY RATES 
Source Number of persons Number of positive 
for whom LD tests LD tests 
were submitted 
Bridgeport, 





Norwalk 135 62 
Remainder of 
the state of 
Connecticut 491 77 
Total 626 139 








i Pneumonia discharges/Total discharges in Patients of All Ages from the Three 
Bridgeport hospitals 
1976 1977 1978 7C2 test of significance 
1978 vs. (1976+1977)/2 
July- 0.91 0.90 1.39 p^0.05 
August 1.50 0.91 0.84 P>0.05 
September 0.74 0.70 2.01 p <0.001 
October 1.29 1.06 2.02 p<0.01 
November 1.29 1.20 1.82 p^0.05 















July 1976 8 31 39 0.21 
1977 2 36 38 0.05 
1978 2 55 57 0.04 
August 1976 6 55 61 0.10 
1977 5 32 37 0.14 
1978 2 33 35 0.06 
September 1976 1 29 30 0.03 
1977 3 24 27 0.11 
1978 8 72 80 0.10 
October 1976 6 47 53 0.11 
1977 3 40 43 0.07 
1978 3 80 83 0.04 
November 1976 2 48 50 0.04 
1977 2 45 47 0.04 
1978 4 66 70 0.06 
December 1976 2 47 49 0.04 
1977 8 72 80 0.10 
1978 4 51 55 0,07 




Particiration of the Sampling Frame 
Category Legionnaires' No previous sere- ^ 
loeic testing for LD 
2 Number Total remain¬ 
disease ’ excluded ing for pos¬ 
sible partiC' 
ipation 
Total eligible 35 88 123 
Not in study 
MD or patient 
refusal 
3(956) 15(17$) 18(15$) 105 
Death 2(6%) 8(9$) 10(8$) 95 
Letter returned 
or natient moved 
No phone or un¬ 
listed phone and 
no contact attempted 
1(3%) 12(14$) 13(11$) 82 
by patient 
Ineomolete serology 
with comrle+e^ c;ms- 
1(3%) 14(161) 15(12$) 67 
tionnaire 0 10(11$) 10(8$) 57 
Number included in our 
case-comparison study 28(80$) 29(33$) 57(46$) 
^The three persons who were originally considered to be non-LD pneumonias but whose 
serology results gave them presumptive LD designations are included in the LD 
category. 




Selected Characteristics of the Sampling' Frame by those "In Study" and "Not in Study' 
In Study Not in Study P value(« = 
TOTAL 57(1003) 66(1003) 
DEMOGRAPHIC CHARACTERISTICS 
Gender Male 34(59.63) 35(53.03) NS 
Female 23(40.43) 31(47.03) NS 
Race White 45(78.93) 50(75.83) NS 
Non-white 12(21.13) 16(24.23) NS 
Age <50 yrs. 14(24.53) 17(25.63) NS 
50-69 yrs. 25(43.8<) 28(43.93) NS 
^70 yrs. 18(31.63) 21(31.8,3) T* T 
C* ~V:n'.L CHARACTERISTICS 
Pre-existing ilLnesses or conditions 
Cardiovascular Present 24(42.13) 27(40.93) NS 
Absent 33(57.93) 39(59.13) NS 
R^srir \r)y*’,r Pr® 15(26.33) 11(16.73) NS 
Absent 42(73.73) 55(23.33) N- 
Renal Present 3( 5.33) 3(4.63) NS 
Absent 54(94.73) 63(95.43) NS 
Neoplasia Present 4( 7.03) 5( 7.63) NS 
Absent 53(93.03) 61(92.43) NS 
Diabetes (with Present 10(17.53) 10(15.23) NS 
or without in¬ 
sulin) Absent 47(82.53) 56(84.83) NS 
Smoking Present 33(67.43) 32(61.53) NS 
Absent 16(32.73) 20(38.53) NS 
MISCELLANEOUS 
Severity as Present 
denoted by use 
1( 1.83) K 1.53) NS 
of respirator Absent 54(94.73) 55(83.33) NS 
Total deaths Before discharge 0 6( 9.13) 







Selected Characteristics of the Sample Population by Case and Control 
Cases Controls P value(°*=0,0 
TOTAL 28(100%) 29(100*) 
DEMOGRAPHIC CHARACTERISTICS 
Gender Male 20(71.4*) 14(48.3*) NS 
Female 8(28.6*) 15(51.7*) 
Race White 22(78.6*) 21(72.4*) NS 
Non-white 6(21.4*) 8(27.5*) 
Age 
<50 5(17.9*) 9(31.0*) NS 
50-69 14(50*) 12(41.4*) NS 
70+ 9(32.1*) 8(27.5*) NS 
Median 64.5 62 
Level of Education 
High School Grad or 11(42.3*) 7(25*) NS 
above 
< High School Grad 
Occupation 
15(57.7*) 21(75*) 
Employed 13(46.4*) 8(27.6*) NS 
Unemployed* 15(53.6*) 21(72.4*) 




Clinical Characteristics of the Sample Populati on by Case and Control 
Cases Controls P value(oc=0.05) 
TOTAL 28(100%) 29(100%) 
CHARACTERISTICS 
Cigarette Smoking 17(60.7%) 15(51.7%) NS 
Alcohol Consumption 16(57.1%) 14(48.3%) NS 
MEDICAL CONDITIONS 
Cardiovascular 12(42.8%) 11(37.9%) NS 
Neoplasm and 3(10.7%) 0(0.0%) NS 
Immunosuppression 
Diabetes 6(21.4%) 4(13.8%) NS 
Kidney Disease 1(3.6%) 1(3.4%) NS 
Respiratory Disease 6(21.4%) 11(37.9%) NS 










P value («=< =0.05) 
ACTIVITY 
Excavation 6(23.08%) 5(18.52%) NS 
Construction 6(23.08%) 8(30.77%) NS 
Excavation and/or 
Construction 
9(33.33%) 10(37.04%) NS 




Selected Characteristics of the Place of Residence by Case and Control 
Cases Controls P value (crt=o.05) 
TOTAL 28 29 
BUILDING MATERIAL 
Brick 6(21.4*) 11(37.9*) NS 
Wood 17(60.7*) 16(55.2*) NS 
Other 5(17.9*) 2(6.9*) NS 
a 
HEATING SYSTEM 
Central Forced Hot Air 7(25/0 9(31*) NS 
Central Radiators 17(60.7*) 16(55.2*) NS 
Electric 2(7.1*) 1(3.4*) NS 
Other 2(7.1*) 3(10.3*) NS 
AIR CONDITIONING 
Present 14(50*) 13(44.8*) NS 
Absent 14(50*) 16(55.2*) 
HUMIDIFYING SYSTEM 
Present 1(4*) 2(7.4*) NS 
Absent 24(96*) 25(92.6*) 
DEHUMIDIFYING SYSTEM 
Present 3(11.1*) 2(7.4*) NS 
Absent 
AGE OF HOUSE 
24(88.9*) 25(92.6*) 
NS 
FAMILIES PER BUILDING (Single vs. Multiple) NS 
PETS IN HOUSE 
Yes 11(39.3*) 9(31*) NS 




Geographical Locations Visited by Cases and Controls 
Cases Controls P value(oC=0.05) 
TOTAL 28(1001) 29(100%) 
LOCATION 
Hospital Visit 8(30.71) 6(21.4%) NS 
Doctor's Office Visit 8(28.6%) 5(20.0%) NS 
Lafayette Shopping Plaza 6(24.01) 12(41.4%) NS 
City Hall 3(12.0%) 1(3.4%) NS 
Barnum Museum 0(0.0%) 1(3.4%) NS 
Railroad Station 2(8.0%) 2(7.1%) NS 
Ferry 1(3.7%) 2(6.8%) NS 
Federal Courthouse 1(3.7%) 2(7.6%) NS 
State Courthouse 0(0.0%) 2(7.6%) NS 
Kline Auditorium 2(7.6%) 0(0.0%) NS 
John Street 11(47.8%) 9(34.6%) NS 
Middle Street 10(40.0%) 7(25.0%) NS 
Logan Street 1(4.0%) 1(3.4%) NS 
Hughes Avenue 1(3.7%) 0(0.0%) NS 
Funston Avenue 5(18.5%) 0(0.0%) p=0.0232065 




Selected Characteristics of the Legionnaires' Disease Pneumonias 








<50 2(16.73) 3(18.83) NS 
50-69 6(503) 8(503) NS 
704- 4(33.33) 5(31.23) NS 
Median 
RACE 
White 12(1003) 11(68.753) p=o.052503* 
Non-White 0 5(31.253) 
CLINICAL CHARACTERISTICS 
Respiratory Disease 1(8.33) 5(31.23) NS 
Cigarette Smoking 6(503) 13(81.23) NS 
Alcohol Consumption 8(72.73) 8(503) NS 
PROXIMITY TO: 
Construction 2(18.23) 4(26.63) NS 
Excavation 1(93) 5(33.33) NS 
GEOGRAPHIC LOCATIONS VISITED (STREETS) 
Funs ton 3(253) 2(13.33) NS 
West 1(8.33) 8(503) p=0.0389553 
Middle 2(18.23) 8(61.53) p=0.04718 
John 2(18.23) 9(753) p=0.016441 
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Name, telephone and/or address of nearest 
Relative 
Occupation 
Chest X-Rayi pneumonia _yes _no 
or infiltrate _ not lone 
Date of positive CXR_ 
Temperature t Admission_ MAx ._ 
January '70 
lion pi tal_ 
Chart //  
A ge_oi-z_ 
Date of Onset_ 
Date of Admission_ 
Date of Discharge_ 
Dr._Tc 1 e._ 
1-cvious iiospi tal ization'. 
(if within 14 days of dat 
of onset) ^ 
Dates 
h'ospi tal 
Cultures! Sputum - Result, Date not done 
(within 2 days of adm 
Blood - Result, 




Erythromyoini yes no if yes, rive date 
Respirator! yes no 




3) Renal (2) 
4) Malignancy 
5) Diabetes mellitus 
6) Drug(s) on Admission 
a) Prednisone (3) 
b) Cytoxan 
c) Immuran 
Accept only from admission H 5 P 
and discharge 
(h) 
Legionnaires' titer(s): (1) Date Result 
(2) Da t e Resu 11. 
(3) Date Re su11 
Mycoplasms Titers: Date Result 
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187. 
Is your home air-conditioned? If 00 
so, do you nave a central system 1. a central refrigerated system 
or individual units? (If applicable) 
what kind of central system do you 2. □ central evaporative cooler ("swamp" 
have? cooler) system 
3. D Individual room unit(s) 
i □ yes, type unknown 
5. □ none 
6. □ unknown 
'*0 Does your home have an exhaust 
to cool the house? 
Yes No Unknown 




home have a 
If so, what 
humidifying 
kind? 1. □ evaporative pan(s) in air duct 
system 
2. □ water spray humidifier(s) in air 
duct system 
3. □ portable steam humidifier(s) 
4. □ portable "cold" humid!fler(s) 
5. □ yes, type unknown 
6. □ none 
7. □ unknown 
Does your 
system? 
home have a dehumidi f y ing0d 
1. □ central system 
2. □ portable or local unit(s) 
3. P yes, type unknown 
4. □ none 




ud) You USi 
AJ0 
>*) D it -rtfe 
Uerh the 
a a 
fV\«t Coub. a o 
£7 c? 
bfc l^iER o n 
<tKm a a 
TU^ UJEEHS 
tALKjug. A Boot ♦ 
AX) 
//©IT a £7 
/4// C©*M. Z7 a 
ifttn a £7 
De //u*'6(</E£ C7 a 
?AfJ £7 n 
6o#w& rtifirr Tt*6? 
yes to* 
feAT a a 
/hz CcfJA. a a 
ffuMibiF&fi. a £3 
a a 







focik/RsPAi*gt>/ bu<t//u& rHose % <u&£*cz £ 
^5 • ^KO ^iXed/h fere. 
















Xi) You HAVE A ‘REfRtfrgRfrToa 
<\%ib/oG. a freeze*. } 
WKS (v*»E«E^ VT FvXE.t^'StRVVCED 
_ H 




;l*0 *Dc> yoM vmc*ji of u)*tsr UJK'C-VK 
Cd U.EC.TE b iM *mt •&BSEH£fcyt tiuRiMfir THE 
« tt 
Two WEEKS 'ggfba.F you XU- £ 
Mo £3 2>oa»V O 
*xr yts, srgary ; 
O No 
Q X)OV •-  
Q Ckt ■- _ _ 
£3 fUa& •• - — 
O :__ _ 
□ Not SORE 
/ES a 
Xf Vcs11 
*D esc.«a^e *. 
*b\t> fou Hkve *ferrS 
T>v>a\w6- THAT “Hhe ? 
a/0 A/«r Su«E 
□ a 
a d 
(u of IG ) 

190. 
ild if -- 
•kJow ^ coooco UK6 to Ask you to tRY to 
CaAiSTROa’tOfiJ £ XCA^AT<d^ ftfMCM 6€K A800T W/w/ C_0AJ£ 
DOR/AJ6- T7<oS€ d U>BSKS ? 
_* * _ -A- f- _ *?DJT7 
m Weas. WoKt *. 
Q Nteft* VjoRK •• 
Q O-rvVER *. 
0 NIokjE 
Q NOT SuR€ 
2.7)‘'UAS THCAE A** „ 
A^g/WAT/Ok/ ? 
a i4ear. \W*e • 




*' lJe&£ bMr&iHQ’ ftnt>/oR G-ARCzv/A/fr 





(13. of /6 ) 

191. 
'' n!ou> u>o u Lb uvk€ *To KSK /oO S0VA6 QJESTIGKIS 




30^ Cf&AfcS T 
3^ £*0# T 
(AcCcHol) 
a ajo 
a /«3 -* P*CKs/tMY „ 






rc»jv\Piue ; a a 
/£5 
Q * / 
a zjtss ~rn*+J 1 zw/vyse&t re£ DAY 
Q J! ** 3 VRlvKS^SZeKS fV# 2Vty 
£3 /Vo«6 s v*i»*$^8E£&S ^Y 
32^ QccuPflTiotJ ?- Q R'Erif^Sb Q ^ajca/Pi&y?~& 
jygcif/ ; v} ^Toe "Tv*tu£ : 
i> TYP£ 6F Work •• 
3> FtACl 61” U)0«K *• 
*0 Address : 
33)*UW/?r £©✓££ 6r fb&HfiL ScHoou^fr GJ& YOU COMMIE f 
a g*aoo*tc ms*w- a ^ sTl 
a Coa*S€ fi-AAHuOlS a " - yie.,s 
□ «l«l Si*..*- t/WfcUATJ Q UlMritWfJ 
(v% 6* \(o ) 

192. 
Do you have any kidney problems 
other than urinary tract 
infections? 
Currently on dialysis 
Functioning renal transplant 
Other (specify_) 
Do you have a chronic cough? By 
this I mean hav^^ouT!a3j^:ough 
with sputum for at least three 
months during each of the past 
two years. 
Yes No Unknown 
□ □ □ 
12 3 
□ □ □ 
12 3 
'□ □ □ 
12 3 
□ □ □ 
12 3 
Do you have diabetes? 1. □ yes, on insulin 
2- □ yea, no insulin 
3. □ no 
4. £2] unknown 
At that time did you have any other 
medical conditions for wh^T^^ousaw 
a doctor or which caused you to /r,, 
limit your activities? I tX‘ 
Specify: ' E’fAPtVy 
Disuse, C/hJc€Rj 






Yes No Unknown 
□ □ □ 
12 3 








Prednisone or other corticosteroids 1 
Cytotoxic or anti-metabolic drugs, or other 2 
drugs used for anti-cancer chemotherapy 
Digitalis 3 
Nitroglycerin or other drugs for angina A 




Other anti-hypertensives 7 
Bronchodilators or other drugs used for 8 
pulmonary disease 
Antibiotics 9 
Have you ever had gtjgumonia 
38} diagnosed by a doctor? 
3ft) Do you have a history of asthma? 
What medi£g£l2|i£ were you taking 
at the time we have been talking 
about? List: 
Please code using following code 

194. 
nrD ^ —-- 
"f^uAccy} -Z une « ^ 
(i'wcuj Of OTrt£&. £*££££ ufit> 
66CAH£ I to- Afount -. Tti£ TihSS Oj£ V€ he 
gsfiu -rAuone A6cut ? c 
□ no 
a y*s 






T/ffi o£ ----- 
CBesr Deiotif'TtoH') 
\to\e \ OaJ &EVBZS6 
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